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Background:  Abdominal solid organ transplantation has evolved from an 
experimental procedure to a well-established therapy within a few decades. 
This success is largely due to the introduction of calcineurin inhibitor 
immunosuppression.  Tacrolimus is the most widely used calcineurin 
inhibitor but has a narrow therapeutic range which requires close drug 
monitoring to prevent both toxicity and inadequate immunosuppression.  
Previous studies in renal transplantation have shown that genetic 
polymorphisms, CYP3A5, CYP3A4*22 and ABCB1 can influence the 
bioavailability and pharmacokinetics of tacrolimus.  These polymorphisms 
are closely linked to ethnicity and have never been studied in a Scottish 
population before.  Additionally, increasing evidence suggests that high 
variability of tacrolimus is linked to increased graft loss in kidney transplant 
patients. 
Methods:  5889 subjects were genotyped for the genetic polymorphisms 
CYP3A5 A>G allele transition, CYP3A4*22 C>T and ABCB1 C>T transition. 
This included 4899 healthy individuals from Generation Scotland bio-
resource and 990 patients who underwent renal, liver, or simultaneous 
pancreas kidney transplants or were organ donors.  Tacrolimus dose, trough 
level and renal function were measured at 11 time points from date of 
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transplant up to and including 12 months post-transplant.  Clinical data 
including episodes of acute rejection, graft and patient survival were 
compared between the different genotypes. Separate analyses were 
undertaken for kidney, SPK transplants, as well as liver transplants, the 
latter looking at recipient and liver donor genotype.  A separate cohort of 
103 renal transplant patients converted from twice-daily to once-daily 
tacrolimus had their tacrolimus variability calculated and compared with 
graft survival. 
Results: The distribution of the 3 different genotypes of CYP3A5, 
CYP3A4*22 and ABCB1 were comparable with other Caucasian populations 
studied previously.  In renal transplant recipient expression of the A allele 
(GA/AA) led to significantly increased dose requirements of tacrolimus and 
initially lower tacrolimus trough levels.  The different genotypes of ABCB1 
had no effect.  Expression of a CYP3A4*22 T allele trended towards a lower 
tacrolimus dose requirement but this was not significant.  There was no 
difference in renal function, graft survival or patient survival with any of the 
polymorphisms.   SPK patients had comparable results.  In the liver 
transplant patients, the donor genotype had a greater influence than the 
recipient one. The donors with CYP3A5 A allele expression had significantly 
higher tacrolimus dose requirements and lower initial tacrolimus levels.  
This was apparent to a lesser extent with the recipient expression of CYP3A5 
 12 
and did not reach statistical significance at all time points.  There was no 
significant difference in tacrolimus dose requirements or level with either 
donor or recipient expression of ABCB1 or CYP3A4*22. There was a 
significantly higher incidence of acute rejection in donor CYP3A5 A allele 
expressers of liver transplant patients in univariate and multivariate 
analysis.  There was no significant different in acute rejection with ABCB1 or 
CYP3A4*22 genotype.  No differences in graft or patient survival with either 
donor or recipient genotype of any of the 3 polymorphisms were noted.  
Conversion from twice-daily to once-daily tacrolimus in the first 12 months 
post-transplant reduced tacrolimus variability.  Patients with high 
tacrolimus variability pre and post conversion had significantly greater graft 
loss than patients with low tacrolimus variability. 
Conclusion:  CYP3A5 expression results in increased tacrolimus 
requirements to achieve adequate immunosuppression in renal transplant 
and SPK patients.  Donor rather than recipient CYP3A5 expression is 
relevant for liver transplantation and dose requirements.  There may be an 
association with donor CYP3A5 expression in liver transplant patients and 
acute rejection which needs further evaluation.  ABCB1 and CYP3A4*22 do 
not appear to have a significant impact in any of the organ transplants.  High 





Organ transplantation has become a well-established treatment which saves 
many lives each year in the United Kingdom. For transplants to be 
successful, patients must take medication to suppress the immune system 
and prevent the body from rejecting the transplanted organ. 
 
One of the main drugs used today to reduce the activity of the immune cells 
in the body and prevent rejection of the transplanted organ is called 
tacrolimus.  This drug is very effective but works within a narrow range – too 
little drug is ineffective whilst too much becomes toxic and can damage the 
kidneys and the nervous system.  A blood test measures how much of the 
drug is in the patient’s system. This is checked regularly after transplant to 
allow changes of the doses to achieve a steady level in the blood. 
 
The way the body metabolises the drug is influenced by certain genes that 
affect how the liver breaks down the drug and how it is absorbed in the 
intestine.  One gene in particular, called CYP3A5, makes a liver protein that 
very rapidly breaks down tacrolimus. This means that if a patient has a 
particular format of that gene, they need much higher doses to achieve a 
sufficient level in the blood to effectively suppress the immune system.   
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Not everyone has an active CYP3A5 gene. This varies in different 
populations and ethnic groups.  We sampled approximately 5000 Scottish 
people and found that around 20% had the active gene. This is similar to 
other studied Caucasian populations.  We looked at two other genes called 
ABCB1 and CYP3A4*22 and found the different variants of these genes were 
also found in similar numbers to previously studied Caucasian populations. 
 
By testing our kidney, liver and combined kidney/pancreas patients as well 
as deceased liver donors, for these 3 genes we were able to determine that 
the ABCB1 and CYP3A4*22 genes did not have much influence on tacrolimus 
doses and levels.  However, we found that those with CYP3A5 activity 
required approximately two times higher doses of tacrolimus and took a 
longer to reach an effective level in their blood.  In liver transplant patients, 
a much bigger effect was seen if the donor liver had the active CYP3A5 gene, 
rather than the recipient.  This was associated with an increased rejection 
rate, but this was only seen if we did not account for other factors that might 
increase rejection and therefore requires further analysis. There was no 
increased rejection in the kidney or combined kidney/pancreas patients. The 
expression of CYP3A5 gene did not affect how long the transplants lasted or 
how long the patients lived.  
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The last part of this thesis examined whether the variability of the 
tacrolimus levels had any impact on the function of the transplanted organ. 
We looked at patients where there has been a conversion from the usual 
twice-daily formulation of tacrolimus to a slow release formulation that is 
taken only once-daily.  We found that high variability of tacrolimus led to 
significantly more patients losing their transplant through a form of low 
level chronic rejection.  Increased variability did not affect how long a 
patient lived.  We found that changing patients from the standard tacrolimus 
to the slow-release tacrolimus reduced this variability but only if the change 
happened within the first year after the kidney transplant.  The three genes 
we examined in this thesis had no impact on tacrolimus variability. However, 
as seen with the other transplants in this thesis, those patients who had 
active CYP3A5 required two-times higher dose of the once-daily drug. 
 
In summary, this thesis found that active CYP3A5 in kidney, combined 
kidney/pancreas and liver transplant patients (particularly the liver donor) 
led to increased tacrolimus dose requirements.  Whilst no significant impact 
on transplant outcomes was noted, patients may have an increased risk of 
rejection, especially in liver transplantation.  We found CYP3A4*22 and 
ABCB1 genes had little influence on tacrolimus or clinical outcome and 
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observed that high tacrolimus variability was associated with increased loss 
































Organ transplantation is a triumph of the modern medical age. 
Transplantation of solid organs such as kidney, liver, heart, lung and 
pancreas are nowadays routine and advances in surgical techniques, peri-
operative care, immunosuppression and organ preservation techniques 
enable us to push the boundaries of human transplantation allowing ever 
more complex procedures to be undertaken.  The relentless desire to replace 
defective or damaged body parts has led to some of the most complex 
surgery undertaken in the world today including composite tissue 
transplantation of whole limbs and even the human face. 
 
1.1 A very brief history of transplantation 
 
Pioneering work by the French surgeon Alexis Carrel at the turn of the 20th 
century in vascular anastomotic techniques laid the foundations for grafting 
transplanted organs into recipients.  By 1918 the enthusiasm for organ 
transplantation was growing almost as quickly as the transplanted organs 
were failing and Carrel was one of the first to encounter the biggest hurdle 
to successful organ transplantation, rejection. 
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In 1933 the Ukranian surgeon Yuri Voronoy attempted the first deceased 
donor kidney transplant but the graft failed due to rejection [1, 2] . 
 
The first cadaveric kidney transplant in the USA took place in 1950.  The 
transplant recipient was a 44 year old woman with polycystic kidney disease 
who lost the graft to rejection 10 months later.  In 1954 a kidney transplant 
between identical twins was performed in Boston and without the need for 
immunosuppression the recipient lived a further 8 years.  In the United 
Kingdom, the first renal transplant was performed in 1960 in Edinburgh, 
again between identical twins, and the recipient lived for another 6 years 
before dying of an unrelated illness.   
 
 
1.1.1 Discovering immunity and the implications for 
transplantation 
 
The German surgeon Georg Schöne was one of the first to describe the 
concept of transplant immunity. However, despite various strategies to 
match the donor and recipient, as well as the attempt to use different agents 
for immunosuppression, the results remained extremely poor such that by 
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the end of the first world war, clinical organ transplantation had all but been 
abandoned.   
 
Towards the end of the 1940s, Peter Medawar began to make significant 
progress in understanding the mechanism of rejection and his seminal paper 
along with R. E. Billingham in the J. Exp. Biol in 1951 described a variety of 
skin graft experiments which laid the foundations for further work in 
describing T-cell mediated rejection of foreign tissue.  Through their work 
Medawar and Billingham were not only able to describe the mechanisms by 
which transplanted tissue was rejected but also discovered immune 
tolerance, whereby the immune system is not pre-programmed to 
distinguish between self and non-self, but rather that the immune system is 
shaped to do so as a result of exposure to self-antigens in early development 
[3].  One of the most significant discoveries by Medawar and Billingham was 
that corticosteroid hormones from the adrenal gland delayed skin graft 
rejection in rabbits showing that this insurmountable barrier to 










Cortisone, the glucocorticoid steroid hormone made by the adrenal gland, 
was discovered in the 1940s by Edward Calvin Kendall while he was a 
researcher at the Mayo Clinic and by the early 1950s it was being 
manufactured commercially although it was not until some time later that is 
was used in transplant patients in the form of prednisolone [5]. 
 
The use of steroid alone would require high doses of Prednisolone in order to 
achieve adequate immunosuppression, resulting in serious side effects 
including insulin resistance and diabetes, osteoporosis, increased 
susceptibility to infection, hypertension and increased risk of malignancy.  
While it seemed plausible that the immune system could be suppressed in 
order to facilitate successful transplantation, it was clear that other 
therapeutic agents would be required in order to reduce the dose of steroid 







In 1957 George Herbert Hitchings and Gertrude Elion synthesized 
Azathioprine.  Originally designed to be a chemotherapy agent, Azathioprine 
is a prodrug, a precursor to 6-mercaptopurine (6-MP).  Azathioprine is 
converted to 6-MP by non-enzymatic reductive cleavage of the thioether (-
S-) mediated by glutathione.  Through various methylation and 
hydroxylation steps the active metabolite of Azathioprine, methyl-
thioinosine monophosphate (MeTIMP), is formed. This inhibits purine 
synthesis and thus significantly reduces the activity of both B and T 
lymphocytes, the prime facilitators of rejection in transplanted organs.  In 
1959 Shwartz and Damashcek found that 6-MP inhibits antibody production 
in rabbits and this, along with Medawar’s previous work, led Sir Roy Calne to 
consider 6-MP as an anti-rejection drug [6, 7].  Calne’s experimental renal 
transplants in dogs confirmed that Azathioprine, rather than 6-MP, provided 
more consistent results and therefore subsequent kidney transplant human 
trials used Azathioprine along with corticosteroids[8][9]. 
 
Azathioprine allowed a reduction in the dose of corticosteroid and for a time 
a combination of the two drugs formed the cornerstone of 
immunosuppression in kidney transplantation. Although progress was made, 
results remained relatively poor.  Murray et al reported in the New England 
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Journal of Medicine in 1963 the first accounts of prolonged survival in 
kidney transplant recipients, but this was measured in months rather than 
years.  The difficulty lay between the requirement of adequate 
immunosuppression to prevent allograft rejection and the severe side effects 
of Azathioprine at the doses required to achieve this.  These side-effects 
included bone marrow suppression leading to anaemia and leukopenia, 
hepatotoxicity, increased risk of malignancy (particularly skin cancer and 




In 1972 Sandoz (now Novartis) discovered that a drug called Ciclosporin A 
(CsA), which had been isolated a few years earlier by Hans Peter Frey from a 
soil sample in Norway, had powerful immunosuppressive effects.  In a case 
series of seven patients who underwent renal transplantation and had CsA as 
the sole immunosuppressant Calne et al demonstrated that CsA could indeed 
be used to provide effective immunosuppression although nephrotoxic and 
hepatotoxic effects of the drug were noted in some of the patients [10].  
Nevertheless, this new drug provided a longer graft survival compared to 
what was achieved so far.  Calne started using CsA in all types of transplants 
and reported good results with the use of CsA in 32 renal transplants, 2 
 24 
pancreas transplants and 2 liver transplants [11].  In 1981 Thomas Starzl 
published a report describing a series of 14 liver transplant patients who 
were immunosuppressed with ciclosporin and prednisolone alone, with 83% 
survival at 12 months follow up despite the fact that liver biopsy showed 
signs of acute rejection in six patients who required adjustments in steroid 
dose [12]. 
 
The discovery of ciclosporin was one of the milestones in transplantation as 
it provided, for the first time, adequate graft survival allowing 
transplantation to become accepted as the treatment of choice for end stage 
diseases of the kidney, liver, lung and heart.   
 
Ciclosporin is still used today, but even back in the 1980s it was recognised 
that it had significant side effects, predominantly nephrotoxicity and the 
development of new onset diabetes after transplantation (NODAT).  Given 
the encouraging results of cyclosporin, but mindful of the serious adverse 
effects, pharmaceutical companies tried to develop alternative 






In 1987, Toru Kino described a novel immunosuppressive agent (FK-506) 
which had been isolated from the fungus Streptomyces [13].  He reported a 
series of mouse experiments where FK-506 was able to suppress the in vitro 
proliferative response of human lymphocytes to alloantigen stimulation 
when added at the initiation of cell cultures [14].   
Tacrolimus has the chemical formula C44H69NO12 and a molecular weight of 
804.018 g/mol.  Tacrolimus is lipid soluble and most commonly administered 
in an oral preparation although intravenous, rectal and sublingual 
preparations are available for systemic administration.  Topical tacrolimus is 
used to treat a variety of dermatological conditions.   The structure of the 
tacrolimus molecule is detailed below. 
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Figure 1.1 Chemical structure of tacrolimus 
(Reproduced from the NIH PubChem database) 
 
These early studies showed that FK-506 was considerably more potent than 
CsA and required concentrations 100 times lower to inhibit the generation of 
cytotoxic T cells.  While FK-506 had a quite distinct molecular structure 
compared with CsA, its mechanism of action appeared to be similar.  During 
the 1990s the mechanism of action of FK-506 became better understood [15, 
16] and  FK-506 was considered as a promising new immunosuppressive 
agent for transplant patients [17].  Following the initial experience using the 
drug as a rescue therapy for liver transplant patients suffering from rejection 
with CsA based immunosuppression [18] the Pittsburgh group reported on 
the use of FK-506 as the primary immunosuppressive agent with promising 
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results [19, 20].  Shortly after other studies reported an improvement in 
patient and graft survival at 1 and 2 years with FK-506 when compared with 
ciclosporin [21].  Similar findings were reported in renal transplant studies 
[22, 23]  where a triple combination of  FK-506, Azathiorpine and steroids 
led to a reduction in rejection rates [24].  
 
In 1994 FK-506 became licensed for use under the unbranded name 
Tacrolimus (sold as Prograf® by Astellas Pharma) and replaced ciclosporin as 
the primary immunosuppressant drug used in solid organ transplantation.  
Similar to ciclosporin, tacrolimus has a narrow therapeutic index with 
neurotoxicity and nephrotoxicity as two of the main side effects.  The 
introduction of routine blood concentrations assays allowed a better 
definition of the therapeutic ranges and a clearer understanding of the side 
effects [25].  The measurement of the tacrolimus trough concentration, 
which is the tacrolimus whole blood concentration taken 12 hours after the 
dose is administered, revealed considerable variability between individuals 
who received the same dose suggesting that maintaining individual patients 
within the therapeutic window would not be achieved by a ‘standard dosing 
regimen’ but would rather require a tailored dose guided by the tacrolimus 
trough concentrations. The detailed aspects of therapeutic monitoring of 
tacrolimus are discussed later in this chapter.  The narrow therapeutic index 
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as well as the significant side effects of the calcineurin inhibitors led to 
development of other immunosuppressant agents.    
 
1.3 A brief summary of transplant immunology  
 
 
Manipulation of the recipient immune system to prevent organ rejection is 
essential for maintaining long term graft function.  Allograft rejection occurs 
when the recipient immune system recognises the transplanted organ as 
‘non-self’ and therefore activates the adaptive immune system which would 
normally respond to foreign antigens.  The normal immune response is 
rapid, antigen specific and protective against invading pathogens although 
this is, of course, an undesirable effect in the case of a transplanted allograft.   
 
1.3.1 Initial Inflammatory Response 
The entire process of allograft rejection is driven by an inflammatory 
response which is multi-faceted but we now know begins before the 
transplant has taken place and, in fact, before the organs have even been 
retrieved in a deceased donor.  The neuroendocrine disturbances often called 
the ‘catecholamine cascade’ in DBD donors, alongside the resultant 
haemodynamic disturbances can initiate the inflammatory process which is 
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further added to by a brief period of warm ischaemia during the retrieval 
operation and then static cold storage while the organs are transported [26].  
Once the initiation of this inflammatory process underway, pro-
inflammatory molecules and cellular pathways lead to the development of 
an ischaemia-reperfusion injury, which will manifest itself following the 
implantation and reperfusion of the allograft. 
 
1.3.2 Ischaemia-Reperfusion Injury 
An ischaemia-reperfusion injury to some degree is inevitable after every 
transplant and is closely related to the cold ischaemic time, with a longer 
cold ischaemic time leading to a more significant ischaemia-reperfusion 
injury [27].  The direct immune response against an allograft is initiated 
when damaged or dying cells release endogenous proteins or molecules, 
which are known as damage-associated molecular patterns (DAMPs) and by 
the release of pro-inflammatory cytokines. This cellular damage occurs due 
to ischaemia, switching the cell to anaerobic metabolism resulting in 
reduced ATP.  Subsequently the Na+/K+ pumps start to fail and the cell 
becomes oedematous and acidotic causing an influx of calcium ions and 
mitochondrial injury.  The cells become apoptotic and release inflammatory 
cytokines and DAMPs which, in turn leads to increased MHC class II 
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expression, furthering the immune response.   Inflammatory DAMPs such as 
heat-shock proteins (HSP), DNA fragments and high-mobility group box 1 
(HMGB-1) are recognised by specific cellular receptors such at toll-like 
receptors (TLRs) [2].  This process occurs very readily in solid organ 
allografts as the apoptotic cells are not so readily cleared following 
ischaemia-reperfusion injury and as the membrane integrity of the cells fails 
large amounts of pro-inflammatory cytokines are released which activate 
dendritic cells which will migrate from the allograft to lymphoid tissue and 
stimulate T cell production [28].  The severity of ischaemia-reperfusion 
injury has been shown to correlate with an increased incidence of acute 
rejection and a study in 2011 by Barba et al reported that a cold ischaemic 
time of > 18 hours increased the incidence of acute rejection in kidney 
transplant patients [29].  Other studies have shown that ischaemia-
reperfusion injury contributes to delayed graft function however the 
relationship between ischaemia-reperfusion injury, delayed graft function 
and acute rejection remains unclear, with some studies suggesting a longer 
CIT leads to increased acute rejection but no overall negative effects [30].  
While ischaemia-reperfusion injury and the long term impact on graft 
function and survival remains a topic for debate, there is evidence to support 
that a more significant ischaemia-reperfusion primes the allograft for a more 
severe immunological response which manifests itself with increased acute 
rejection. 
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1.3.3 Immune Response Following Transplantation 
The main components of the adaptive immune systems are the cellular 
response (T cells) and the humoral response (B cells/antibodies) and both 
play a role in graft rejection.  T cells are formed in the thymus derived from 
stem cells which originate in the bone marrow [31].  T cells differentiate into 
different subtypes while in the thymus and T cells designated CD4+ and 
CD8+ are of particular relevance in cellular immunity.  T cells can recognise 
antigens presented by the major histocompatibility complex (MHC), which is 
also known as the human leukocyte antigen, (HLA) through T cell receptors 
(TCRs) expressed on their cell surface.  B cells express surface 
immunoglobulins which act as their antigen receptor and are the precursor 
to plasma cells which, when activated, will secrete soluble immunoglobulin 
in the form of antibody.  In addition to the adaptive system of immunity, 
there is the innate immune system which comprises of a molecular 
component (cytokines, Toll-like receptors and complement) and a cellular 
component (macrophages, dendritic cells, natural killer cells and 
neutrophils).  There are important interactions between the adaptive and 
innate immune systems when mounting an immune response.  The primary 
targets of the alloimmune response are HLA antigens (MHC).  Class I MHC 
molecules (HLA A, B, and C) are expressed on all cells and are recognised by 
CD8+ T cells.  Class II MHC molecules (HLA DR, DQ, and DP) are recognised 
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by CD4+ T cells and are found on a few specialised cell types known as 
antigen presenting cells (APCs) which include dendritic cells, macrophages 
and B cells.   
Allograft rejection is primarily mediated by T cells and many 
immunosuppressive agents target T cell signalling pathways to prevent T 
cell activation.  In order for T lymphocytes to achieve optimal activation and 
expansion, they must receive two coordinated signals [32].  The first signal is 
provided by the T cell receptor (TCR) as it recognises the MHC-antigen 
complex expressed on the surface of the APC and the second signal comes 
from costimulatory molecules on the T cells which interact with ligands on 
the APC [33]. 
Costimulatory molecules (receptor-ligand pairs) can result in both activation 
of T cell activity or cause T cell activity to wane depending on which 
costimulatory molecules are involved in TCR signal transduction.  In general 
terms, binding of the T cell based CD28 molecule results in T cell activation 
and binding of the CD152 molecule, also known as cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) results in reduced T cell activity.  The ligands 
for CD28 and CTLA-4 are the B7 molecules, CD80 and CD86, both of which 
can bind to either CD28 or CTLA-4, although CTLA-4 has a much higher 
affinity [34, 35].  This process describes a two-signal model for positive and 
negative co-stimulation of T cells.  In order for a T cell to become activated 
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it must first receive signal one from MHC-antigen complex interacting with 
the TCR and the second positive co-stimulatory molecule interacting with 
their respective ligand on the APC.  Once this occurs, T cells will proliferate, 
secrete cytokines and differentiate into effector cells [32].  The cytokines IL-
2 and IFN-γ from T cells and IL-12 from APCs produce an environment 
which favours the recruitment of T cells and clonal expansion [36].  
Interleukin-2 works as an autocrine agent, actively upregulating IL-2 from 
the cell which is secreting it, as well as upregulating CD25, the high-affinity 
receptor for IL-2.  IFN-γ will induce the expression of class II MHC molecules 
on non-lymphoid graft tissue and upregulate class I MHC molecules, 
increasing the amount of alloantigen present [37].   
The rejection of the transplanted allograft is brought about by the cytotoxic 
effect of CD8+ cells as they bind to MHC class I.  Cell death occurs by a Ca2+ 
dependent mechanism whereby Ca2+ influx results in the exocytosis of 
cytolytic granules which contain a lytic protein called perforin which 
perforates the cell membrane and serine proteases called granzymes which 
then lyse and destroy the cell [38].  In the absence of Ca2+, CD8+ cells can 
initiate cellular apoptosis by upregulating fas ligand on it cell surface.  
Crosslinking of fas on target cells with the fas ligand on the CD8+ cells will 
then induce programmed cell death of the target cell.  If this process is 
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allowed to go on unchecked after solid organ transplantation, the inevitable 
outcome is acute cellular rejection and the loss of the transplanted allograft.   
In order to prevent this and maintain function of the transplanted organ, 
immunosuppressive drugs are required to inhibit T cell activity and the 
associated pathways.   
Therefore, immunosuppression is usually provided by a combination of 
different drugs which include a calcineurin inhibitor in most cases.  
Currently, tacrolimus is the most commonly used calcineurin inhibitor for all 
types of organ transplantation. 
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Figure 1.2 Key steps in T-cell mediated acute cellular rejection outlining 
interaction with the T cell receptor, different signalling pathways leading to 
the transcription factors that upregulate interleukins and other cytokines 
which act as co-stimulatory molecules in the activation and proliferation of T 
cells. 
Immunosuppressive Drugs for Kidney Transplantation, New England Journal 
of Medicine [39]. 
 
1.3.4 Tacrolimus Mechanism of Action 
In order to understand the mechanism of action of tacrolimus it is necessary 
to first look closely at what happens when a T cell encounters an alloantigen 
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and, in particular, its interaction with the intracellular molecule calcineurin, 
which plays a critical role in the process of IL-2 production and therefore T 
cell activation and proliferation.  The TCR encountering alloantigen leads to 
an increase of intracellular calcium within the T cell.  Calcineurin is formed 
from 2 subunits: calcineurin A (CnA) which is responsible for the 
phosphatase activity of calcineurin and acts as a catalyst and calcineurin B 
(CnB) which regulates the activity of CnA.  CnB is particularly responsive to 
the increase in intracellular calcium which occurs upon TCR interacting with 
alloantigens.  The activation of CnB initiates the phosphatase activity of 
CnA which then dephosphorylates cytoplasmic Nuclear Factor of Activated 
T-cells (NFATc), a gene transcription factor [40].   NFATc, along with 
activated calcineurin, translocates to the nucleus of the T cell where it 
facilitates the transcription and upregulation of various cytokines and 
growth factors including IL-2, IL-4, IFN-γ and TNF-α, [41] .  
Calcineurin inhibitors block the action of calcineurin within the T cell and 
thus prevent the dephosphorylation of NFATc, preventing gene 
transcription of IL-2 and considerably reducing T cell activity.  Ciclosporin 
and tacrolimus achieve this in slightly different ways.  Both bind to 
intracellular proteins known as immunophilins but whilst Ciclosporin A 
binds to the immunophilin called cyclophilin, tacrolimus (FK506) binds to 
the FK-binding protein (FKPB). This FK506-FK PB complex will then bind to 
 37 
calcineurin phosphatase, inhibiting its activity and preventing the 
dephosphorylation of NFATc.  In addition to blocking IL-2 transcription, 
tacrolimus also inhibits other calcium dependent events such as nitric oxide 
synthase activation, cell degranulation and apoptosis, markedly reducing T 
cell activity [42].  
 
1.3.5 Tacrolimus bioavailability and pharmacokinetics 
Currently, there are several forms of Tacrolimus, either as immediate release 
preparation administered twice daily (Tac-BD) or a modified release 
administered once daily (TAC-QD).  The once-daily modified release version 
of tacrolimus has different pharmacokinetics to the original twice daily 
preparation. 
Tac-BD is absorbed throughout the gastrointestinal tract but absorption is 
incomplete and is highly variable between individual patients.  The absolute 
bioavailability of tacrolimus is 18±5% in adult healthy volunteers, 17±10% in 
adult renal transplant patients and 22±6% in adult liver transplant patients 
(National Center for Biotechnology Information. PubChem Compound 
Database; CID=445643).  There have been some studies published that report 
bioavailability, ranging as widely as 4 -93% [43, 44].  Numerous factors are 
thought to affect the bioavailability of Tac-BD including the time between 
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administration and last ingestion of food, corticosteroid dose, haematocrit 
level, and variations in cytochrome P450 activity. 
Tac-BD binds extensively to erythrocytes, albumin and α1-acid glycoprotein, 
is metabolised by cytochrome P450 enzymes in the liver and is counter-
transported by the drug efflux pump p-glycoprotein in the enterocyte [45].  
The drug is almost entirely excreted through the biliary tract with only 1% 
excreted in the urine [46].   
The half-life (the time taken for half of the drug to be cleared) is variable 
depending on whether the drug is administered to a healthy volunteer, a 
renal transplant patient or a liver transplant patient, paediatric or adult 
patients.  Studies in renal transplant patients suggest a median half-life of 
approximately 19 hours with the mean in the region of 48 hours (range: 4.6 – 
939 hours) [43].  The drug has different pharmacokinetics in the liver 
transplant population, particularly in the early post-transplant period, given 
the fact that the drug is metabolised in the liver [47]. 
 
1.4 Tacrolimus formulations and Pharmacokinetics 
 
1.4.1 Once-daily Modified Release Tacrolimus (Tac-QD)/Advagraf® 
A modified release preparation of tacrolimus which could be taken once-
daily has been available since 2004.  The once-daily preparation, developed 
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as a means of reducing the pill burden and improving adherence among 
patients, does have some key differences to its standard-release predecessor.  
It is absorbed more distally in the gut than the standard twice-daily 
preparation (Tac-BD) which may make polymorphisms of ABCB1 and P-gp 
expression more relevant as P-gp expression in the proximal and distal gut is 
different. 
 
Early studies in healthy volunteers and also stable renal and liver transplant 
patients reported that conversion on a mg:mg basis from twice daily 
tacrolimus (Tac-BD, Prograf®) to once-daily modified release tacrolimus 
(Tac-QD, Advagraf®) was both safe and effective [48].  It was hoped that Tac-
QD would improve patient adherence by reducing the pill burden and that 
the modified release formulation would reduce the within-patient variability 
of tacrolimus which has been shown to be detrimental to long term graft 
survival [49].  Further studies of both renal and liver transplant recipients 
concluded that patients converted on a mg:mg basis had stable tacrolimus 
levels with no difference in the acute cellular rejection or graft loss 
compared with patients on the standard twice-daily Tac-BD formulation [50, 
51]. 
As further studies started to emerge, it became apparent that Tac-BD and 
Tac-QD were not, in fact, bioequivalent and there was a lower tacrolimus 
trough concentration (C0) following conversion [52, 53].  By 2011 there had 
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been 15 published studies comparing Tac-BD and Tac-QD, 4 of which were 
industry designed phase-II pharmacokinetic studies in adult kidney, adult 
liver, adult heart and paediatric liver transplants.  Barraclough et al 
published a comprehensive review examining these studies and concluded 
that while the Tac-BD and Tac-QD formulations were bioequivalent by Food 
and Drug Administration (FDA) and European Medicines Agency (EMA) 
standards, there was a reduction of total tacrolimus exposure of between 5-
15% following conversion to Tac-QD necessitating numerous dose changes 
in several cases [54].  Furthermore de novo transplant recipients exhibited 
reduced AUC24 requiring higher initial doses whilst data from some phase III 
studies suggested reduced efficacy of Tac-QD with higher rates of acute 
rejection in both liver and kidney transplant cohorts.   
 
More recently, the OSAKA trial (a randomized controlled trial comparing de-
novo Tac-BD and Tac-QD without basiliximab induction in kidney 
transplantation) reported that there was no significant difference in clinical 
outcomes between patients prescribed 0.2 mg/kg/day of Tac-BD compared 
with 0.2 mg/kg/day Tac-QD [55]. 
 
Tac-QD is increasingly used in clinical transplantation. Given the obvious 
differences in the pharmacokinetics between the standard and the modified 
release preparation it cannot be assumed that the SNPs will impact in the 
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same way.  Gut expression of CYP3A5 is more abundant in the proximal gut, 
such as the jejunum, whereas there is increased P-gp expression more 
distally in the gut in the colon [56].  It is therefore conceivable that the 
ABCB1 polymorphisms may have a greater impact on Tac-QD than Tac-BD 
whilst the gut expression of CYP3A5 could impact less on the 
pharmacokinetics of Tac-QD.  Niioka et al reported that the ABCB1 
polymorphism had no impact on the bioavailability of either Tac-BD or Tac-
QD, although an overall reduced bioavailability of Tac-QD was noted.  
However, CYP3A5 expressers had significantly reduced bioavailability for 
both preparations meaning that CYP3A5 expressers who were prescribed 
Tac-QD had the lowest bioavailability [57].  Glowacki et al reported a reduced 
tacrolimus exposure (AUC24) when renal transplant patients were converted 
from Tac-BD to Tac-QD. This reduction in exposure was most pronounced in 
those individuals who were carriers of the CYP3A5*1 allele and therefore 
CYP3A5 expressers [58].  These studies support the view that tacrolimus 
exposure reduces when patients are converted from Tac-BD to Tac-QD and 
highlight the possibility that CYP3A5 expressers may be particularly at risk 
of achieving sub-therapeutic tacrolimus levels when converted and require 
careful monitoring post conversion. 
 
In addition to the variability of tacrolimus C0/D levels seen between different 
patients, there is now increasing evidence that there can be significant 
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intra-patient variability.  Studies investigating this phenomenon are still 
relatively few but recent data suggests that high levels of intra-patient 
variability result in poorer patient outcomes. In a cohort of 297 renal 
transplant patients treated with Tac-BD, Borra et al found that, patients who 
were deemed to have ‘high within-patient variability’ had significantly 
higher rates of graft loss compared with the patients in the low variability 
group [49].  Wu et al demonstrated that conversion from Tac-BD to Tac-QD 
resulted in a significant drop in C0 immediately after conversion but also 
reported a significant reduction in the intra-patient variability [59].  These 
two studies used different methodologies.  Borra et al based their 
estimations on an equation which calculated a percentage by which each 
patient deviated from their own mean dose corrected tacrolimus levels. In 
contrast, Wu et al used the coefficient of variation to calculate the variability 
and used C0 levels that were not corrected for the dose. 
 
There have been very few studies examining the relationship between the 
genetic polymorphisms and tacrolimus intra-patient variability, as well as 
whether this is impacted by a change to Tac-QD.  In a study of 29 healthy 
Korean volunteers who took either branded immediate release tacrolimus 
(Prografâ) or a generic formulation of tacrolimus, Yong et al  performed 
AUC24 and genotype analysis and suggested that individuals who carried the 
CYP3A5*1 allele had reduced intra-individual variability compared with 
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those of the CYP3A5*3/*3 genotype [60].  Another study by Pashaee et al, 
however, examined 208 renal transplant patients taking tacrolimus found no 
significant link between CYP3A5 genotype and the intra-patient variability 
of tacrolimus, although the preparation of tacrolimus is not specified in this 
study [61].   
 
Most recently, Stifft et al published a prospective study of kidney transplant 
patients and using AUC24 and the coefficient of variation found that Tac-QD 
had significantly reduced variability compared with Tac-BD.  They suggested 
that this reduction was more pronounced in patients who carried the 
CYP3A5*1 allele and concluded that as there was a very small number of 
subjects who carried this allele, this warrants further study [62].  This study 
was robust in that it looked at AUC24 profiles and the dose of tacrolimus 
remained constant throughout.  What has not yet been established by any 
study to date is whether the reduction in variability persists long term after 
conversion and whether thus leads to an improvement in graft survival. 
 
1.4.2 Envarsus® XR 
Recently another modified release preparation of tacrolimus that is taken 
once-daily has come on the market with a different pharmacokinetic profile 
to both Tac-BD (Prograf®) and Tac-QD (Advagraf®).  The 2 main studies to 
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date by Gaber et al which reported on  kidney transplant patients and 
Alloway et al which studied liver transplant patients suggest that 
approximately a 30% lower dose is required to achieve comparable 
tacrolimus exposure as the twice-daily capsules [63, 64].  Envarsus® XR uses 
a different type of modified release technology to release the drug called 
MeltDose® which offers increased solubility and bioavailability compared 
with other Prograf® [65].  It appears to have a flatter pharmacokinetic profile 
and reduced peak/tough fluctuations as well as a lower peak concentration 
(Cmax) and a longer time to reach that peak (Tmax) [66].  The pharmacokinetic 
profile and AUC24 for Prograf®, Advagraf® and Envarsus® XR is shown in 




Figure 1.3 Pharmacokinetic whole blood time-concentration curves of 
Prograf® (IR-Tac), Advagraf® (ER-Tac) and Envarsus® XR (LCPT). 
Observed steady-state pharmacokinetic profiles of the 3 tacrolimus formulations.  
AM morning, AUC area under the curve, ER-Tac tacrolimus extended release, IR-
Tac tacrolimus immediate release, LCPT life cycle pharma tacrolimus.  Reproduced 
from Tremblay S, Nigro V, Weinberg, J, Woodle ES, Alloway RR.  A Steady-State 
Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) 
Formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-




Sirolimus was isolated in 1975 from the fungus Streptomyces hygroscopicus 
found in a soil sample collected from Rapa Nui (Easter Island).  It inhibits 
the action of mammalian Target of Rapamycin (mTOR), blocking several 
signal transduction pathways that results in the arrest of the cell cycle in the 
G1 phase, preventing the up-regulation of IL-2 mediated by CD28 [68] thus 
inhibiting T-cell activity.  Sirolimus is not used as widely as tacrolimus 
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although studies have shown that it can be used effectively as an 
immunosuppressive drug [69, 70].   
 
1.4.4 Mycophenolate Mofetil 
Mycophenolate mofetil (MMF) inhibits purine synthesis and selectively 
inhibits the proliferation of B and T cells while maintaining haematopoiesis 
and neutrophil activity [71].  Early clinical trials of MMF in renal 
transplantation showed promising results with a reduction in the rate of 
acute rejection by 30 to 50% when compared with Azathioprine [72, 73].  
This resulted in MMF being widely adopted by the transplant community as 
a more favourable agent to Azathioprine for renal transplantation and 
thereafter for liver, lung and heart transplant patients.  The Symphony study 
explored different immunosuppression regimens and showed that MMF in 
conjunction with low dose tacrolimus results in lower rates of acute 
rejection in renal transplant recipients, improved graft survival and better 
renal function [74, 75].  As a result of this study, MMF has largely replaced 
Azathioprine as part of the primary immunosuppressive regimen across 
renal transplantation, due to better outcomes in terms of acute rejection and 
graft survival as well as allowing a reduction in calcineurin inhibitor 
exposure (primarily tacrolimus) with an associated reduction in side-effects. 
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1.4.5 Belatacept and Biological Agents 
 
The current ‘triple therapy’ immunosuppression regimen of a calcineurin 
inhibitor, an antiproliferative agent and steroids has allowed successful 
transplantation of kidneys and other organs and undoubtedly saved and 
improved many lives.  The burden of immunosuppression, however, is not 
without its drawbacks such as the nephrotoxicity and diabetogenic effects of 
tacrolimus.  The variability of tacrolimus can also be problematic and thus 
interest in other types of immunosuppression has developed in a bid to 
circumvent these problems.  Belatacept, a fusion protein composed of the Fc 
fragment of IgG1 linked to the extracellular domain of cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4), selectively inhibits T-cell 
activation through co-stimulation blockade [76].  The BENEFIT was a 
randomised trial that compared  belatacept based immunosuppression (an 
intense and less intense regimen) against ciclosporin and reported 
significant reduction of 43% risk of death or graft loss for both the intensive 
and less intensive or belatacept compared with ciclosporin. Belatacept is 
associated, however, with increased rates of acute rejection.  A large 
multicentre trial comparing belatacept and tacrolimus is still needed 
however a smaller randomised study of 40 kidney transplant by de Graav et al 
compared tacrolimus with belatacept de novo following kidney 
transplantation and found higher rates of acute rejection at 1 year [77].  The 
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role for belatacept is still under evaluation and with other biological agents 
coming on the market, this expanding class of drugs may help to reduce the 
burden of calcineurin inhibitors in transplant patients. 
 
1.5 Antibody induction 
 
A different group of immunosuppressive agents used routinely in modern 
solid organ transplantation are antibody induction agents.  These agents 
were introduced as early as the 1960s however towards the end of the 1980s 
and early 1990 their use in renal transplantation became much more widely 
established, primarily due to the development of more modern agents that 
could be used in the short term immediately following transplantation 
(known as induction agents) while standard immunosuppression with oral 
medications (calcineurin inhibitor, antiproliferative and steroids) was 
established.  These agents have a defined role for induction of 
immunosuppression although they are not used routinely for maintenance 
immunosuppression.  
The 3 most commonly used induction agents are: 
• Basiliximab (Simulect©), a monoclonal antibody interleukin-2 
receptor antagonist (IL-2RA), which inhibits CD25; 
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• alemtuzumab (Campath©), another monoclonal antibody that 
inhibits CD52 and causes lymphocyte depletion 
• rabbit anti-thymocyte globulin (Thymoglobulin©) a polyclonal anti-T 
cell antibody [78]   
Basiliximab and alemtuzumab have been routinely used for induction 
immunosuppression however basiliximab is now the most widely used 
induction agent in solid organ transplantation.   Anti-thymocyte globulin is 
more commonly used for the induction of ‘high immunological risk’ renal 
transplants (where patients are highly sensitized and have increased risk of 
acute rejection) or the treatment of steroid resistant rejection [78].  
1.5.1 Basiliximab 
Basiliximab is a murine-human chimeric monoclonal antibody to the 
interleukin-2a receptor expressed on the surface of T cells.  Basiliximab has 
a high affinity for the IL-2a receptor and therefore competes with IL-2 and 
blocks the receptor from signalling.  Inhibition of IL-2 signalling prevents 
the upregulation and proliferation of T-cells upon which IL-2 co-
stimulation is dependent.  Basiliximab is the most widely used antibody 
induction agent in renal and simultaneous pancreas-kidney (SPK) 
transplantation, and is used routinely in this unit as induction therapy in 
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combination with tacrolimus, MMF and prednisolone as maintenance 
immunosuppression.   
1.5.2 Alemtuzumab  
Alemtuzumab is a monoclonal antibody directed at the surface glycoprotein 
CD52.  Its exact mechanism remains unclear however its effect is to cause 
significant leukopenia by means of antibody-derived cell lysis of 
lymphocytes which leads to the depletion of T cells and B cells.  It has never 
been licensed for organ transplantation and there have been no phase II/III 
trials performed in solid organ transplantation [79].  Nevertheless its use as 
induction therapy in transplantation has been increasing world-wide (off-
label) and there have therefore been clinical trials conducted to examine its 
efficacy, although the results have been conflicting [80, 81].  A recent multi-
centred randomised trial in the UK, the 3C study, compared alemtuzumab-
based induction therapy followed by low dose tacrolimus, mycophenolate 
and no steroids with standard basiliximab-based therapy (basiliximab 
induction with standard dose tacrolimus, mycophenolate and prednisolone) 
in kidney transplant patients.  This large multicentre study reported a 
significant reduction in biopsy proven acute rejection at 6 months (7% 
alemtuzumab vs 16% basiliximab group, hazard ratio 0.42, log-rank 
p<0.0001) [82].  The long term follow up on graft and patient outcomes is 
still awaited but this could potentially reduce the burden of tacrolimus on 
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transplant patients, reducing nephrotoxicity and other side effects such as 
new onset diabetes after transplantation.  A smaller study by Hanaway et al 
in the New England Journal of Medicine in 2011 examined induction with 
alemtuzumab compared with conventional induction therapy (basiliximab 
for low immunological risk transplants or rabbit antithymocyte globulin 
[rATG] for high immunological risk kidney transplant recipients).  Similar to 
the 3C study, there was a significantly lower rates of acute rejection in the 
alemtuzumab group compared with the basiliximab group at 6 months (3% 
vs 15%, p<0.001) and at 12 months (5% vs 17%, p<0.001).  At 3 years the rate 
of biopsy proven acute rejection in the low-risk group remained significantly 
lower in the alemtuzumab group compared with the basiliximab group (10% 
vs 22%, p=0.003).  There was no significant difference between the 
alemtuzumab group and the rATG group in the high-risk patients (18% vs 
15%, p=0.63) suggesting that the superiority of alemtuzumab was restricted 
to low immunological risk transplants only [83]. 
1.5.3 Rabbit anti-thymocyte globulin (rATG) 
 
Anti-thymocyte globulin (ATG) is a polyclonal antibody derived from the 
sera of rabbits (but also horses and on rare occasions goats) with human 
thymocytes or T cells.  The precise mechanism of action of ATG is not fully 
understood, however its administration brings about T cell depletion by 
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complement-dependent lysis in the blood compartment but it is also 
thought to bring about apoptosis and phagocytosis by macrophages in the 
lymphoid tissue [84].  The effects of ATG are more wide-reaching however 
and B lymphocytes are also targeted by ATG, as it contains a number of 
antibodies against B cell antigens.  There have been both in vitro and in vivo 
studies that have shown how ATG can modulate various other parts of the 
immune system such as intracellular adhesion molecules (ICAM), plasma 
cells, monocytes and dendritic cells, all of which might play a role in the 
human response to ATG administration [85, 86]. 
1.6 Immunosuppression in the Future 
 
 
There have been remarkable developments in immunosuppressive drugs 
since the early days of transplantation such that today organ transplantation 
is highly successful with very significant improvements in short and long-
term outcomes.  Nevertheless, the immunosuppressive agents carry 
significant side effects, require close therapeutic monitoring and are 
expensive for the NHS.  The continued drive to develop new 
immunosuppressive drugs has been more lacklustre in recent years with very 
few new drugs coming on to the market for some time now.  There is 
undoubtedly scope for further improvements of the current 
immunosuppressant regimens, perhaps drugs that do not require to be 
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monitored, a single monotherapy rather than a combination of drugs, fewer 
side effects and so on but it is less certain if, and when, these advances are 
likely to happen or whether an entirely new approach to preventing 
rejection, such as the induction of immune tolerance, will replace standard 
immunosuppression.    
A summary diagram of the different targets of the most common modern 
immunosuppressants is shown below. 
 
Figure 1.4 Cellular targets of modern immunosuppressant drugs 
demonstrating interaction between the T cell receptor and the intracellular 
cascade that follows for steroids, calcineurin inhibitors, mTOR inhibitors and 
anti-prolific agents. 
Kobashigawa et al, Nat Clin Pract Cardiovasc Med, 2006 [87] 
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1.7 Unit Protocols for Immunosuppression in Liver, Kidney 
and SPK Transplants 
 
 
The transplant unit in Edinburgh has standard protocols for induction and 
immunosuppression for liver, kidney and SPK transplantation.   
 
1.7.1 Liver Transplant Immunosuppression 
 
Liver transplant patients do not routinely receive induction therapy with 
basiliximab in the unit.  Standard immunosuppression is with tacrolimus in 
the immediate release formulation Prograf® given at a dose of 0.05 mg/kg 
twice daily.  Azathioprine is given at a dose of 1 mg/kg daily.  Hydrocortisone 
100 mg twice daily is given intravenously on day 1 until the patient is able to 
take prednisolone orally which is then given as 20 mg daily on a reducing 
dose at 5 mg intervals a month at a time.  Prednisolone is eventually 
stopped, with the exception of some conditions such as autoimmune 
hepatitis.  Patients with renal impairment are prescribed mycophenolate 
mofetil 1g twice-daily instead of azathioprine. 
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1.7.2 Kidney Transplant Immunosuppression 
 
The standard immunosuppression protocol consists of induction with 
basiliximab and then ‘triple therapy’ consisting of tacrolimus, 
mycophenolate mofetil and prednisolone for maintenance.  Basiliximab is 
given intravenously in theatre (20 mg) and then again on day 4 post 
transplant.  Tacrolimus is given at 0.05 mg/kg in the form of Prograf® twice-
daily.  Mycophenolate mofetil is given as 1g twice-daily if tolerated and 
prednisolone is given as 20 mg on a reducing dose, every 4 weeks until a 
maintenance dose of 5 mg once daily is achieved.  Methylprednisolone 500 
mg is given in theatre and also at 24 hours post transplant.  The target 
tacrolimus trough concentration range for standard risk transplants is 
between 5-7 µg/L. 
 
Some kidney transplant patients are considered intermediate risk and these 
include SPK recipients, previous transplants, sensitised patients (with a 
calculated reaction frequency of >20%, flow crossmatch positive, HLA-DR 
mis-match or a non-favourable match.  The immunosuppression protocol is 
essentially the same for these patients however the trough concentration is 
kept at between 10-14 µg/L for the first 3 months following transplantation 
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(and are therefore likely to require higher doses of tacrolimus in the region 
of 0.1 mg/kg twice daily) and then 5 – 10 µg/L after 3 months. 
 
Rabbit antithymocyte globulin (rATG) induction therapy is infrequently used 
in this unit however it may deemed appropriate in some high immunological 
risk patients.  It is used at clinician discretion on a case by case basis 
alongside tacrolimus, MMF and prednisolone. 
 
1.7.3 SPK Immunosuppression 
The protocol for SPK transplant patients is the same as for intermediate risk 
kidney transplant patients as described above.  Induction is with basiliximab 
20 mg on day 0 and day 4 and the tacrolimus trough concentrations are kept 
higher for the first 3 months. 
 
1.7.4 Adjusting Tacrolimus Dose in Response to Out of Range Tac 
Level 
When a tacrolimus trough level is below the expected value then the dose of 
tacrolimus will be increased by the transplant physician, normally by 0.5 mg 
per dose.  If the trough concentration is significantly lower than the 
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therapeutic range then the dose may be increased by 1 mg per dose but this 
is at the discretion of the transplant team.  For tacrolimus trough 
concentrations that are higher than the therapeutic range a reduction in the 
dose of tacrolimus by 0.5 mg will usually be made.   
For a trough concentration that is very high, it would be confirmed firstly 
that the trough concentration was a true C0 value by checking the time that 
the tacrolimus was taken and the time that the blood sample was taken.  If 
this confirmed an excessively high trough concentration then often the next 
dose will be omitted, followed by a reduction in the routine dose deemed 
appropriate by the clinical team. 
 
1.8 Therapeutic Drug Monitoring and Tacrolimus 
 
The narrow therapeutic range and the reported patient variability pose 
challenges to transplant clinicians as tacrolimus trough levels require close 
monitoring and adjustments to ensure effective immunosuppression whilst 
minimising the risk of significant systemic side effects and toxicity.  These 
include nephrotoxicity leading to renal impairment, neurological toxicity 
leading to seizures, impairment of glucose tolerance resulting in new onset 
diabetes after transplantation (NODAT), myositis, gastrointestinal 
disturbances such as diarrhoea, hypertension, increased risk of malignancy 
 58 
such as skin cancers as well as increased risk of cardiovascular disease [88, 
89].  The requirement to keep tacrolimus within a narrow therapeutic 
window has resulted in therapeutic drug monitoring being utilised to 
monitor tacrolimus levels and make dose adjustments based on tacrolimus 
trough (C0) concentrations from whole blood.  
A variety of methods can (and have) been used to monitor the trough levels 
of different immunosuppressant drugs including immunoassays and 
chromatography based methods [90].  While immunoassays are widely used 
in therapeutic drug monitoring generally, they fall short in monitoring 
immunosuppressant medication due to the lack of specificity for the parent 
drug such as tacrolimus or ciclosporin, as they tend to overestimate the drug 
levels [91].  The alternative to the immunoassay technique are 
chromatographic techniques.  These are much more selective and have 
higher sensitivity and specificity than immunoassays.  Gas chromatography 
has been used but it requires the drug to be volatile in order to be measured 
requiring additional steps in the process making it less efficient and 
potentially more costly.  Liquid chromatography with ultraviolet detection is 
another method which has been used for therapeutic drug monitoring 
(TDM), but there are limitations of specificity with certain compounds 
requiring extensive sample preparation.  A newer technique is now available 
which couples liquid chromatography to a mass spectrometer, so called 
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liquid chromatography tandem mass spectrometry (LC-MS/MS) [91].  The 
LC-MS/MS method is favoured due to its high sensitivity, specificity, short 
analysis time and therefore increased throughput and lower cost.  
Additionally, it can be used to monitor levels of tacrolimus, ciclosporin, 
sirolimus and everolimus simultaneously making it efficient and cost 
effective.  The LC-MS/MS method is used in the hospital laboratory at this 
centre for measuring the tacrolimus trough levels in transplant patients. 
 
1.9 Inter patient variability in tacrolimus trough levels 
 
 
Therapeutic drug monitoring is required for patients taking tacrolimus not 
only because it is effective within a narrow therapeutic range, but also 
because the dose of the drug required in order to achieve that therapeutic 
level, without causing toxicity, varies considerably from person to person 
and can be influenced by a number of different  factors which include, but 
are not limited to, age, gender, weight, ethnic group, post-operative day (in 
the immediate transplant period before steady state is reached), number of 
days following starting tacrolimus therapy, liver metabolic function,  
haematocrit, albumin, creatinine clearance, corticosteroid dose, 
concomitant drug therapies which are inducers of cytochrome P450, time 
taken in relation to food and patient adherence with medication [43, 92].  
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Additionally, underlying disease process requiring a transplant (e.g. diabetes 
with associated GI tract complications) and the type of organ transplanted 
(liver, kidney, pancreas, small bowel etc.) can influence the 
pharmacokinetics of tacrolimus [93, 94].  
Most patients will, therefore, require several dose adjustments in the early 
post-transplant period until they reach a ‘steady state’ (a consistent blood 
concentration of the drug).  This also means that the early post-transplant 
period is the time with the highest risk of acute rejection which can have a 
negative impact on long term graft survival [95].   
Despite the numerous factors that influence tacrolimus trough levels, 
current practice is to prescribe the initial dose of tacrolimus based on the 
weight of the patient and the desired initial tacrolimus level for each type of 
transplant.  While this method remains adequate for most patients, 
publications in the late 1990s have shown that different ethnic groups, such 
as black ethnic origin, required significantly higher doses of tacrolimus in 
order to achieve comparable therapeutic levels [96-98].  Given the presumed 
genetic basis for these observed differences among different ethnic groups, 
researchers began to consider the possible genes which could influence drug 
pharmacokinetics as an explanation for these variations.  It was known that 
tacrolimus was transported out of the enterocyte by the drug transporter P-
glycoprotein, thus reducing the amount available for systemic absorption, 
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and also that it was almost completely metabolised in the liver by 
cytochrome P450 [45, 99]. 
In 2002 Macphee et al investigated the expression of different single 
nucleotide polymorphisms (SNPs) of the multi-drug resistance gene (MDR-
1) which encodes for P-glycoprotein and the CYP3AP1 pseudogene which 
was closely related to CYP3A5 activity in renal transplant recipients of 
different ethnicity [100].  The authors showed that patients who possess a G 
allele at the 44 locus of CYP3AP1 had a significant reduction in tacrolimus 
concentrations compared with those of the AA genotype.  The effect was 
noted in all patients, although G allele expression was more common in 
black transplant recipients.  This suggested that SNPs of genes relating to 
hepatic cytochrome P450 (3A5) activity rather than ethnicity itself are 
responsible for the differences seen between individuals in the tacrolimus 
exposure following standard dose administration.  Macphee et al also 
examined a SNP of the MDR-1 gene, namely the C3435T transition, where 
expression of a T allele (much more common in Caucasians) is associated 
with decreased P-glycoprotein expression which should therefore increase 
systemic absorption from the gastrointestinal tract.  A modest reduction in 
tacrolimus concentrations was noted in transplant recipients who expressed 
the CC genotype (no T allele expression and therefore no reduction in P-
glycoprotein activity).  This was a novel finding as the consensus at the time 
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was that gut absorption of tacrolimus, influenced by P-glycoprotein 
expression, was the major contributor of systemic bioavailability [101].  
Macphee et al demonstrated that the influence of P-glycoprotein on 
tacrolimus bioavailability was lower than previously predicted and that 
cytochrome P450 3A5 activity had the greater influence.   
 
1.10 Genetic Polymorphisms and Tacrolimus   
Pharmacokinetics 
 
The impact of the polymorphisms of genes related to drug transport and 
metabolism on tacrolimus exposure in transplant patients led to further 
research in this field  [102-104].  Two main SNPs are thought to play a major 
role – the CYP3A5 6986A>G transition and the ABCB1 3435 C>T transition 
(ATP-binding cassette sub-family B member 1) which encodes P-
glycoprotein.  As the evidence base for CYP3A5, in particular, started to 
increase, researchers started to look other potential SNPs which might 
influence tacrolimus pharmacokinetics.  In 2011 Elens et al described a new 
functional CYP3A4 polymorphism on intron 6, named CYP3A4*22, which 
influenced the pharmacokinetics of tacrolimus in renal transplant 
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patients[105].  This is a topical subject and there is an ongoing search for 
further SNPs that influence tacrolimus pharmacokinetics. 
 
1.10.1  ABCB1 3435 C>T 
 
ABCB1 is a gene which encodes for the ATP-dependent drug efflux 
transporter molecule P-glycoprotein.  It is located on chromosome 7q21.12 
and consists of 29 exons which span a genomic region of 209.6 kilobases 
(kb).  The messenger RNA (mRNA) consists of 4872 base pairs which, in turn, 
results in a protein of 1280 amino acids named P-glycoprotein [106].   
 
Figure 1.5 ABCB1 position on Chromosome 7 
(www.genecards.org - GC07M087504) 
P-glycoprotein (P-gp) is a transmembrane protein which functions as an 
ATP-dependent efflux pump for xenobiotic compounds with broad substrate 
specificity.  It can be found expressed in many body tissues (adrenal gland, 
gut, bile ducts, lung, brain, ovaries and numerous different cells of the 
immune system)  [102, 107].  The P-gp protein actively pumps certain 
molecules (of which tacrolimus is one), out of the cell and therefore normal 
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physiologic expression of P-gp can result in reduced drug uptake in certain 
key tissues where it is widely expressed.  Therefore P-gp plays a vital role in 
the bioavailability of various drugs including chemotherapy agents, 
antibiotics, immunosuppressants and anti-retroviral protease 
inhibitors[108].  Pre-clinical studies with P-gp knockout mice have shown 
significantly higher concentrations of both ciclosporin and tacrolimus in the 
brain [109, 110].   
Of the numerous SNPs of ABCB1 three have been widely studied – C1236T 
(rs1128503), C3435T (rs1045642) and G2677T/A (rs2032582). 
The C3435T mutation is found on exon 26 at the 3435 position and results in 
a ‘wobble’ rather than an amino acid change whereby a small mutation 
occurs in the codon resulting in a different base pair however the amino acid 
produced is the same.   The wild type sequence is AGATCGTGA and the 
mutation is AGATTGTGA so the ‘wobble’ is at the 3435 position C>T.  It has 
been suggested that this mutation may exert an effect by linkage 
disequilibrium [111], reducing the stability of mRNA leading to a reduction 
in ABCB1 mRNA [112] or by affecting the timing of folding and insertion of 
P-gp into the cell membrane which, in turn, reduces its substrate specificity 
[113].  The C3435T mutation has been shown to decrease the amount of P-gp 
expressed in the duodenum of healthy volunteers with those of the CC 
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genotype expressing the most P-gp and those of the TT genotype expressing 
the least [114]. 
C3435T and G2677T/A SNPs have been reported to play a role in tacrolimus 
pharmacokinetics [100, 115, 116].  
To date there have been numerous studies examining the relationship 
between the C3435T SNP and the pharmacokinetics of calcineurin inhibitors.  
Most studies have looked at adult renal transplant patients although there 
have been reports into liver, heart, lung and paediatric renal transplantation 
too.  A small number of studies have shown that a TT allele expression of the 
C3435T SNP was associated with a higher dose corrected tacrolimus level 
[tacrolimus trough (C0)/dose value], which meant that there was a lower dose 
requirement to reach therapeutic target levels [100, 117-120].  Hesselink et al 
reported such findings in a study of 136 renal transplant patients and found 
that patients with the TT genotype had a 23% higher dose corrected 
tacrolimus level and a 19% lower tacrolimus dose requirement when 
compared with the CC genotype patients [119].   
There are, however, more than 20 studies which have not demonstrated an 
effect of the C3435T mutation of ABCB1 on tacrolimus pharmacokinetics 
which suggest, perhaps, that when looked at in isolation, the C3435T 
mutation of ABCB1 does not exhibit as significant an effect as first thought 
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[103, 104, 116, 121-137].  There are some studies that suggest the C3435T 
mutation of ABCB1 may have more of an effect when combined or linked 
with other SNPs rather than in isolation.  In a study of 44 renal transplant 
patients, there was a cumulative effect of three SNPs of ABCB1 (C3435T, 
C1236T and T-129C) suggesting that patients who express more variant 
alleles of ABCB1 SNPs have reduced P-glycoprotein functionality leading to 
greater systemic drug absorption as less of the substrates are actively 
pumped out of the enterocyte by P-gp [111][125].  In this study patients who 
had less than 3 of the variant ABCB1 alleles (3435T, 2677T, -129C) had a 
significantly reduced dose corrected tacrolimus level when compared with 
patients who expressed the variant allele of all 3 SNPs.  
 
1.10.2  CYP3A5 6986 A>G  
 
The cytochromes P450 are a superfamily of enzymes which play a significant 
role in the metabolism of drugs, steroid synthesis and the synthesis of 
cholesterol and other lipids. Their name is derived from the spectral 
absorbance peak when bound with carbon monoxide at 450 nm. These 
enzymes use haem iron (hence why they are often known as 
haemeoxygenases) in order to oxidise compounds and make them water 
soluble and easier to clear.  
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The cytochrome P450 enzymes are monooxygenases due to the fact that 
they catalyse only one atom of molecular oxygen into the substrate and 
reduce the other one to water.  The cytochromes P450 proteins form part of 
an electron transport system where they will accept 2 electrons from 
nicotinamide adenine dinucleotide phosphate (NADPH) sequentially to 
cytochrome P450, catalysed by cytochrome P450 reductase.  This process is 
characterised as follows, where RH is the substrate: 
RH + O2 + NADPH + H+                                          ROH + H2O + NADP+                            [138] 
 
The human genome project has identified 57 different genes and 58 
pseudogenes which encode for the cytochrome P450 proteins.  These have 
been assigned agreed nomenclature by the human cytochrome P450 
nomenclature committee such that each enzyme name starts with CYP, 
followed by a numerical family number, a letter designating the sub-family 
and then a number designating the polypeptide if appropriate.  The different 





Table 1.1 Different classifications of the currently identified cytochrome P450 
subgroups. 
sterols xenobiotics fatty 
acids 
eicosanoids vitamins unknown 
1B1 1A1 2J2 4F2 2R1 2A7 
7A1 1A2 4A11 4F3 24A1 2S1 
7B1 2A6 4B1 4F8 26A1 2U1 
8B1 2A13 4F12 5A1 26B1 2W1 
11A1 2B6  8A1 26C1 3A43 
11B1 2C8   27B1 4A22 
11B2 2C9    4F11 
17A1 2C18    4F22 
19A1 2C19    4V2 
21A2 2D6    4X1 
27A1 2E1    4Z1 
39A1 2F1    20A1 
46A1 3A4    27C1 
51A1 3A5     
 3A7     
 
Cytochromes P450 are the key component of phase I drug metabolism in 
humans, found primarily in hepatocellular microsomes,  but can also be 
found in many other tissues such as the prostate, kidney and gut  [140]. 
Cytochromes P450 metabolise thousands of endogenous and exogenous 
substances with considerable variation in the number of substrates any one 
cytochrome P450 protein will act upon.  Overall, cytochrome P450 enzymes 
are involved in the metabolism of approximately 75% of the drugs commonly 
used today [141]. 
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Tacrolimus undergoes extensive oxidative metabolism by liver microsomes 
when it is given orally or intravenously with only a small amount of drug 
excreted unchanged in the urine [142].  The cytochrome P450 enzymes 
involved in the metabolism of tacrolimus belong to the CYP3A subfamily, 
primarily CYP3A4 and CYP3A5.   
The gene which encodes for CYP3A5 is located on chromosome 7 at position 
7q22.1 and consists of 13 exons and spans 31.8 kilobases.  It is closely 
related to a cluster of cytochrome P450 genes and pseudogenes on 7q22.1, 
one of which is the pseudogene CYP3A5P1 which is very similar to CYP3A5.  
The CYP3A5 protein consists of 502 amino acids with a molecular weight of 
52.5kD. 
 
Figure 1.6 CYP3A5 position on Chromosome 7 
www.genecards.com - GC07M099648 
 
CYP3A4 and CYP3A5 are the two major isoforms of the CYP3A family which 
are expressed in humans.  While CYP3A4 is found in all humans and 
expressed predominantly in the liver and the small intestine, CYP3A5 is only 
expressed in those individuals who carry at least one copy of the A allele 
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(which is known as CYP3A5*1).  Although the CYP3A5*1 (A allele) is the wild 
type it is, somewhat unusually, expressed less frequently than variant allele 
CYP3A5*3 or the G allele.  Those individuals who are homozygotes for the G 
allele (and are therefore designated CYP3A5*3/*3), will only make a 
negligible amount of CYP3A5 which will not play a role in tacrolimus 
metabolism, while conversely those who carry the  CYP3A5*1 allele will 
produce functional CYP3A5 which will extensively metabolise tacrolimus in 
vitro [143-145]. 
CYP3A4 differs from CYP3A5 in that although there are numerous genetic 
polymorphisms of CYP3A4, there is no SNP which results in an absence of 
CYP3A4 functionality.  In contrast, only those individuals who 
polymorphically express a CYP3A5*1 allele (either as a *3/*1 heterozygote or 
a *1/*1 homozygote) will make any functional CYP3A5.  This SNP is a result 
of an A>G transition at the 6986 position of intron 3 of the CYP3A5 gene.  
Therefore, those who carry a CYP3A5*1(A) allele are termed ‘expressers’ of 
CYP3A5 and those who do not are termed ‘non-expressers’ [143, 146]. 
Tacrolimus is transformed into eight different metabolites [M-I to M-VIII] 
and consist of three mono-demethylated metabolites, three di-methylated 
metabolites, one mono-hydroxylated metabolite and a final metabolite 
which undergoes multiple different reactions [147, 148].  Of these 8 
metabolites, there are 4 primary metabolites which clear the majority of 
 71 
tacrolimus [13-O-desmethyl tacrolimus (13-DMT or M-I), 15-O-desmethyl 
tacrolimus (15-DMT or M-III), 31-O-desmethyl tacrolimus (31-DMT or M-II) 
and 12-hydroxy tacrolimus (12-HT or M-VI)] [145]. 
In-vitro studies of both human and animal models have shown the formation 
of the M-I metabolite (13-O demethylation) was the most significant 
metabolic pathway in the first stage of tacrolimus metabolism when cultured 
with liver microsomes fortified with NADPH under aerobic conditions [149].  
These in vitro studies suggest that tacrolimus goes through sequential 
metabolism from M-I to M-VII before proceeding to more polar metabolites, 
catalysed by CYP3A4/5. 
In vitro porcine models have shown that CYP3A5 produces both desmethyl 
and hydroxyl metabolites of tacrolimus whereas CYP3A4 only results in 
desmethyl metabolites suggesting that CYP3A5 plays the more significant 
role in the metabolism of tacrolimus [150]. 
There is considerable variation in the expression of CYP3A5 across different 
ethnic groups. Approximately 15-20% of Caucasians express CYP3A5 either 
as a *3/*1 heterozygote (13-15%) or as a *1/*1 homozygote (3-5%).  
Conversely approximately 85% of individuals of African (Black) ethnicity 
express CYP3A5 as *1/*3 (60%) or *1/*1(25%) [151].  In the South Asian 
ethnic group, approximately 38% of patients express the *1/*3 genotype and 
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13% express the *1/*1 genotype [152].  Variation has also been reported in 
Chinese patients, however the approximate distribution of genotypes in 
these patients show around 11-15% of the *1/*1 genotype, 35-40% of the 
*1/*3 genotype and 55-60% of the *3/*3 genotype [120, 133].  
Furthermore, differences in the genotype distribution and allele frequencies 
of CYP3A5 were noted even across different Caucasian populations, different 
Asian groups and even across different regions of the one country such as 
China [153].  To date no study explored the allele frequencies or genotype 
distribution of the different SNPs in a Scottish population. 
In stark contrast to the equivocal nature of the impact of ABCB1 
polymorphisms on tacrolimus pharmacokinetics, the polymorphisms 
associated with CYP3A5, namely the A6986G transition, have been 
consistently shown to impact on tacrolimus metabolism and clearance 
across different organ transplants including kidney, liver and heart as well as 
in healthy volunteers [111].  In renal transplantation nearly all studies have 
shown an increased dose requirement and a significantly reduced dose 
corrected tacrolimus level (suggesting lower tacrolimus exposure) in those 
individuals who are carriers of at least one CYP3A5*1 allele (CYP3A5 
expressers) compared with individuals who are CYP3A5*3 homozygotes 
(CYP3A5 non-expressers)  [154].  Most studies have shown that patients who 
are CYP3A5 expressers require nearly twice as much tacrolimus in order to 
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achieve the same therapeutic trough levels (C0) as CYP3A5 non-expressers 
[104, 119, 122, 124, 131, 137, 152, 155-157].  A study by Op den Buijsh et al 
examined 63 Caucasian renal transplant patients and found that the dose 
corrected level (C0/D) was 2-fold lower in CYP3A5 expressers compared with 
non-expressers [123].  Similarly, a study by Hesselink et al in 136 renal 
transplant recipients reported that CYP3A5 expressers had a 68% higher 
dose requirement by day 3 after transplantation compared with non-
expressers of CYP3A5 [119]. 
Individuals who are CYP3A5*1 allele carriers may have different 
pharmacokinetics of tacrolimus and given the narrow therapeutic index of 
the drug, this could have a significant clinical impact with an increased risk 
of rejection if there are delays in reaching therapeutic level post-transplant 
and low systemic exposure to tacrolimus [158].  There is evidence that 
CYP3A5 expressers take a longer time to reach therapeutic tacrolimus levels, 
even as part of a therapeutic drug monitoring (TDM) strategy, with some 
patients still not achieving therapeutic C0 levels as far as 2 weeks post 
transplant [103][125].   Some studies described increased acute rejection 
rates within the first 3 months following transplantation in CYP3A5 
expressers [159, 160] although this was not seen in other reports [119].   
However, a recent meta-analysis by Tang et al concluded that CYP3A5 
expressers run a higher risk of acute rejection within the first month post 
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transplantation because of the longer time to achieve therapeutic tacrolimus 
levels and the reduced initial tacrolimus exposure [161]. 
The correlation between CYP3A5 expression and other clinical outcomes, 
such as renal function and the nephrotoxic effects of tacrolimus have been 
investigated [162].  As for acute rejection there are some conflicting data. 
Most studies did not find any association between CYP3A5 A6986G genotype 
and renal function [119] [163] [164] [125] [127])  although a study by Fukudo 
et al found that recipient non-expression of CYP3A5 (*3/*3 homozygotes) 
had greater nephrotoxicity compared with expressers [165].  The authors 
suggested that CYP3A5 expression in the kidney may have had a protective 
effect but further work in this area is needed before any definitive 
conclusions can be drawn.  
There appears to be an association between CYP3A4/CYP3A5 and salt 
dependant hypertension [166] and CYP3A5*1 allele carriers renal transplant 
recipients demonstrated a sustained elevation of their mean arterial blood 
pressure when compared with CYP3A5*3 homozygotes [163].  There have 
been no studies to date examining a correlation with the development of 
diabetes after transplantation (NODAT) whilst graft survival and patient 
survival appear to be unaffected by CYP3A5 expression [135, 162]. 
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While the clinical impact of the CYP3A5 SNP is highly variable and 
considerably less well established, the impact on tacrolimus 
pharmacokinetics is well established in in all organ transplants and appears 
to be independent of the patient’s ethnic group (although expression of 
CYP3A5 is very closely related to ethnicity), gender and age [154].   
 
1.10.3 CYP3A4*22 15389 C>T  
 
CYP3A4 is expressed in all individuals and is found primarily in the liver and 
small intestine with very little expression in the renal tissue [167].  Similar to 
CYP3A5, CYP3A4 is polymorphically expressed, although a polymorphism 
that results in total loss of CYP3A4 activity has not yet been identified.  
CYP3A4 metabolises tacrolimus in a NADPH dependent fashion similar to 
CYP3A5, although when CYP3A5 is expressed it appears to have a more 
dominant role than CYP3A4 does.   
CYP3A4 is found in the same cluster of genes on chromosome 7 (7q22.1) as 
CYP3A5 and is 23.7kb in size.  It encodes a protein consisting of 503 amino 




Figure 1.7 CYP3A4*22 position on Chromosome 7 
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Until recently, the most studied SNP of CYP3A4 was the A>G transition at 
position -392 in the nifedipine specific element (NFSE) of the 5’-flanking 
promotor region of the CYP3A4 gene [111].  There are some in vitro studies 
which suggest that the CYP3A4 A-392G polymorphism is associated with 
increased CYP3A4 activity [168] although this is not widely supported [169, 
170].  The evidence suggesting that CYP3A4 A-392G SNP influences 
tacrolimus pharmacokinetics is scarce, but the data are so limited that is 
difficult to determine whether this is a true effect or whether it is artefactual 
and is secondary to expression in different ethnicities and/or linkage 
disequilibrium with CYP3A5 A6986G [104, 119, 123]. 
Interest in CYP3A4 activity was re-ignited when Elens et al reported the 
discovery of a functional new CYP3A4 polymorphism which had been termed 
CYP3A4*22.  This SNP was found on intron 6 of the CYP3A4 gene and 
consisted of a C>T transition at the 15389 position (rs35599367) and was 
associated with reduced CYP3A4 activity resulting in increased systemic 
exposure to tacrolimus in renal transplant patients [171].  This study 
reported that the variant (T) allele frequency was low (3.5%) but it was also 
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not in linkage disequilibrium with CYP3A5*3.  The expression of the variant 
CYP3A4*22 T allele corresponds with significantly increased tacrolimus C0 
levels when corrected for dose and a reduced dose requirement to achieve 
therapeutic levels compared with the wild type CYP3A4*1/*1 genotype (CC) 
[105].  T allele carriers had a significantly higher C0 level (20.5 µg/L) 
compared with the CC non expresser genotype (14.9 µg/L), (p=0.05) despite 
similar doses of tacrolimus (both groups in the region of 13 mg/day) [105]. 
In vitro studies using hepatic tissue have also demonstrated that expression 
of the CYP3A4*22 variant is associated with reduced CYP3A4 activity in 
response to statin drugs, as well as a reduction in CYP3A4 mRNA expression 
[172, 173]. 
Elens et al used the breakdown of midazolam into its hydroxylated 
metabolite 1-OH-MDZ as a drug probe to assess the in vivo activity of 
CYP3A4*22 and concluded that those patients who carried the variant T 
allele of CYP3A4*22 had 20% lower CYP3A4 activity compared with those 
who did not [174].  Using a similar method, Jonge et al suggested that the 
renal transplant patients who were non-expressers of CYP3A5 (*3/*3) but 
who expressed the CYP3A4*22 variant genotype had significantly higher 
exposure to tacrolimus at 12 months when steady state had been achieved.  
They reported that the mean total oral clearance of tacrolimus was 36.2% 
lower in those patients who carried the variant CYP3A4*22 (T) allele and this 
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translated into a 50% reduction in tacrolimus dose requirement in order to 
achieve a therapeutic C0 level [175].  Furthermore, these patients had greater 
tacrolimus exposure, reduced dose requirements and achieved supra-
therapeutic tacrolimus levels with potential adverse effects related to 
tacrolimus toxicity [176]. 
While Elens et al have consistently shown a significant influence of the 
CYP3A4*22 genotype on tacrolimus pharmacokinetics, Moes et al and 
Santoro et al showed only a trend towards reduced tacrolimus exposure in 
their respective cohorts (the latter a Brazilian population where CYP3A5 
expression is more prevalent) [177, 178].  These inconsistencies may be 
explained by the very low allele frequency of CYP3A4*22 with only 8% of the 
Caucasian population expressing a T allele variant of CYP3A4*22.  Similarly, 
the effect of CYP3A4*22 expression appears to be more pronounced in 
CYP3A5*3/*3 non-expressers so in populations where CYP3A5*1 expression 
is greater, the impact of CYP3A4*22 expression may be reduced. 
The effect of CYP3A4*22 requires further investigation but there is 
increasing evidence suggesting that it may play a significant role in 
tacrolimus pharmacokinetics in the small number of individual who express 
the variant allele.  However, the clinical impact of the expression of 
CYP3A4*22 is still unclear.  Elens et al have shown that renal transplant 
patients who expressed the CYP3A4*22 variant allele and were taking 
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ciclosporin immunosuppression had significantly increased rates of delayed 
graft function (DGF) and a 20% lower creatinine clearance compared with 
the CYP3A4*1/*1 wild type [179].  Somewhat surprisingly, a recent 
longitudinal study suggested that there may be a protective effect of 
tacrolimus over-exposure in the CYP3A4*22 variant group with creatinine 
clearance on average 21% higher compared with the wild type CYP3A4*1/*1 
genotype [180]. 
Given that evaluation of this SNP is still in early stages, further studies are 
required before the clinical impact of the CYP3A4*22 polymorphism in 
relation to tacrolimus exposure is fully understood. 
 
1.11 Pharmacogenomics and organ transplantation 
 
Transplantation poses an interesting challenge, as the pharmacokinetics of 
tacrolimus will be influenced by each patient’s specific genotype as well as 
the genotype of the transplanted organ.  Multiple factors can play an 
important role including the genotype of the recipient and the donor, the 
disease process requiring transplantation in the first place and the type of 
tacrolimus preparation.   
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In renal transplantation, the recipient’s own genotype is likely to have the 
predominant influence on tacrolimus pharmacokinetics. While there is 
evidence of some CYP3A5 expression in the kidney, the hepatic and gut 
expression are far more influential. Therefore, the recipient’s native 
cytochrome P450 SNPs of CYP3A4(*22) and CYP3A5, as well as ABCB1 
polymorphisms and P-gp expression account for most differences. Studies 
examining the impact of the donor genotype in renal transplantation are 
scarce however Glowacki et al showed that donor genotype of both CYP3A5 
and ABCB1 had no impact on tacrolimus pharmacokinetics [181].  
In liver transplantation, things are somewhat different. The majority of 
cytochrome P450 activity takes place in liver tissue and therefore the donor 
genotype, particularly that of CYP3A5, could exert a much more significant 
role, possibly even more than the recipient’s own CYP3A5 genotype.  There 
is some evidence to support this hypothesis. Wei-lin et al found that the 
donor’s CYP3A5 genotype in association with the recipient’s ABCB1 
genotype significantly affected tacrolimus pharmacokinetics in Chinese liver 
transplant patients [120].  Yu et al also found that donor liver expression of 
CYP3A5*1 allele was associated with a reduced dose corrected tacrolimus 
level (C0/D) at 1 month  but critically, the donor genotype had a greater 
influence than the recipient genotype [182].  This was also seen in a 
Caucasian population in an Italian study that suggested that the donated 
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liver genotype played a more significant compared to the recipient genotype. 
Recipients who received a liver graft from a CYP3A5 expresser had 
significantly higher dose requirements, whilst the recipients who carried at 
least one CYP3A5*1 allele only tended towards higher dose requirements 
(without reaching statistical significance) [183]. 
A recent meta-analysis of 8 studies which included 694 adult liver transplant 
recipients found that donor livers that carried a CYP3A5*1 allele had 
significantly reduced C0/D ratios compared with those livers that did not 
express CYP3A5 (*3/*3 homozygotes) [184].  To date, there have been no 
studies in UK liver transplant patients examining the role of CYP3A5 or 
ABCB1 polymorphisms in the donor or recipient and the influence on 
tacrolimus pharmacokinetics.  Furthermore, there have no studies 
examining the impact of donor or recipient CYP3A4*22.  
There is a lack of data on ABCB1 polymorphisms or CYP3A4/3A5 
polymorphisms in simultaneous pancreas-kidney (SPK) transplant 
recipients. It is conceivable that these patients have an identical 
pharmacokinetic profile to renal transplant patients based on the genotype 
expression of CYP3A4/CYP3A5/ABCB1 polymorphisms. However due to the 
higher incidence of gastroparesis and gut dysmotility secondary to diabetic 
autonomic neuropathy, the Absorption, Distribution, Metabolism and 
Excretion (ADME) parameters may be different.  In particular the ABCB1 
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C3435T polymorphism which encodes P-gp may be more relevant here as the 
transit of tacrolimus and the rate of gut absorption may be altered in SPK 
patients who have gastroparesis or gut dysmotility.  As the expression of P-
gp differs between the proximal and distal gut [56] the expression of a T 
allele in of the C3435T polymorphism of ABCB1 may have a more 





The last 20 years of tacrolimus use in organ transplantation have clearly 
demonstrated multiple factors which can influence its pharmacokinetics and 
the narrow therapeutic window in which tacrolimus is effective means these 
factors require thorough investigation.  By understanding the influence of 
genetic polymorphisms on tacrolimus pharmacokinetics across different 
organ transplant groups, we can begin to move towards individualised 
dosing plans for every patient, minimising the risk of sub-therapeutic or 
supra-therapeutic tacrolimus exposure and the sequelae that come with 
that.  We hope this study will re-enforce work already done in renal 
transplant patients, and add to the currently small evidence base in liver 
transplant patients, particularly in relation to donor genotypes.  There is 
currently no published data on the influence of genetic polymorphisms in 
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SPK transplantation and we hope to provide some of the earliest data in this 
transplant group.  As use of modified release tacrolimus (Tac-QD) becomes 
more widespread it will be important to understand how genetic 
polymorphisms might affect tacrolimus exposure and we hope to add 
valuable data to this field. 
 
1.13 Aims of the thesis 
 
 
This study aims to describe the distribution of genetic polymorphisms of 
ABCB1, CYP3A5 and CYP3A4*22 in a representative sample of the Scottish 
population and investigate to what extent these polymorphisms affect the 
pharmacokinetics of tacrolimus in patients who have undergone, liver, 
kidney or combined pancreas-kidney transplantation.  We aim to achieve 
this by: 
 
1. Performing a genotype analysis of CYP3A5 A6989G, ABCB1 C3435T 
and CYP3A4 C15389T in a large sample of Scottish population who 
have donated their DNA to Generation Scotland bioresource.  We will 
compare this genotype analysis to previously published data in 
different countries. 
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2. Performing a donor and recipient genotype analysis of these three 
SNPs in a cohort of liver transplant patients and investigate the 
impact of the expression of these polymorphisms in donor and 
recipient on tacrolimus dose requirements and C0 levels and relate 
these to clinical outcomes. 
3. Performing a genotype analysis of the SNPs in a cohort of renal 
transplant patients and correlate the expression of these 
polymorphisms with the tacrolimus dose requirements and C0 levels 
and the clinical outcomes. 
4. Performing a genotype analysis in a cohort of simultaneous pancreas-
kidney (SPK) transplant patients and investigate the same 
pharmacokinetic and clinical outcomes. 
5. Investigating a cohort of stable renal transplant patients who have 
been converted from twice-daily tacrolimus (Tac-BD) to once-daily 
modified release tacrolimus (Tac-QD) in relation to dose 
requirements and tacrolimus C0 levels following conversion.  We will 
investigate a smaller sub-cohort of these patients where stored DNA 
is available for genotype analysis and determine what impact the 
three SNPs of interest on Tac-QD pharmacokinetics.  Finally, we will 
analyse the intra-patient variability and determine if there is any 
difference in intra-patient variability between Tac-BD and Tac-QD.  
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We will explore whether increased intra-patient variability has any 




1. The genotype analysis of the Scottish population in this study will 
reveal that the genotypes and allele frequencies of CYP3A5, ABCB1 
3435 C>T and CYP3A4*22 are similar to other Caucasian populations 
that have previously been studied. 
2. In liver transplant patients – for CYP3A5 and CYP3A4*22 which are 
cytochrome P450 enzymes found primarily in liver tissue – the donor 
genotype will have a greater influence than the recipient on 
tacrolimus pharmacodynamics. 
3. Patients who express the CYP3A5 enzyme (genotype GA or AA) or for 
liver transplant patients where the donor expresses CYP3A5 will 
require a significantly higher dose of tacrolimus to achieve a 
therapeutic concentration and are likely to take longer to reach a 
therapeutic concentration compared with non-expressers of CYP3A5. 
4. ABCB1 genotype is less likely to significantly change tacrolimus 
pharmacodynamics in any of the patient groups. 
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5. Patients who express the CYP3A4*22 T allele (genotype CT or TT) or 
for liver transplant patients where the donor expresses a T allele may 
require a reduced dose of tacrolimus in order to achieve a therapeutic 
trough concentration. 
6. Patients who express CYP3A5 or liver transplant patients where the 
donor expresses CYP3A5 may have increased rejection due to a likely 
delay in achieving a therapeutic trough concentration. 
7. Graft and patient survival is unlikely to be significantly influenced by 
the different genotypes of CYP3A5, ABCB1 and CYP3A4*22 
8. Renal transplant patients who are converted to once-daily tacrolimus 
are likely to require an increased dose if they are CYP3A5 expressers 
and may require a reduced tacrolimus dose if they express a T allele of 
CYP3A4*22. 
9. Conversion from twice-daily tacrolimus to once-daily tacrolimus in 
renal transplant patients is likely to reduce intra-patient variability.  
Patients with high intra-patient variability are likely to have greater 





















2 MATERIALS AND METHODS 
 
There were 3 distinct cohorts of patients that were included in this thesis.  
The first is a large sample of the healthy Scottish population who were 
genotyped for the 3 SNPs of interest in order to describe the distribution in a 
Scottish population.  The second group were patients who had undergone 
liver, renal or combined kidney/pancreas transplant in the Edinburgh 
transplant unit and the third were a group of renal transplant patients who 
had been converted from the standard twice-daily Tac-BD formulation of 
tacrolimus to the modified release, once-daily Tac-QD.  The clinical and 
laboratory methodology for each of these groups is described below. 
 
 
2.1 Generation Scotland Methodology 
 
 
DNA samples from a total of 5889 subjects were genotyped for CYP3A5 6986 
A>G transition, ABCB1 3435 C>T transition and the CYP3A4*22 intron 6 C>T 
transition using the Taqman® drug metabolism genotyping assay and real-
time PCR technique described below in the laboratory methodology section.  
The DNA for analysis was available from two distinct sources.  The first 
source was stored DNA in the Histocompatibility and Immunogenetics 
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laboratory involved in the tissue typing of transplant patients.  We analysed 
DNA samples from 305 kidney transplant recipients, 48 simultaneous 
pancreas-kidney transplant recipients, 252 liver transplant recipients and 
385 deceased organ donors.   
The second cohort of DNA samples for analysis was obtained from the 
Generation Scotland Bioresource. The cohort of samples used in this study 
was from the Generation Scotland 3D (GS:3D) study where healthy blood 
donors consented for the storage of their DNA following blood donation.  
The DNA from this cohort was obtained from the leukocyte filters used as 
part of the blood donation process [185].  A total of 4899 GS:3D samples 
were used in this study.  In addition to the genotype of each sample, basic 
demographic (gender, ethnic group and age) data was collected for the entire 
cohort. 
 
2.2 Patient selection process 
 
 
All adult patients (> 18 years of age) who received a kidney or a simultaneous 
kidney-pancreas transplant between January 2008 and August 2012 and were 
prescribed tacrolimus in the form of PrografÒ (Tac-BD) were included in the 
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analysis.  Patients who were prescribed AdvagrafÒ (Tac-QD) modified release 
or those who were not prescribed tacrolimus were excluded from the study. 
For the liver transplant study the same inclusion/exclusion criteria were 
applied however patients were transplanted between January 2007 and 
August 2012.   
Patients without a stored DNA sample were excluded.  In the liver transplant 
cohort, patients where no recipient and donor DNA sample was stored were 
excluded.  Figure 2.1 (below) shows the numbers of patients included in each 




Figure 2.1 Flow diagram demonstrating the inclusion and exclusion of 
patients within this study.  Several patients are excluded due to missing data 





2.3 Patients converted to Tac-QD 
 
In the final results chapter (Chapter 6) a different cohort of patients were 
used.  103 patients receiving a kidney transplant between April 1983 and 
April 2011 and converted from twice-daily Tac-BD (PrografÒ) to once-daily 
Tac-QD (AdvagrafÒ) were investigated.  Of those 103 patients, 43 had stored 
DNA for genotyping and all of them had adequate clinical data.  A more 
detailed methodology for this patient cohort is given at the beginning of 
chapter 6. 
 
2.4 Laboratory Methodology 
 
Frozen human deoxyribonucleic acid (DNA), stored at -20°C, was used for 
the laboratory experiments.  The DNA was extracted from whole blood and 
prepared and stored as part of the normal clinical practice within the 
transplant unit.  We used a technique called MagtrationÒ described by Obata 
et al in 2001, where magnetic particles are used to selectively bind to DNA 
and are then extracted [186].  The device used in our laboratory is the 12GC 
MagtrationÒ System (Precision System Science Company, Ltd.)  All DNA 
extractions had taken place prior to the start of this study. 
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2.4.1 Materials Required for Laboratory Experiments 
 
1. Aliquot of genomic DNA stored at -20°C 
2. Aliquot of sterile water stored at -20°C 
3. TaqMan® SNP Drug Metabolism Genotyping Assay from Applied 
Biosystems™ (Life Technologies) for each of the three different SNPs 
– ABCB13435 C>T(rs1045642, assay ID C_7586657_20, product code 
4362691), CYP3A5 6986A>G (rs776746, assay ID C_26201809_30, 
product code 4362691) and CYP3A4*22 intron 6 C>T (rs35599367, 
assay ID C_59013445_10, product code 4351379). 
4. TaqMan® genotyping mastermix (which contains reaction mix, 
AmpliTaq® Gold, dNTPs and ROX passive reference dye) from Applied 
Biosystems ä (Life Technologies), product code 4381656. 
5. MicroAmp® Optical 96-well reaction plate (skirted) from Applied 
Biosystems™ (Life Technologies), product code N8010560. 
6. MicroAmp® Optical adhesive film cover from Applied Biosystems™ 
(Life Technologies), product code 4360954. 
7. MicroAmp® Optical film compression pad from Applied Biosystems™ 
(Life Technologies), product code 4312639. 
8. Pipettes, tips and eppendorfs. 
9. DNA storage boxes. 
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2.4.2 Non-consumable equipment 
 
1. Veriti ä PCR 96 well Thermal Cycler (Applied Biosystemsä). 
2. ABI Prismâ 7500 Real-Time PCR machine. (Applied Biosystemsä) 
3. NanoDropä mass spectrophotometer (ThermoScientificä) 
4. Vortex mixer (Fisher Scientificä). 
 
2.4.3 Planning and Preparation 
 
A 96 well plate template was created in a word document and divided into 3 
sections of 32 wells each.  Each section of the plate would have 29 subject 
DNA samples, 1 sample of a known genotype (positive control) which was 
kindly donated by St George’s Hospital in London (courtesy of Prof. 
McPhee), and two non-template controls (NTCs) which were DNA-free 
samples of sterile water (negative controls). 
 
Each sample was genotyped 3 times on every plate each with a different 
assay (CYP3A5, ABCB1 and CYP3A4*22).  Samples were assigned a unique 




2.4.4 Standardising the DNA concentration 
 
Once the 29 samples for the run were identified, they were removed from the 
freezer and allowed to thaw.  The NanoDropä spectrophotometer was 
initialised, blanked and then checked with sterile water.  A 2µL drop of DNA 
was placed on the device and the spectrophotomer initiated on the nucleic 
acid setting. The concentration of the DNA was then entered into a pre-
prepared excel spreadsheet which automatically calculated the required 
volume of sterile water to be added in order to achieve a concentration of 
10ng/µL.  This process was repeated for each of the samples, ensuring that 
the spectrophotometer was cleaned and reset between each sample to 
prevent cross contamination of DNA. 
 
2.4.5 Preparing the DNA and Sterile Water 
 
Each assay requires a total volume of 11.25 µL of DNA and sterile water. 
Therefore, for each assay a total of 2 µL of DNA (10ng/µL) and 9.25 µL of 
sterile water was used and as the genotyping assay was set up for n=4 
samples (one additional sample to allow for errors) a total of 8 µL of DNA 
and 37 µL of sterile water was placed into a pre-labelled Eppendorf for each 
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DNA sample to be genotyped.  The labelled DNA samples were kept 
refrigerated at 4°C until they were ready to be used. 
 
2.4.6 Preparing the Genotyping Assays 
 
Three Eppendorfs were prepared and labelled CYP3A5, ABCB1 and 
CYP3A4*22.  Each assay was removed from the freezer and allowed to thaw, 
centrifuged to 1500 rpm and then swirled using the Vortex machine as per 
the manufactures guidelines.  To each of the pre-labelled assay Eppendorfs 
437.5 µL of genotyping mastermix was added followed by 43.75 µL of the 
corresponding drug metabolising assay to give a total volume of 481.25 µL 
per Eppendorf which was enough for 35 individual wells on the plate (32 + 3 
extra).  Once the assay was added to the genotyping mastermix, each 
Eppendorf was centrifuged to 1500 rpm and then swirled using the Vortex 
machine. 
A clean unused MicroAmp® 96 well plate was placed in a cool rack and 11.25 
µL of the DNA/sterile water mix is added to the corresponding well for the 
CYP3A5 assay based on the previously prepared plate layout.  This is 
repeated for the ABCB1 and CYP3A4*22 section of the plate, again adding 
the same volume of DNA/sterile water mix.  For the 2 NTCs 11.25 µL of 
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sterile water alone is added to the appropriate well in the corresponding 
genotype section. 
 
Figure 2.2 A MicroAmpÒ 96 well Optical Reaction Plate manufactured by 
Applied BiosystemsÔ used to carry out the PCR reaction for genotyping 








2.4.7 Plate layout 
 
An example of a plate layout showing 29 subjects genotyped for each of the 
drug-metabolising assays.  The NTCs and positive controls are also shown in 
this layout. 
 
Figure 2.3 Diagram of the plate layout used demonstrating the unique 
identifier for each sample, the non-template controls (NTC) and the known 
genotype controls (MP) as laid out in each 96 well plate.  The CYP3A5, 
ABCB1 and CYP3A4*22 assay is run on each plate simultaneously as shown 
in the layout above. 
 




Once the DNA/sterile water mix is added to the plate for each of the subjects 
and the NTCs and positive controls have been plated out, 13.75 µL of 
genotype assay is added to each well with the first 4 x 8 block of the plate 
being the CYP3A5 assay, the middle 4 x 8 block being ABCB1 and the final 4 
x 8 block for CYP3A4*22.  The total volume in each well is then 25 µL (11.25 
µL of DNA/sterile water, 13.75 µL of assay/mastermix). 
The plate was then sealed with a MicroAmpÒ optical film lid and kept 
refrigerated at 4°C until ready for the PCR run. The PCR was run on the 
Veritiâ thermocycler and the pre and post plate reads were done on the ABI 
Prismâ 7500 RT-PCR machine. The standard operating procedures for the 
drug metabolism assays from Applied BiosystemsÔ describe this method of 
running the experiment as an alternative to running the entire PCR on the 
ABI Prismâ 7500 RT-PCR system. 
 
2.4.8 Pre-Read on ABI Prismâ 7500 RT-PCR  
 
A new file was created for each run of the plate and named “pre-read [date]”. 
The system was set for ‘alleic discrimination’. The volume in each well was 
set to 25 µL. On the very first run a template for each of the genotyping 
assays was created which could then easily be used for all subsequent runs 
on the RT-PCR machine.  The creation of this template involved assigning 
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the reporter dyes, named VIC and FAM to an allele for each of the drug 
metabolism assays.  For CYP3A5, the 6986G allele was assigned to the FAM 
reporter dye and the 6986A allele was assigned to the VIC reporter dye.  For 
ABCB1 the 3435C allele was assigned to the FAM reporter dye and the 3435T 
allele was assigned to the VIC reporter dye and for CYP3A4*22 the C allele 
was assigned to the VIC reporter dye and the T allele assigned to the FAM 
reporter dye.   
Once the template was loaded and the pre-read file created with all of the 
subject numbers entered and the NTCs specified, the pre-read run was 
initiated.  This essentially scans the pre-PCR plate and ensures that no 
reporter dyes are detected at this stage.  Once the pre-read was complete it 
was saved and this file was later used for the post-read run. 
 
2.4.9 Running the PCR 
 
The VeritiÒ thermocycler was programmed to run the cycle as described in 
the manufacturers standard operating procedure document for the 3 assays.  
All 3 assays were run on precisely the same thermocycler program.  The 
plate was placed into the thermocycler and the MicroAmpâ compression pad 
placed on top, shiny side down.  The programme was then initiated as shown 
in the table below. 
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PCR (50 cycles) Hold 
HOLD Denature Anneal/Extend Until ready for 
post-read 
10 mins at 
95°C 
15 secs at 92°C 90 secs at 60°C 4°C 
 
 
Once the thermocycler program was complete the plate was removed from 
the thermocycler, ready to be read on the ABI Prismâ 7500 RT-PCR machine. 
 
2.4.10 Post-Read on ABI Prismâ 7500 RT-PCR  
 
The plate was placed in the RT-PCR machine and the previously created pre-
read file opened.  The machine was set for ‘automatic-calling’ and the 
quality set to 90%.  This means that any wells that do not have a quality 
result of at least 90% (which is deemed by the manufacturer as the 
appropriate cut-off) will not have a result called and ensures a high quality 
of results.  Two-cluster calling was also selected.  Once these settings are 
entered and checked, the plate is scanned for each assay in turn, selecting 




Once all 3 assays have been scanned the results are displayed both 
graphically and as a list which are then recorded next to the patients 
anonymised dataset number in a spreadsheet that was kept separate to the 
clinical data set.   
The graphical output of the RT-PCR machine is shown below in Figures 2.4, 
2.5 and 2.6 and demonstrates the distribution of the alleles for each of the 













2.4.11 CYP3A5 Output 
 
Figure 2.4 RT - PCR output for CYP3A5 Alleles.  Allele X is the wild type A 
allele (*1/*1) represented by red dots and allele Y is the mutant G allele 
(*3/*3) and both alleles present GA (*3/*1) are represented by the green 
triangle. The NTCs are grey squares. 
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2.4.12 ABCB1 Output 
 
Figure 2.5 RT-PCR output for ABCB1 Alleles.  CC represented by the blue 
squares, CT by the green triangle and TT by the red dots, again the grey 
squares are the NTCs. 
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2.4.13 CYP3A4*22 Output 
 
Figure 2.6 RT - PCR output for CYP3A4*22 Alleles.  The CC genotype 
represented by the red dots and the CT allele represented by the green 
triangles, note there are no TT genotypes in this run, a reflection of the rarity 
of this genotype.  Grey squares are NTCs. 
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2.5 Large Volume Genotyping 
 
A total of 203 patients had their genotype for CYP3A5, ABCB1 and 
CYP3A4*22 determined by the method described above and genotyping of 
the remaining 787 samples was out-sourced to the Clinical Research Facility 
at the Western General Hospital, the Wellcome Trust Clinical Research 
Facility (WTCRF) due to the clinical demands for the PCR machine. The 
same preparation process was followed. However, the subsequent process 
was slightly different as WTCRF used a PicoGreenÒ assay on the NanoDropÒ 
fluorescent spectrophotometer.  This assay binds selectively to only double 
stranded DNA (dsDNA) and gives a more accurate concentration by 
eliminating single strand DNA (ssDNA) and other contaminants such as 
proteins and extraction buffers. 
 
The WTCRF standardised the concentration of the DNA for the assay at 50 
ng/µL as compared to the 10 ng/µL used in the Royal Infirmary of Edinburgh. 
 
The WTCRF used a 7900HT RT-PCR machine from Applied BiosystemsÔ 
which is a high-throughput system that is fully automated.  The samples 
were run on 384 well plates rather than 96 well plates for maximum 
throughput.  The thermocycler settings were the same as used on the VeritiÒ 
machine.   
 106 
The same research facility was used to determine the genotypes of the 
Generation Scotland cohort and the process was exactly the same as used for 
the transplant patients. 
 
2.5.1 Hardy-Weinberg Equilibrium 
 
Hardy-Weinberg equations are used to describe and predict the genotype 
and allele frequencies of a non-evolving population from one generation to 
the next.  Given a set of 5 assumptions – a large sample is used and there is 
no genetic drift, there is no gene flow between populations (from migration), 
mutations are negligible, individuals are mating randomly and natural 
selection is not operating on that population – then a population’s genotype 
and allele frequencies will remain unchanged from one generation to the 
next.  A significant deviation from Hardy-Weinberg equilibrium would 
suggest systematic genotyping errors or other biases that could invalidate 
the results and therefore it is recommended to perform a Hardy-Weinberg 
analysis for any large population based genetic study.  The most commonly 
used statistical model used to detect a departure from Hardy-Weinberg 
equilibrium is the goodness-of-fit c2 test and this is the model used in this 
study.  This is the standard model used in large unrelated populations as 
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analysed in our data.  All of the assays that were run for CYP3A5, ABCB1 and 
CYP3A4*22 were found to be in Hardy-Weinberg equilibrium. 
 
2.6 Clinical Data Collection 
 
 
The clinical data for the studies were acquired from a combination of clinical 
case notes and electronic patient records and laboratory systems.  A 
proforma was generated to collect patient data from the case notes and the 
electronic patient records.  Once the proforma was complete the data was 
then entered into an anonymised excel spreadsheet which did not contain 
the patient genotypes but did have the matching patient identifier for the 
genotypes held on a separate secure drive in the tissue typing laboratory.   
 
The clinical data consisted of tacrolimus dose and trough level at 14 
different time points up to and including 12 months, 3 time points in the 
first, second and third week, 1 month, 2 months, 3 months, 6 months and 12 
months.  Patient demographic data included gender, age, ethnicity, primary 
disease, transplant graft number, renal replacement therapy, HLA mis-
match, virology status for cytomegalovirus (CMV), hepatitis B virus (HBV), 
hepatitis C virus (HCV), human immunodeficiency virus (HIV), and the 
donor virology for the same viruses.  Donor and recipient blood group and 
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relevant recipient pre-transplant co-morbidity (hypertension, diabetes and 
established cardiovascular disease) data were collected. 
 
Clinical outcome data included duration of cold ischemic time, renal 
function, biopsy proven acute rejection (BPAR), post-transplant infections, 
new onset diabetes after transplant, significant cardiovascular events, 
development of post-transplant malignancies, graft and patient survival.  
The full list of collected clinical data items is included in the appendix. 
 
Once the clinical data collection was completed the 2 excel spreadsheets 
(one containing only the genotype of CYP3A5, ABCB1 and CYP3A4*22 and 
the patient identifier and the other containing only clinical data and the 
identifier) were merged to form a single database.  All patient specific 
identifiers were removed and only the study identifier remained, allowing 
for a completely anonymised dataset containing both clinical and genotype 
data. 
 
2.6.1 Laboratory Tacrolimus Assay 
 
The clinical laboratory in this unit measure the trough concentration of 
tacrolimus in whole blood samples using a liquid chromatography tandem 
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mass spectrometry technique, which is used widely in transplant units.  In 
this centre the laboratory has both a low and a high quality-control (QC) 
concentration and results should be within 2 standard deviations of this 
value.  The low QC mean is 2.86 ± 0.76 µg/L and the high QC mean is 16.6 ± 
2.2 µg/L for the assay in our clinical laboratory and the quality control 
checks are performed in line with the standard operating procedures for the 
laboratory. 
 
2.7 Data Analysis 
 
 
All data was analysed on IBMÒ SPSSÒ version 21 statistical analysis software.  
All graphs were drawn on either GraphPad PrismÒ version 7.0a or MicrosoftÒ 
Excel version 15.30.  Continuous variables were analysed using one-way 
analysis of variance (ANOVA) test and categorical variables analysed by Chi-
square test unless otherwise stated.  Graft and patient survival was 
determined by Kaplan-Meier curves and log-rank test in univariate analyses 
and by Cox Regression in multivariate analyses.  Continuous variables are 
expressed as the mean±standard deviation unless otherwise stated.  Error 























It is widely recognised that there are considerable differences in the 
pharmacokinetics and pharmacodynamics of certain drugs between different 
ethnic groups and wider populations.  Variations in polymorphisms of genes 
involved with drug metabolism, such as cytochrome P450 or drug 
transporters such as MDR-1 (ABCB1), can play a pivotal role in these 
observed differences [153].  This is particularly relevant in transplantation as 
expression of certain genetic polymorphisms can influence the 
pharmacokinetics of immunosuppressant drugs and therefore have a 
significant clinical impact.   
 
There is much variation of the expression of these genetic polymorphisms 
between different ethnic groups and geographical populations and these 
variations go some way in explaining the observed differences in the 
pharmacokinetics of certain drugs between ethnic groups. 
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Within the United Kingdom the study of these polymorphisms has been 
undertaken predominantly in renal transplant patients in the London area.  
London has an ethnically more diverse population than Scotland, with some 
40% of people living there being born out with the UK.  It cannot therefore 
be assumed that the distribution of the genotypes of interest for this study 
will be the same in Scotland, nor that the distribution of these 
polymorphisms within a renal transplant population is representative of the 
population as a whole.  To date there have been no studies examining the 
distribution of single nucleotide polymorphisms (SNPs) of CYP3A5, 
CYP3A4*22 or ABCB1 in a Scottish population. 
 
Scotland has primarily a Caucasian population although smaller numbers of 
people from many different ethnic groups live here.  Previously published 
data has shown that expression of CYP3A5 (AG/AA or *1*3/*1*1) occurs in 
15-20% of Caucasians with only minor variations in allele frequency across 
Europe.  Conversely around 85% of individuals of sub-Saharan African 
ethnicity (Black), will express functional CYP3A5 while those individuals 
from an Asian ethnic group fall somewhere in the middle, with nearly 50% of 
them expressing a copy of the A (*1) allele of CYP3A5 [143, 187].  Within the 
Asian population itself there are significant differences between Eastern 
Asian countries (Japan, Korea, China); South East Asian countries (Thailand, 
Vietnam, Singapore) and South Asian countries such as India [153]. 
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CYP3A4*22 involvement with tacrolimus pharmacokinetics has only recently 
been investigated and the published literature is considerably less than that 
for CYP3A5.   Studies to date have shown that individuals who express a T 
allele and therefore have the CT or the TT genotype require lower doses of 
tacrolimus in order to achieve therapeutic levels.  The T allele frequency in 
Caucasians is around 4- 5% and represents a C>T transition in intron 6 
resulting in reduced mRNA expression of CYP3A4 and therefore lower 
enzyme activity [105, 172].  The T allele frequency of CYP3A4*22 has been 
reported as 1% in individuals of African ethnic origin (Black) [188].  There is 
currently very little data on the allele frequency of CYP3A4*22 T allele in 
any Asian ethnic groups however a paper by Okubo et al examining a 
Japanese cohort of 53 patients did not find any expression of a CYP3A4*22 T 
allele however in the same study a cohort of 41 Caucasian patients found T 
allele expression was 6.1%.  They estimated the expression of a CYP3A4*22 
allele in a Japanese population at less than 1% but further studies of this 
polymorphism in Asian ethnic groups is required to fully evaluate its 
expression this population [173]. 
 
There are several polymorphisms of ABCB1 which can alter the expression of 
P-gp in the enterocyte, however the most commonly studied SNP in terms of 
tacrolimus pharmacokinetics is the 3435 C>T transition.  Expression of a T 
allele occurs commonly in Caucasians with approximately 28% expressing 
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the CC genotype, 48% expressing the CT genotype and 24% expressing the 
TT genotype [189].  Subjects of African ethnic origin (Black) have a different 
distribution of these genotypes with 68% expressing the CC genotype, 31% 
expressing the CT genotype and only 1% expressing the TT genotype [190].  
The reported distribution in an Asian (Chinese) population shows CC 
expression at 32%, CT expression at 48% and TT expression at 20% [191].  In 
an Indian population, however, the distribution is yet again different with 
CC genotype reported at 19.7%, the CT genotype reported at 51.4% and the 
TT genotype reported at 28.9% [192]. 
 
The current published literature demonstrates wide variation in the 
expression of SNPs of the three genes of interest in this study between 
different ethnic and geographical groups.  The aim of this study was to 
establish the expression of the described polymorphisms of CYP3A5, 
CYP3A4*22 and ABCB1 in a representative sample of the healthy Scottish 
population and compare it with expression of the polymorphisms of the 
same genes in kidney transplant recipients, liver transplant recipients, 




3.2 Study Methods 
 
 
DNA samples from 5889 subjects were genotyped for CYP3A5 6986 A>G 
transition, ABCB1 3545 C>T transition and the CYP3A4*22 intron 6 C>T 
transition using the Taqman® drug metabolism genotyping assay and real-
time PCR technique.  The DNA for analysis was available from 2 distinct 
sources.  The first source was frozen, stored DNA in the Histocompatibility 
and Immunogenetics (H&I) laboratory involved in the tissue typing of 
transplant patients.  There were a total of 990 DNA samples available for 
genotyping from the H&I laboratory: 305 kidney transplant recipient 
samples, 48 simultaneous pancreas-kidney transplant recipient samples, 252 
liver transplant recipient samples and 385 deceased organ donor samples.   
 
The second source of DNA samples for analysis was a bio-resource facility 
called Generation Scotland.  Generation Scotland is a bio repository that 
collects basic demographic data (age, gender, ethnicity) and stores DNA 
samples from volunteers. The cohort of samples used in this study was from 
the Generation Scotland 3D (GS:3D) study, where healthy blood donors were 
asked to allow the storage of their DNA following blood donation for use in 
the bio-repository.  The DNA from this cohort was obtained from the 
leukocyte filters used as part of the blood donation process and all 
participants had given written consent [185].  A total of 4899 GS:3D samples 
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were used in our analysis.  In addition to the genotype, basic demographic 




All genomic DNA samples were standardised to a 10ng/µl concentration and 
genotyped for each of the 3 genetic polymorphisms using the TaqMan® drug 
metabolism genotyping assay as described in detail in Chapter 2.  
 
3.2.2 Missing Data 
 
The majority of subjects have a complete dataset in this study however there 
are small numbers where data is missing both in terms of demographic and 
genotyping data.  There are 104 (1.8%) subjects where the age was not 
determined and 107 (1.8%) where the gender was not recorded.  The majority 
of missing data of these variables occurred in the organ donor group where 
historically recording of these data occurred on paper forms could result in 
erroneous omissions.  There were 10 patients (0.2%) where the ethnic group 
was not recorded. 
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Failure to identify the genotype of a subject can occur when the quality of 
the genomic DNA is poor, is contaminated or by chance.  In order for a 
genotyping run to be considered successful 95% of the subjects must have 
their genotype identified. Of the 5889 samples tested there were 122 (2.1%) 
of the subjects where the CYP3A5 genotype was not determined, 136 (2.3%) 
where the CYP3A4*22 genotype was not determined and 210 (3.6%) where 
the ABCB1 genotype was not determined. 
 
3.2.3 National Census Data 
 
Comparisons of demographic data was made with the 2011 national census 
data for Scotland and the rest of the United Kingdom using data from the 












There were a total of 3214 (55.6%) male subjects and 2568 (44.4%) female 
subjects overall in this study, excluding the 107 subjects (1.8%) where the 
gender information was unavailable.  This differs significantly from the 2011 
census data for Scotland where the population had 2567444 males (48.5%) 
and 2727959 females (51.5%), p<0.0001, Chi-square test.  The England and 
Wales census data and the UK as a whole are very similar to the Scottish 
census data and thus also differ, in terms of gender distribution, to this 
study cohort (Table 3.2). 
 
The kidney transplant cohort of patients has significantly more men (208, 
68.2%) compared to women (97, 31.8%), p<0.0001 Chi-Squared test, but this 
in itself would be unlikely to change the overall gender distribution 
significantly given the overall size of the cohort.  There were also more men 
in the Generation Scotland cohort (2696, 55.2%) compared with women 
(2189, 44.8%), which is why this overall number is higher in the cohort.  
Within the transplant cohort as a whole, there were 518 males (57.7%) 
compared with 379 (42.3%) females.  These data suggest that males are over-
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represented in our cohort of subjects compared with the census data of both 




The subjects in this study were categorised into 11 different age brackets 
starting at <17 and then 17 – 25 years and then increasing in 4 year age 
brackets up to and including >66 years of age, shown in Table 3.1 below.  The 
majority of the subjects in the Generation Scotland cohort were in the 41 – 
45 years age bracket (788, 16.1%).  There was variation in age across the 
different groups within the transplant cohort of patients also shown in Table 
3.1.  The highest number of kidney transplant patients were in the 41 – 45 
years age bracket (45, 14.8%), as were the SPK patients (13, 27.1%) similar to 
the Generation Scotland cohort, however in the liver transplant cohort most 
patients were in the 56 – 60 years age bracket (53, 21.0%).  Most of the organ 
donors were in the >66 year age group (43, 11.2%) but this may not be 
representative of the true age spread in the organ donor group as there are 
94 donors (24.4%) where the age was unavailable or not recorded.   
The age distribution differs between the different groups in the transplant 
cohort and reflects the disease burden of each group (SPK patients tend to be 
younger, liver disease patients tend to be older) and this therefore also 
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differs from the Generation Scotland group who are a sample of the healthy 
population.  The age distribution of the Generation Scotland group is also 
different from the Census data for both Scotland and England and Wales, 
primarily due to the extremes of age that are obviously captured in census 
data but will not be blood donors.  Age clearly has no influence on genotype 
expression however the census data is also recorded in Table 3.1 below to 
give a complete detail of demographics in our patient cohort compared with 






Table 3.1 Age distribution of the subjects in this study grouped by different cohorts.  Comparison is shown with the census 






















































































3.3.3 Ethnic Groups 
 
The participants in this study were mostly Caucasian accounting for 99.3% 
of the Generation Scotland group and 98.1% of the Transplant cohort.  While 
the Scottish population is primarily Caucasian this is a significantly higher 
percentage of Caucasians than the general population of Scotland in the 
2011 Census (96.0%) and even more so than in England and Wales where the 
Caucasian population is 85.9%.  p<0.0001, Chi-Square test.  This data 
suggests that Caucasians may be over-represented in this study compared 
with the general population of Scotland but also shows that England and 
Wales is a more diverse population in terms of ethnicity than Scotland. 
 
There was a single black subject in this study who was in the liver transplant 
cohort however even in the largest cohort in this study, the Generation 
Scotland Group, there were no other black subjects.  The percentage of black 
people resident in Scotland compared with the rest of the population in the 
2011 census was low at 36178 (0.7%) however this is still considerably higher 
than the number in this study (0.02%) and therefore it is reasonable to 
conclude that black subjects are under-represented in this study when 
compared with the 2011 National Census data for Scotland.  This difference 
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is even more marked when compared with the census data for England and 
Wales where 3.3% of the population are of the black ethnic group and the UK 
overall where the proportion of the population that is black sits at 3.0%. 
 
Asian subjects are also under-represented in this study when compared with 
the census data for Scotland, England and Wales and the UK as a whole.  
There were a total of 25 Asian subjects overall in this study, 7 from the 
Generation Scotland cohort (0.1%) and 18 as part of the transplant patient 
cohort (1.8%).  The 2011 Scottish census data shows that 2.7% of the 
Scottish population were of the Asian ethnic group and in England and 
Wales this figure rises to 7.5%, giving the overall UK census figure as 6.9% of 
the population described as Asian in the 2011 census.   
 
These findings are summarised in the table below comparing the gender and 
ethnic groups of the transplant cohort, the Generation Scotland data and the 













Table 3.2 Gender and ethnic groups of the Generation Scotland cohort and the transplant cohort and compared with the 















Eng/Wales Census Data UK 
Gender       
 Male 
2696 (55.6%) 518 (52.3%) 2567444 (48.5%) 27573376 (49.2%) 31028143 (49.1%) 
 Female 
2189 (44.4%) 379 (38.3%) 2727959 (51.5%) 28502536 (50.8%) 32154035 (50.9%) 
 Unknown 14 (0.3%) 93 (9.4%) 
   
Ethnic 
Group  
     
 Caucasian (White) 
4864 (99.3%) 971 (98.1%) 5084407 (96.0%) 48151715 (85.9%) 55010359 (87.1%) 
 White: Scottish 4317 (88.1%) 691 (69.8%) 4445678 (83.9%) no separate data no separate data 
 
White: Other 
British 463 (9.5%) 127 (12.8%) 417109 (7.9%) no separate data no separate data 
 White: Irish 47 (1.0%) 1 (0.1%) 54090 (1.02%) no separate data no separate data 
 White: Other   37 (0.8%) 152 (15.4%) 167530 (3.2%) no separate data no separate data 
 Black 0 (0.0%) 1 (0.1%) 36178 (0.7%) 1864890 (3.3%) 1904684 (3.0%) 
 Asian 7 (0.1%) 18 (1.8%) 140678 (2.7%) 4213531 (7.5%) 4373339 (6.9%) 
 Asian: Chinese 3 (0.1%) 2 (0.2%) 33076 (0.64%) 393141 (0.7%) 433150 (0.7%) 
 Asian: Indian 3 (0.1%) 16 (1.6%) 32706 (0.62%) 1412958 (2.5%) 1451862 (2.3%) 
 Asian: Other 1 (0.02%) 0 (0.0%) 74266 (1.4%) 2407432 (4.3%) 2488327 (3.9%) 
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The distribution of polymorphisms of the CYP3A5 genotype across the 
entire cohort which included the Generation Scotland subjects as well as all 
of the transplant patients revealed 5038 (87.4%) were CYP3A5 non-
expressers of the GG (*3/*3) genotype and therefore made no functional 
CYP3A5.  There were a total of 701 subjects (12.2%) who were CYP3A5 
heterozygotes of the GA (*3/*1) genotype, expressing a single copy of the 
wild type allele and therefore making functional CYP3A5.  A considerably 
smaller number of subjects, 28 in total (0.5%), were homozygotes for the 
wild type A allele (*1/*1).   
 
A similar genotype distribution is seen in the cohort of White – Scottish 
subjects with 4306 (87.7%) of the GG genotype, 582 (11.9%) of the GA 
genotype and 22 (0.4%) were of the AA genotype, which is to be expected 
given the majority of the subjects in this study are of the White – Scottish 
ethnic group.  The other Caucasian ethnic groups have similar proportions 
although there is some slight variation between the different Caucasian 
groups as shown in Table 3.3.   
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The near exclusively Caucasian cohort makes interpretation of the genotype 
in other ethnic groups difficult due to their very small numbers however in 
the largest non-Caucasian group (Asian-Indian), n=19, the genotype 
distribution of CYP3A5 was different from the Caucasian group.  In this 
group the GG (*3/*3) genotype was less common with only 10 subjects 
(52.6%) who were CYP3A5 non-expressers, however there were 6 (31.6%) 
subjects who expressed the GA genotype and 3 (15.8%) who were AA 





The distribution of the 3435 C>T transition of ABCB1 differs somewhat from 
the CYP3A5 polymorphism.  In the overall cohort there were 1182 (20.8%) 
subjects who expressed the CC genotype, 2796 (49.2%) who expressed the CT 
genotype and was therefore the most common genotype expressed and 1701 
(30.0%) subjects of the TT genotype.  As with the distribution of the CYP3A5 
genotype the distribution in the White – Scottish ethnic group very closely 
resembled that of the overall cohort with 1021 (21.1%) being of the CC 
genotype, 2372 (49.0%) of the CT genotype and 1443 (29.8%) subjects who 
expressed the TT genotype. 
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While most of the other Caucasian ethnic subgroups in this study followed a 
similar pattern, those patients that identified as White – Irish had a different 
distribution with 4 subjects (8.3%) were of the CC genotype, 20 (41.7%) were 
of the CT genotype and 24 (50.0%) were of the TT genotype.  There is no 
published literature specifically examining the distribution of this particular 
SNP of ABCB1 at this time and therefore it is difficult to know if this 
difference is truly reflective of the Irish population or whether it is anomaly 
due to small numbers. 
As before there are very small numbers of non-Caucasian subjects and only 
the Asian – Indian group has sufficient numbers to give any meaningful 
description with 4 subjects (22.2%) expressing the CC genotype, 8 (44.4%) 
were of the CT genotype and 6 (33.3%) were of the TT genotype.  The single 




The CYP3A4*22 SNP has been described much more recently than either 
CYP3A5 or ABCB1 and, as such, the literature regarding the genotype 
distribution in different populations and ethnic groups is more limited.  In 
this study the overall cohort there were 5185 (90.1%) subjects who expressed 
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the CC genotype (wild-type), 554 (9.6%) who expressed the CT genotype and 
only 14 (0.2%) subjects expressed the TT genotype of CYP3A4*22.  
 
As with the other polymorphisms the White – Scottish subjects almost 
exactly mirrors the overall genotype distribution [4410 (90.2%) CC, 472 
(9.7%) CT, 9 (0.2%) TT].  Other Caucasian sub-groups are very similar.  
Interestingly, with the exception of a single subject in the group ‘other’ who 
expresses the CT genotype, there is no expression of the T allele in any of 
the non-Caucasian ethnic sub-groups.  Published data on this polymorphism 
is relatively scarce however it does suggest that T allele expression is found 
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3.5 Genetic Distributions in the Transplant Cohort 
 
Given that the incidence of diabetes, renal failure and liver disease can vary 
between different ethnic groups, we analysed the transplant cohort 
separately so they could be compared with the healthy cohort of volunteers 




There was some minor variation between the different transplant groups of 
the CYP3A5 genotypes however none of these were significant (Chi-squared 
test).  The kidney transplant group had 241 (79.0%) subjects with the GG 
(*3/*3) non-expresser genotype while in the SPK cohort this was 36 (75.0%), 
218 (86.5%) in the liver transplant cohort and 325 (84.4%) of the organ donor 
group.  There were 4218 (86.1%) of the Generation Scotland cohort who had 
the GG (*3/*3) genotype of CYP3A5.   
 
The GA (*3/*1) genotype of CYP3A5, which does result in functional CYP3A5 
activity, was seen in 48 (15.7%) of the kidney transplant cohort, 9 (18.8%) of 
the SPK cohort, 27 (10.7%) of the liver transplant patients and 47 (12.2%) of 
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the organ donors.  There was no significant difference among any of the 
transplant groups in the expression of this genotype or the Generation 
Scotland cohort where 570 (11.6%) expressed the GA (*3/*1) genotype (Chi-
squared test). 
The AA (*1/*1) genotype of CYP3A5 was expressed in 9 (3.0%) of the kidney 
transplant patients, 1 (2.1%) of the SPK cohort, 2 (0.8%) of the liver 
transplant patients and was not found in any of the liver donors.  The 
Generation Scotland cohort had only 16 (0.3%) subjects with the AA 
genotype which was significantly lower than that of the transplant cohort 




The distribution of the ABCB1 genotype was broadly similar in the 
transplant cohort with 63 (20.7%) of the kidney transplant patients, 9 
(18.8%) of the SPK cohort, 59 (23.4%) of the liver transplant group and 77 
(20.0%) of the organ donors all expressing the CC genotype.  This compared 
with 974 (19.9%) of the Generation Scotland group who had the CC genotype 
and was not found to be significantly different on Chi-Squared test. 
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The distribution of the CT genotype of ABCB1 was also found to be similar 
between the transplant groups - kidney 143 (46.9%), SPK 24 (50.0%), liver 
108 (42.9%) and organ donor 187 (48.6%).  This was again found to be 
comparable to the Generation Scotland cohort of 2334 (47.6%) who 
expressed the CT genotype. 
The distribution of the TT genotype of ABCB1 was unsurprisingly similar 
between the transplant groups – kidney 97 (31.8%), SPK 15 (31.3%), liver 76 
(30.2%) and organ donor 96 (24.9%).  There was no significant difference 
between the distribution of the TT genotype among the transplant groups or 
compared with the Generation Scotland cohort where there were 1417 




The T allele is so infrequently expressed that demonstrating a statistical 
difference between the transplant groups would be difficult and, indeed, 
there is no significant difference in the percentage of individuals with any 
given CYP3A4*22 genotype across the different transplant groups.  The most 
common CC genotype is found in 276 (90.5%) of the kidney transplant 
patients, 44 (91.7%) of the SPK patients, 225 (89.3%) of the liver transplant 
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cohort and 327 (84.9%) of the organ donor cohort.  This is comparable with 
the Generation Scotland cohort where 4313 (88.0%) express the CC genotype 
of CYP3A4*22. 
The CT genotype is seen in 25 (8.2%) of the kidney transplant patients, 3 
(6.3%) of the SPK patients, 16 (6.3%) of the liver transplant patients and 38 
(9.9%) of the organ donors which was again comparable with the Generation 
Scotland cohort expression of the CT genotype, 472 (9.9%) subjects. 
The TT genotype of CYP3A4*22 is very rarely expressed and was found only 
in 2 (0.7%) of the kidney transplant patients and only 1 (0.3%) of the organ 
donors.  None of the SPK patients or the liver transplant patients expressed 
the TT genotype of CYP3A4*22.  The Generation Scotland cohort also had a 
very low incidence of this genotype with only 11 (0.2%) subjects expressing 
it.  
Table 3.4 below summarises the genotype distribution of the different 






Table 3.4 Genotype distribution of CYP3A5, ABCB1 and CYP3A4*22 between the different cohorts of Generation Scotland 
















GG (*/3*3) GA (*3/*1) AA 
(*1/*1) 













472 (9.6%) 11 (0.2%) 
KIDNEY 
TRANSPLANT 
241 (79.0%) 48 (15.7%) 9 (3.0%) 63 (20.7%) 143 (46.9%) 97 (31.8%) 276 (90.5%) 25 (8.2%) 2 (0.7%) 
SPK TRANSPLANT 36 (75.0%) 9 (18.8%) 1 (2.1%) 9 (18.8%) 24 (50.0%) 15 (31.3%) 44 (91.7%) 3 (6.3%) 0 (0.0%) 
LIVER TRANSPLANT 218 (86.5%) 27 (10.7%) 2 (0.8%) 59 (23.4%) 108 (42.9%) 76 (30.2%) 225 (89.3%) 16 (6.3%) 0 (0.0%) 













554 (9.4%) 14 (0.2%) 
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3.6 Allele Frequencies 
 
 
3.6.1 CYP3A5 allele frequencies 
 
It is also possible to describe the distribution of alleles of a particular gene in 
a population by the allele frequency. The genotype could not be determined 
for 122 subjects (2.1%) and in order to express the allele frequency 
accurately these patients were removed from the analysis leaving 5767 
individuals for whom the frequency can be calculated. Taking the single 
nucleotide polymorphism of CYP3A5 as an example, there are 2 alleles (G or 
A) but a total of 3 possible genotypes (GG, GA or AA).  Looking at the overall 
cohort we can see that 5038 individuals (85.5%) express the GG (*3/*3) 
genotype, 701 (11.9%) express the GA (*3/*1) genotype and 28 (0.5%) 
express the AA (*1/*1) genotype.  The total number of alleles in this cohort 
is (5767 x 2) = 11534.  Of these there are 10777 G alleles and 757 A alleles, 
giving a G allele frequency of 0.934 and an A allele frequency of 0.066.   
The allele frequency for the 4910 White – Scottish ethnic group individuals 
with a determined genotype is 0.936 for the G allele of CYP3A5 and 0.064 for 
the A allele frequency.  The allele frequency for the 575 White – other 
British ethnic group individuals was comparable with a G allele frequency of 
0.934 and an A allele frequency of 0.066, suggesting that the White – 
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Scottish population is similar to the rest of the Caucasian population of the 
UK.  Although the other ethnic groups are less well represented, the largest 
non-Caucasian group [Asian – Indian (n=19)] had a significantly different 
allele frequency.  In this group the G allele frequency was 0.684 and the A 
allele frequency was 0.316.  Despite the small numbers in this study, this 
frequency is very similar to previously published work in Indian populations 
where the G allele frequency has been shown to be between 0.635 and 0.683 
[194, 195]. 
 
3.6.2 ABCB1 allele frequencies 
 
The allele frequencies of ABCB1 are quite different from the cytochrome 
p450 3A5 and 3A4*22 SNPs, as reflected in the distribution of the different 
genotypes already discussed in this chapter.  The ABCB1 genotype could not 
be determined for 210 individuals who were excluded from the allele 
frequency calculations.  This gives a total of 5679 specimens for analysis and 
a total of 11358 alleles (either C or T).  There were 5160 C alleles giving a C 
allele frequency of 0.454 and 6198 T alleles giving a T allele frequency of 
0.546 for the entire cohort.   
The C allele frequency of the 4836 White – Scottish ethnic group was 0.456 
and the T allele frequency was 0.544. The 567 White – other British 
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individuals had a C allele frequency of 0.446 and a T allele frequency of 
0.554, comparable to that of the White – Scottish population. Interestingly 
the allele frequency seen in the White – Irish ethnic group is different with a 
C allele frequency of 0.292 and a T allele frequency of 0.708.  As there are 
only 48 individuals in this group, this may not be a true representation of the 
Irish population, but nevertheless it is an interesting observation worthy of 
further evaluation in a larger sample.  Again, the other ethnic groups are 
very small in number but the distribution in the largest of the non-
Caucasian ethnic shows that the C allele frequency of the Asian – Indian 
ethnic group was 0.444 whilst the T allele frequency was 0.556, similar to the 
White – Scottish and the White – other British ethnic groups.   
 
3.6.3 CYP3A4*22 allele frequencies 
 
CYP3A4*22 is a more recently discovered polymorphism and as such there 
are few studies investigating population distribution of the CYP3A4*22 
genotype.  The allele frequency of the T allele appears to be very low in 
Caucasian populations that have been studied so far [175, 179, 180, 193].  In 
the overall cohort there were 5753 subjects with determined genotypes 
suitable for analysis.  The C allele frequency of the cohort as a whole was 
0.949 and the T allele frequency 0.051. 
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In the White - Scottish ethnic group of the cohort, again the values are 
comparable with a C allele frequency of 0.950 and a T allele frequency of 
0.050.  Similarly in the White – other British ethnic group the C allele 
frequency is 0.942 and the T allele frequency is 0.058.  The White – Irish 
ethnic group is very similar for the other Caucasian groups in terms of the 
allele frequency and has a C allele frequency of 0.958 and a T allele 
frequency of 0.042. 
 
The Asian – Indian ethnic group had no individuals who expressed a T allele 
in this study giving it a C allele frequency of 1.000.  It is unknown if this is a 
true representation of this ethnic group, but does suggest that the T allele 
frequency is either very low or possibly absent in this ethnic group.  Further 
evaluation of this is required in order to draw reasonable conclusions. 
 
The allele frequencies of the different Caucasian groups in this study are 
summarised in Table 3.5 below and also include the allele frequencies for the 





Table 3.5 Allele frequencies of CYP3A5, ABCB1 and CYP3A4*22 in different 









G (*3) A (*1) C T C T 
Overall 0.934 0.066 0.454 0.546 0.949 0.051 
White - 
Scottish 
0.936 0.064 0.456 0.544 0.950 0.050 
White - 
Other British 
0.934 0.066 0.446 0.554 0.942 0.058 
White - Irish 0.935 0.065 0.292 0.708 0.958 0.042 
White - 
Other 
0.920 0.080 0.471 0.529 0.951 0.049 
Asian - 
Indian 




3.7 Allele Frequencies of other Populations 
 
 
This study has revealed the allele frequencies of a large sample of almost 
exclusively Caucasian Scottish individuals however it is worth exploring the 
allele frequencies of other populations as a comparison.  Kurose et al 
published a comprehensive review in 2012 of the allele frequencies of 
numerous different genes involved in drug metabolism across several 




The table is grouped by continent and demonstrates the similarities between 
neighbouring regions where the ethnic groups will be similar such as Japan, 
Korea and China.  Among these 3 countries the CYP3A5 G allele frequencies 
are similar, 0.762, 0.759, 0.737 respectively but quite different from the 
majority of the European countries where the G allele frequencies are in the 
region of 0.9.  The Singaporean distribution is interesting in that the Malay, 
Chinese and Indian Singaporean ethnic sub-groups have different G allele 
frequencies of CYP3A5 at 0.61, 0.76 and 0.59 respectively.   
 
The African countries report much lower G allele frequencies of CYP3A5 as 
might be expected with South-Africa and Ethiopia having very G allele 
frequencies of 0.145 and 0.205 respectively.  Interestingly Zimbabwe and 
Tanzania have a higher G allele frequency reported than might be expected 
at 0.776 and 0.640 respectively.  African-Americans are reported as having 
an G allele frequency of 0.357.   
 
Across European countries which all have predominantly Caucasian 
populations the allele frequency of CYP3A5 still tends to be in the region of 
0.9 with some minor variation among different countries.  Interestingly, 
there are only minor differences between Scandinavian, central European, 
Eastern European or Mediterranean countries.  Portugal is the only 
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European country where the G allele frequency of CYP3A5 drops below 0.9, 
at 0.875. 
 
The allele frequencies of ABCB1 shown in table 3.6 below also show some 
variation among the different countries with African countries tending to 
have a lower T allele frequency in the region of 0.1 – 0.2 compared to both 
Caucasian populations and indeed Asian populations where the T allele 
frequency of ABCB1 is between 0.4 and 0.6. 
 
The minor allele frequency (T allele) of CYP3A4*22 is only shown for a few 
countries in table 3.6 below as it has only been discovered more recently and 
there are few publications where it has been studied.  Scotland has an almost 
identical allele frequency to France for CYP3A4*22, at 0.051 and 0.050 
respectively.  Data from the Netherlands reports an allele frequency slightly 
higher at 0.08 and Greece higher still at 0.1.  Studies from America however 
reveal a lower allele frequency at 0.04 and lower still for African Americans 
at 0.01.  There are 2 papers where Chinese subjects have been genotyped for 






Table 3.6 Variations in allele frequencies of CYP3A5, ABCB1, CYP3A4*22 reported in different countries. 
CYP3A5	(G/*3	allele) ABCB1	(T	allele) CYP3A4*22	(T	allele)
Country Asia Japan 0.762 0.43 no	data
Korea 0.759 0.431 no	data
China 0.737 0.44 0
Thailand 0.669 no	data no	data
Singapore	(Malay) 0.61 0.52 no	data
Singapore	(Chinese) 0.76 0.54 no	data
Singapore	(Indian) 0.59 0.62 no	data
India 0.648 0.6 no	data
Europe Scotland,	UK	 0.934 0.546 0.051
Denmark 0.948 no	data no	data
Finland 0.91 0.37 no	data
Sweden 0.919 0.53 no	data
UK 0.926 0.42 no	data
Germany 0.942 0.48 no	data
Netherlands 0.917 no	data 0.08
France 0.948 0.43 0.05
Greece 0.944 0.435 0.1
Italy 0.933 0.4 no	data
Portugal 0.875 0.57 no	data
Spain 0.921 0.48 no	data
Bosnia-Herzegovina 0.932 no	data no	data
Russia 0.916 0.54 no	data
Poland 0.94 0.38 no	data
Africans South	Africa 0.145 0.11 no	data
African-Americans 0.357 0.16 0.01
Zimbabwe 0.776 no	data no	data
Ghana no	data 0.17 no	data
Tanzania 0.64 0.22 no	data
Ethiopia 0.205 0.16 no	data
America USA no	data no	data 0.04
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3.8 Chapter Summary 
 
The single nucleotide polymorphisms evaluated in this thesis are involved in 
drug metabolism and can influence the pharmacokinetics of tacrolimus, the 
most common calcineurin inhibitor used to prevent allograft rejection in 
solid organ transplantation.  It is known that expression of different SNPs of 
a particular gene will vary depending on the population studied and the 
greatest difference in genotype expression and/or allele frequency is seen 
between different ethnic groups. To date there has been no study examining 
the genotype distribution of the three SNPs in a Scottish population.   
 
The Generation Scotland cohort is a large cohort but is, interestingly, 
somewhat different in its ethnic make-up compared with both Scottish and 
UK census data from 2011.  Ethnic minorities in the Generation Scotland 
cohort are significantly under represented when compared with this census 
data.  The reason for this almost certainly lies with the source of DNA used 
for analysis.  The Generation Scotland 3D study acquired its DNA from the 
white cell filters used during the blood donation process and it is well known 
that there are difficulties in recruiting ethnic minorities to donate blood, 
which may reflect differences in cultural practices, and as such are likely to 
lead to under-representation in this cohort.  As one might anticipate, there 
are a greater number of Asian subjects in the renal transplant group 
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compared with the other cohorts, as a reflection of a higher incidence of 
renal failure in this ethnic group. 
 
Scotland has overall a fairly homogenous Caucasian population with the vast 
majority described as White – Scottish. Therefore, despite the under-
representation of the small ethnic minority population, Generation Scotland 
cohort gives us a large sample of people to evaluate.  The White – Scottish 
population has a very similar genotype expression for the SNPs of CYP3A5, 
ABCB1 and CYP3A4*22 to the White – other British ethnic group.  This is in 
keeping with other previously studied Caucasian populations for these 3 
SNPs (allowing for the fact that CYP3A4*22 has only recently been 
discovered and published data on the expression of this SNP in different 
ethnic groups is very limited).  The White – Irish ethnic group in this study 
have similar distributions of the CYP3A5 and CYP3A4*22 SNPs to other 
Caucasian groups however, interestingly, ABCB1 shows a slightly different 
genotype expression with greater numbers of TT genotype expression and 
fewer CC genotype expression compared to other Caucasian groups.  There is 
no obvious explanation for this phenomenon, particularly when the 
cytochrome P450 SNPs are consistent with the other Caucasian groups 
reported elsewhere.   
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The low numbers of ethnic minority groups throughout this study make any 
meaningful evaluation of the genotype expression of CYP3A5, ABCB1 and 
CYP3A4*22 challenging and one can, at best, note that in the Asian ethnic 
groups there is greater expression of the A (*1) allele in CYP3A5, in keeping 
with other studies.  ABCB1 expression is similar to Caucasian groups and for 
CYP3A4*22 all non-Caucasian subjects are of the CC genotype, the 
significance of which is unknown. 
 
In conclusion this study shows that the White – Scottish population has a 
similar distribution of genotypes for CYP3A5, ABCB1 and CYP3A4*22 SNPs 
to the White – other British (representing the rest of the UK) and this is in 




























Tacrolimus is the most commonly used immunosuppressant to prevent 
allograft rejection in patients who undergo liver transplantation.  As with 
kidney transplantation, the narrow therapeutic window of tacrolimus 
requires therapeutic drug monitoring to ensure whole blood tacrolimus 
trough levels (C0) remain within the target range in order to prevent allograft 
rejection but also to ensure the concentrations do not become supra-
therapeutic, increasing the risk of toxicity and significant adverse events.  As 
with renal transplant recipients, there is significant variation in dose 
requirements between individuals and this is, to some extent, attributable to 
the polymorphisms that encode key genes involved in drug metabolism 
[197].  Genetic polymorphisms which have been most reliably shown to 
influence the absorption and metabolism of tacrolimus include ABCB1 and 
CYP3A5 with more recently CYP3A4*22 being described.  The SNP which has 
been shown to have the most significant impact on tacrolimus 
pharmacokinetics is CYP3A5 A6986G and individuals who carry the 
CYP3A5*1 allele and therefore make the functional protein require, on 
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average, double the dose of tacrolimus in order to achieve therapeutic levels 
[111].   
 
Most studies to date exploring the relationship between these genetic 
polymorphisms and tacrolimus pharmacokinetics have been in renal 
transplant recipients where the impact of CYP3A5 expression, in particular, 
is now well established. However, liver transplant patients are especially 
interesting because CYP3A5 is predominantly expressed in the liver tissue. 
As we hypothesise that CYP3A5 is the dominant factor in tacrolimus 
metabolism (as it is the case for renal transplantation), and given that 
patients receive a new liver, this raises an obvious question:  Is it the 
recipient or the donor genotype of CYP3A5 which has the most significant 
impact on tacrolimus pharmacokinetics in liver transplant patients? 
 
4.1.1 Current literature 
 
A paper by Shi et al in 2013 performed a genotype analysis of the 3 SNPs of 
interest in this study, CYP3A5 A6986G, CYP3A4*22 and ABCB1 C3435T in a 
cohort of 216 liver transplant recipients in Asia.  The liver donors were not 
genotyped.  They did not find a single recipient that expressed the 
CYP3A4*22 polymorphism and to date there are no studies that have shown 
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expression of the CYP3A4*22 polymorphism in Asian populations.  This 
study did find that individuals who expressed the CYP3A5*1 allele had 
higher dose requirements than those of the *3/*3 genotype (non-expressers) 
similar to what has been previously observed in renal transplant patients 
[193].  An earlier paper by Yu et al in 2006 had found that while both liver 
donors and recipients who expressed CYP3A5*1 had higher dose 
requirements and lower tacrolimus trough concentration divided by dose 
(C0/D) levels, the donor genotype appeared to have a greater influence [182].  
A Korean study in 2012 found that the recipient expression (gut expression) 
of CYP3A5 was the most significant factor in tacrolimus C0/D requirements 
in the first month. However after the first month, the donor genotype took 
over as the most influential factor in tacrolimus metabolism, a donor 
expression of CYP3A5 resulting in persistently lower C0/D levels up to 48 
months after transplant [198]. In 2011, Muraki et al found very similar 
results, the recipient CYP3A5 expression having a more significant role in 
tacrolimus pharmacokinetics in the early post transplant period, whilst the 
donor genotype played the most important role in the later post-transplant 
period [199].  This study also found an increase in post transplant infectious 
complications when both recipient and donor were CYP3A5 expressers.   
There have been further studies, primarily in Asian subjects, which have 
supported the view that both recipient and donor genotype influence the 
pharmacokinetics of tacrolimus in liver transplant patients [200].  While 
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CYP3A5 expression in both liver recipients and donors may have an 
influential role in tacrolimus pharmacokinetics there is no convincing 
evidence that the ABCB1 C3435T polymorphism has any significant impact.  
Furthermore, there are no published studies to date suggesting a role for the 
CYP3A4*22 SNP.  While evidence regarding the role of recipient and donor 
genotype influence of CYP3A5 on tacrolimus pharmacokinetics is becoming 
more consistent, the clinical impact is far from certain.  Some studies report 
no impact on rejection or renal function, whilst others suggest that CYP3A5 
expression increases the risk of acute rejection, renal injury or sepsis.  
 
4.1.2 Study aims 
 
The aim of this chapter was to examine the impact of donor and recipient 
SNPs of CYP3A5, CYP3A4*22 and ABCB1 in a cohort of 194 liver transplant 
patients and assess their correlation with tacrolimus pharmacokinetics and 
clinical outcomes.  Tacrolimus dose requirements, C0 levels, C0/D ratios and 
time until therapeutic C0 level reached were evaluated for both donor and 
recipients.  Additionally, clinical outcomes of biopsy proven acute rejection, 
renal function, graft survival, patient survival and biochemical liver function 
were investigated.   
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4.2 Chapter Methodology 
 
194 liver transplants were included in this study. Stored frozen DNA samples 
were available for 137 liver recipients and 191 donors.  DNA samples were 
genotyped for the CYP3A5 A6986G transition (rs776746), the ABCB1 C3435T 
transition (rs1045642) and the CYP3A4*22 C15389T transition (rs35599367) 
using the Taqman® genotyping assay and real-time polymerase chain 
reaction (RT-PCR) technique as described in the materials and laboratory 
methodology chapter.  Clinical data was collected from a variety of sources 
including medical case notes, electronic medical records, donor information 
records and the unit’s prospectively collected database.  Genotype data was 
assigned study numbers with no patient identifiable information and 
recorded and stored separately from the clinical data.  Clinical data was 
collected using patient identifiable information and once the dataset was 
complete, it was anonymised and linked with the genotype data using the 
unique study number.  The resulting dataset had no patient identifiers and 
included all of the clinical data as well as the recipient and donor genotypes. 
 
Clinical data collected were recipient demographics such as gender, age, 
ethnic group, height, weight, BMI, liver disease diagnosis, medical 
comorbidities, blood group, MELD score at listing, type of liver disease 
(cirrhosis/malignancy/fulminant), number of transplant, and virology status 
 152 
(HCV/HBV/HIV/CMV).  Donor demographics included gender, age, ethnic 
group, height, weight, BMI, blood group, donor type (DBD/DCD/LIVE), cause 
of death, region of donation, comorbidities, liver function tests and virology 
status (HCV/HBV/HIV/CMV).  Additional information included the cold 
ischaemic time (CIT), graft steatosis and whether it was a whole or a split 
graft.  
 
Tacrolimus dose and trough levels (C0) were collected at a total of 14 time 
points: 3 time points in the first week, 3 time points in the second week, 3 
time points in the third week, 2 time points in the 4th week, 3 month time 
point, 6 month time point and 12 month time point.  The time to reach the 
therapeutic C0 tacrolimus level was recorded.  Biopsy proven acute rejection 
episodes, the development of significant post operative complications and 









4.3 Chapter Results 
 
4.3.1 Recipient Demographics 
 
194 patients transplanted between 17-Jan-2007 and 23-Aug-2012 in the 
Scottish Liver Transplant Unit at the Royal Infirmary of Edinburgh were 
included in this study [89 female recipients (45.9%) and 105 male recipients 
(54.1%)].  The majority of the recipients were Caucasian (186, 95.9%) but 
there were 7 Asian recipients (3.6%) and 1 black recipient (0.5%).  The mean 
age of the liver recipients was 53.39±11.82 years (range 18 – 72 years).  There 
were 175 (90.2%) recipients who received their first liver transplant, 16 
(8.2%) patients had their 2nd liver transplant whilst 3 (1.5%) patients received 
their 3rd liver transplant. The mean recipient weight was 77.7±20.29 kg (39.0 
– 177.0 kg) with a mean recipient body mass index of 26.83±5.04 (16.38 – 
41.18).   
 
4.3.2 Indication for transplant 
 
Cirrhosis secondary to alcoholic liver disease was the most common 
pathology requiring liver transplantation [51 patients (26.3%)] followed by 
cirrhosis secondary to hepatitis C (HCV) infection in 33 (17.0%) patients and 
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primary biliary cirrhosis (PBC) in 26 patients (13.4%). 15 patients (7.7%) 
required liver transplantation for cirrhosis secondary to primary sclerosing 
cholangitis (PSC).  The most common cause of fulminant liver failure was 
paracetamol overdose which accounted for 9 patients (4.6%) requiring liver 
transplantation.   
 
While the majority of the patients had a single pathological diagnosis 
resulting in their liver failure, there were 83 (42.8%) patients with a 
secondary pathology, the most common being hepatocellular carcinoma [47 
patients (24.2%)].  Other secondary diagnoses include alcoholic liver disease 
(7 patients, 3.6%), autoimmune hepatitis (5 patients, 2.6%), primary 
sclerosing cholangitis (8 patients, 4.1%), hepatopulmonary syndrome (4 
patients, 2.1%) and non-alcoholic fatty liver disease (4 patients, 2.1%).  The 










Table 4.1 Primary and secondary diagnoses of patients undergoing liver 
transplantation in this study group. 
  Number Percentage 
PRIMARY DIAGNOSIS    
 Alcoholic Liver Disease 51 26.30% 
 Hepatitis C 33 17.00% 
 Primary Biliary Cirrhosis 26 13.40% 
 Primary Sclerosing Cholangitis 15 7.70% 
 Non-Alcoholic Fatty Liver 
Disease 
14 7.20% 
 Cryptogenic 11 5.70% 
 Paracetamol Overdose 9 4.60% 
 Hepatic Artery Thrombosis 7 3.60% 
 Autoimmune Hepatitis 6 3.10% 
 Primary Non Function 5 2.60% 
 Chronic Rejection 5 2.60% 
 Haemachromatosis 3 1.50% 
 Polycystic Liver Disease 2 1.00% 
 Adult Idiopathic Ductopenia 1 0.50% 
 Cholangiopathy 1 0.50% 
 Giant Cell Hepatitis 1 0.50% 
 Granulomatous Hepatitis 1 0.50% 
 Hepatitis B 1 0.50% 
 Liver Failure Post Resection 1 0.50% 
 Non A-E Hepatitis 1 0.50% 
 TOTAL 194 100% 
    
SECONDARY 
DIAGNOSIS 
   
 None 111 57.20% 
 Hepatocellular Carcinoma 47 24.20% 
 Primary Sclerosing Cholangitis 8 4.10% 
 Alcoholic Liver Disease 7 3.60% 
 Autoimmune Hepatitis 5 2.60% 
 Hepatopulmonary Syndrome 4 2.10% 
 Non Alcoholic Fatty Liver 
Disease 
4 2.10% 
 Haemachromatosis 2 1.00% 
 Agille's Syndrome 1 0.50% 
 Biliary Atresia 1 0.50% 
 Cryptogenic 1 0.50% 
 Drug Induced Liver Disease 1 0.50% 
 Primary Biliary Cirrhosis 1 0.50% 
 Budd Chiari Syndrome 1 0.50% 
 TOTAL 194 100% 
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4.3.3 Transplant Categories 
 
Patients who undergo a liver transplant fall into two categories:  fulminant 
hepatic failure and chronic liver failure. In this study, 14 patients (7.2%) 
were transplanted for acute fulminant liver failure, 9 patients (4.6%) as 
urgent re-transplants whilst 155 patients (79.9%) were transplanted from the 
chronic liver failure waiting list in accordance with nationally agreed 
guidelines. The mean MELD score for the liver recipients at the time of being 
placed on the waiting list was 19.39±7.68. 
 
4.3.4 Donor Demographics 
 
194 liver donors were included in this study of which 176 (90.7%) had 
donated following brain stem death (DBD), 16 (8.2%) who donated after 
circulatory death (DCD) and 2 live donor transplants (1.0%). 99 donors were 
male (51.0%) and 95 female (49.0%).  Most were of Caucasian ethnicity [175 
(90.2%)] whilst 2 (1.0%) were Asian and 17 (8.8%) did not have the ethnic 
group recorded.  The mean age of the liver donors was 46.87±16.86 years 
with a mean height of 169.93±12.71 cm (71.00 – 193.00cm) and a mean 
weight of 75.33±16.16 kg (39.00 – 177.00 kg).  The calculated mean donor 
body mass index (BMI) was 25.70±4.41 (16.38 – 41.18). 
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4.3.5 Type of Liver Allograft 
 
173 whole liver grafts (89.2%) and 21 split liver grafts (10.8%) were 
transplanted.  The livers are assessed visually for steatosis at the time of 
retrieval and 128 liver allografts had no features of steatosis (66.0%), whilst 
all the other had varying degrees of steatosis [24 livers (12.4%) - mild 
steatosis; 36 livers (18.6%) - moderate steatosis and 6 livers (3.1%) - severe 
steatosis].  
 
The mean cold ischaemic time was 09:07±02:10 (hh:mm) with a range of 
02:54 – 15:51. The mean second warm ischaemic time (liver out of ice until 
reperfusion) was 36±7 minutes with a range of 13 – 62 minutes. 
 









Table 4.2 Donor demographics of the liver transplant cohort 
Donor 
Characteristics 
 Value  
Donor Type DBD 176 90.70% 
 DCD 16 8.20% 
 LDLT 2 1.00% 
Gender Male 99 51.00% 
 Female 95 49.00% 
Ethnicity Caucasian 175 90.20% 
 Asian 2 1.00% 
 Unknown 17 8.80% 
Cause of Death CVA 101 52.10% 
 Anoxia 13 6.70% 
 Trauma 27 13.90% 
 Other 8 4.10% 
 Live Donor 2 1.00% 
 Unknown 43 22.20% 
Virology CMV + 85 43.80% 
 CMV - 101 52.10% 
 Unknown 8 4.10% 
 HCV + 1 0.50% 
 HCV - 191 98.50% 
 Unknown 2 1.00% 
 HBV + 0 0.00% 
 HBV - 192 99.00% 
 Unknown 2 1.00% 
 HIV + 0 0.00% 
 HIV - 192 99.00% 
 Unknown 2 1.00% 
Comorbidities Hypertension 30 15.50% 
 Diabetes 7 3.60% 
 Cardiovascular Disease 10 5.20% 
 Obesity 21 10.80% 
Region Local 28 14.40% 
 Regional 57 29.40% 
 National 98 50.50% 
 Unknown 11 5.70% 
Blood Group O 107 55.20% 
 A 64 33.00% 
 B 16 8.20% 
 AB 7 3.60% 
Demographics Age (Years) 46.87±16.86 11 - 81 
 Weight (kg) 75.33±16.16 47 - 180 
 BMI 25.70±4.41 18.30 - 49.12 
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4.3.6 Cytochrome P450 3A5 (CYP3A5) Expression 
 
Of the 194 recipients in this study there were 136 valid samples available for 
analysis.  58 samples had no genotype data available because there was no 
stored DNA available or, occasionally the assay failed to determine the 
genotype. 
 
119 (87.5%) liver transplant recipients were GG homozygotes (*3/*3), 16 
(11.8%) were GA heterozygotes (*3/*1) and 1(0.7%) patient was an AA 
homozygote (*1/*1).  Individuals with either the *3/*1 or the *1/*1 genotype 
make functional CYP3A5 and were therefore termed CYP3A5 expressers 
(n=17). *3/*3 genotype does not make any functional CYP3A5 and therefore 
these recipients are termed CYP3A5 non-expressers. 
 
The liver donors were also genotyped and there were 181 valid samples for 
analysis. 161 donors (89.0%) were GG homozygotes (*3/*3, CYP3A5 non-
expressers), 19 (10.5%) were GA heterozygotes (*3/*1, CYP3A5 expressers) 
and 1 (0.5%) who was AA homozygote (*1/*1, CYP3A5 expresser). 
 
It was possible to obtain a full set of genotype data (recipient and donor) for 
124 patients (63.9%) and then group them according to both recipient and 
donor expression of CYP3A5.  Recipients were labelled expressers or non-
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expressers (RE or RnE) and similarly donors were labelled as expressers or 
non-expressers (DE or DnE).  In 96 cases (49.5%) neither the donor nor the 
recipient (RnE/DnE) expressed CYP3A5 (both had CYP3A5 *3/*3 genotype). 
In 13 (6.7%) cases the recipient expressed CYP3A5 whilst the donor did not 
(RE/DnE).  Similarly, there were 13 (6.7%) combinations where the recipient 
did not express CYP3A5 but the donor did (RnE/DE).  Finally, there were 2 
patients (1.0%) where both the donor and the recipient were expressers of 
CYP3A5 (RE/DE). 
 
4.3.7 Recipient CYP3A5 and tacrolimus dose requirements 
 
By the end of the first week following transplantation (WK1-3 time point) 
liver transplant recipients who are CYP3A5 expressers required a 
significantly higher dose of tacrolimus (5.82±2.63 mg) compared with non-
expressers of CYP3A5 (4.50±1.90 mg), p=0.015, one-way ANOVA.  The dose 
remained significantly higher up to and including the 3 month time point 
with the exception of the third time point in the second week (WK 2-3) and 
the third time point in the third week (WK 3-3) where the difference in dose 
did not reach statistical significance.  This is likely, in part, to be due to the 
smaller numbers of available data at these 2 time points compared with the 
rest, as only some liver transplant patients attended clinic appointments at 
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these time points.   At 6 months and 12 months there was no significant 
difference in the prescribed doses of tacrolimus for the expressers and non-
expressers of CYP3A5.  This suggests, perhaps, that the impact of recipient 
CYP3A5 expression (which accounts primarily for gut expression) is less 
important after the early transplant period.   
 
The tacrolimus dose requirements relative to recipient genotype are shown 
in Figure 4.1 below. 
 
4.3.8 Donor CYP3A5 and tacrolimus dose requirements 
 
Patients who receive a liver transplant from a donor who expresses CYP3A5 
[*3/*1 or *1/*1 genotype] require significantly higher doses of tacrolimus in 
order to achieve therapeutic trough levels.  As early as the second time point 
within the first week (WK1-2), patients transplanted with CYP3A5 
expressers donor livers were prescribed significantly higher doses of 
tacrolimus (4.77±1.52 mg) compared with those patients with a non-
expresser donor liver (3.94±1.52 mg), p=0.045, one-way ANOVA.  The 
magnitude of the effect increased during the follow-up (Figure 4.1).   
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Patients who received a liver from a CYP3A5 expresser donor had 
significantly higher tacrolimus dose requirements at every time point from 
WK1-2 up to and including 12 months post-transplant, by which time they 
required approximately double the dose of tacrolimus (6.29±3.60 mg) 
compared to the liver transplant recipients of a CYP3A5 non-expresser 
donor (3.99±1.84 mg), p<0.0001, one-way ANOVA.   
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Figure 4.1 Tacrolimus dose requirements relative to CYP3A5 expression for 
both the donor genotype and recipient genotype at each time point. * signifies 






4.3.9 Recipient CYP3A5 and Tacrolimus Trough Levels 
 
The tacrolimus C0 levels are lower in the recipient expressers of CYP3A5 up 
to the start of the second week (WK2-1), however these differences do not 
reach statistical significance.  There is no significant difference between the 
C0 levels at any of the subsequent time points between recipient CYP3A5 
expressers and non-expressers.   
 
While the difference in the achieved C0 levels does not differ significantly, it 
does appear that recipient CYP3A5 expressers do not achieve a therapeutic 
C0 level at the first time point as shown in Figure 4.2 below.  It is only at the 
2nd time point (WK1-2), usually around day 5, that recipient CYP3A5 
expressers breach the 5 µg/L therapeutic level. 
 
4.3.10 Donor CYP3A5 and Tacrolimus Trough (C0) Levels  
 
Patients who received a liver transplant from a CYP3A5 expresser donor had 
a significantly lower tacrolimus trough (C0) level (3.15±1.88 µg/L) 
immediately post transplantation (WK1-1) compared with those 
transplanted with a liver from a CYP3A5 non-expresser donor (4.96±3.66 
µg/L), p=0.036, one-way ANOVA.  Patients who received a liver from a 
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CYP3A5 expresser donor had persistently lower tacrolimus C0 levels 
throughout the first week and at the beginning of the second week post 
transplantation (up to and including time point WK2-1).  Furthermore, at 
time point WK2-3 patients transplanted with a CYP3A5 expresser liver had a 
significantly lower tacrolimus C0 level (4.48±1.63 µg/L) compared with those 
transplanted with a non-expresser liver (6.69±3.18 µg/L), p=0.007, one-way 
ANOVA, and this was also seen at time point WK3-2 (5.18±1.43 vs 7.43±2.66 
µg/L), p=0.003, one-way ANOVA.   
 
This shows that individuals transplanted with a CYP3A5 expresser liver have 
significantly lower tacrolimus trough (C0) levels and only after the dose is 
sequentially increased they achieve a therapeutic tacrolimus level.  Figure 
4.2 below demonstrates that the mean tacrolimus trough (C0) level was 
below the 5 µg/L therapeutic threshold right up until the beginning of the 
second week (WK2-1) and remained lower than 6 µg/L up to three weeks, 
potentially exposing the patient to inadequate immunosuppression and an 




Figure 4.2 Tacrolimus trough concentration (C0) relative to CYP3A5 
expression for both donor and recipient genotype at each time point. * 





4.3.11 Dose Corrected Tac Levels relative to Recipient and Donor 
CYP3A5  
 
Given that the tacrolimus trough (C0) level is related to the dose 
administered then one could argue that these differences are a reflection of 
the different doses prescribed rather than anything else.  As a means of 
trying to address this, the dose corrected tacrolimus level has been proposed 
as a measure of tacrolimus exposure. This is quite simply the tacrolimus 
level (C0) divided by the dose (D) [C0/D] and is also referred to as the ‘dose-
adjusted tacrolimus level’, the concentration/dose ratio.   
 
4.3.12 Recipient CYP3A5 and Dose Corrected Tacrolimus Level 
 
Recipients who were CYP3A5 expressers had slightly lower dose corrected 
tacrolimus levels at the first time point (1.00±0.69 µg/L per mg) compared 
with CYP3A5 non-expressers (1.55±1.24 µg/L per mg) however this did not 
reach statistical significance, p=0.097, one-way ANOVA.  Overall, the dose 
corrected tacrolimus level was lower at each time point for those recipients 
who were CYP3A5 expressers, but this only reached statistical significance at 
2 time points [WK3-1 (0.98±0.35 vs 1.74±1.25µg/L per mg), p=0.027, one-way 
ANOVA and WK4-2 (0.92±0.34 vs 2.10±1.74 µg/L per mg), p=0.036, one-way 
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ANOVA].    The dose-corrected tacrolimus levels relative to recipient 
CYP3A5 expression are shown in Figure 4.3 below. 
 
4.3.13 Donor CYP3A5 and Dose Corrected Tacrolimus Level 
 
The initial dose corrected tacrolimus level at time point WK1-1 was 
significantly lower in patients with a CYP3A5 expresser liver (0.90±0.48 µg/L 
per mg) compared with patients transplanted with a non-expresser liver 
(1.55±1.17 µg/L per mg), p=0.031, one-way ANOVA.  At every time point up 
to and including the 12 months time point, the dose corrected tacrolimus 
level (C0/D) was significantly lower in patients with a donor CYP3A5 
expresser liver when compared with patients who received a liver transplant 
from a CYP3A5 non-expresser liver.   Figure 4.3 below shows the dose 




Figure 4.3 Dose corrected tacrolimus trough concentration (C0/D) relative to 
CYP3A5 expression for both donor and recipient genotype at each time 








4.3.14 Grouped Genotype Analysis 
 
In order to evaluate whether the recipient or donor CYP3A5 genotype has 
the greater influence on tacrolimus pharmacokinetics and exposure, patients 
were grouped based on recipient and donor expression of CYP3A5.  Four 
groups were defined:  
• recipient and donor both non-expressers of CYP3A5 (RnE/DnE) 
• recipient expresser and donor non-expresser (RE/DnE) 
• recipient non-expresser and donor expresser (RnE/DE) 
• both recipient and donor expressers of CYP3A5 (RE/DE). 
 
4.3.15 Grouped CYP3A5 Genotype Analysis of Tacrolimus Dose 
 
There were significant differences in the tacrolimus dose requirements 
between these 4 groups by the end of the first week (time point WK1-3) with 
the mean tacrolimus dose for the RnE/DnE group of 4.31±1.75 mg, 5.88±2.95 
mg for the RE/DnE group, 6.30±2.25 mg for the RnE/DE group and 5.75±2.47 
mg for the DE/RE group, p=0.004, one-way ANOVA. 
 
This suggests that the DnE/RnE group require the lowest doses of 
tacrolimus, whilst the RnE/DE and the RE/DE groups require the highest 
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doses of tacrolimus in order to achieve therapeutic levels.  Given that there 
are only 2 patients in the RE/DE group, the results from this group must be 
interpreted cautiously. From time point WK1-3 onwards, the doses of 
prescribed tacrolimus were significantly different between the 4 groups at 
each subsequent time point and up to and including 12 months.   
 
Figure 4.4 below plots the mean dose at each time point for each of the 
genotype combinations of CYP3A5.  All lines start at exactly the same place 
as all patients are given approximately the same starting dose of tacrolimus 
based on their weight but separate out and appear to support the previous 
findings that the donor liver genotype has a greater impact than the 




Figure 4.4 Tacrolimus dose requirements relative to CYP3A5 combination 
genotype of both the liver donor and recipient at each time point.  * signifies 
significant result p<0.05 (RE = recipient expresser, RnE = recipient non-
expresser, DE = donor expresser, DnE = donor non-expresser) 
 
4.3.16 Grouped CYP3A5 Genotype of Tacrolimus Trough Levels 
 
There was no significant difference between the tacrolimus trough levels of 
the 4 groups at any of the time points with the exception of WK1-2 where 
the mean tacrolimus trough level for the RnE/DnE group was 6.73±3.68 µg/L, 
for the RE/DnE group was 5.68±3.71 µg/L, for the RnE/DE group was 
3.52±1.50 µg/L and for the RE/DE group was 3.35±0.78 µg/L, p=0.017, one-
way ANOVA.  While the statistical significance of between the groups in the 
early post transplant period is lacking, the graphical representation of the 
data in Figure 4.5 below suggests similar trends to previously described in 
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this chapter, where CYP3A5 expressers appear to have lower trough levels of 
tacrolimus.  Donor expressers of CYP3A5, either in isolation or in 
combination with recipient expression, appear to have lower tacrolimus 







Figure 4.5 Tacrolimus trough concentration (C0) relative to CYP3A5 
combination genotype of both the liver donor and recipient at each time point.  
* signifies significant result p<0.05 (RE = recipient expresser, RnE = recipient 






4.3.17 Grouped CYP3A5 Genotype of Dose-Corrected Tac Trough 
Levels 
 
There were significant differences in the dose corrected tacrolimus levels 
(C0/D) between the four donor/recipient genotype combinations at a few 
time points (WK-3-1, WK3-2, WK4-2 and 12 months).    Figure 4.6 below 
shows that the DnE/RnE group (where neither patient or recipient express 
CYP3A5) appears to have the greatest exposure to tacrolimus (the highest 
C0/D levels).   
 
 
Figure 4.6 Dose corrected tacrolimus trough concentration (C0/D) relative to 
CYP3A5 combination genotype of both the liver donor and recipient at each 
time point.  * signifies significant result p<0.05 (RE = recipient expresser, 




4.3.18 ABCB1 Recipient Genotype in Relation to Tacrolimus Dose  
 
 
The recipient genotype of ABCB1 does not appear to influence the required 
dose of tacrolimus in this study.  Individuals with the CC, CT or TT genotype 
have similar doses of tacrolimus prescribed at all time points up to and 
including 12 months as shown in Figure 4.7 below. 
 
4.3.19 Donor ABCB1 Genotype in Relation to Tacrolimus Dose  
 
 
The donor genotype of ABCB1 C3435T also appears to have very little effect 
on the tacrolimus dose requirements of liver transplant patients.  There were 
two time points where the donor genotype of ABCB1 resulted in a 
statistically significant difference in the dose requirements between the 
groups (WK4-1 and WK4-2).  At WK4-1 the mean tacrolimus dose for the 
donor CC genotype was 6.66±2.34 mg compared with 5.16±2.81 mg for the 
CT genotype and 5.90±2.83 mg for the TT genotype, p=0.028, one-way 
ANOVA.  A post-hoc Bonferroni analysis reveals that the significant 
difference lies between the CC and the CT values, (p=0.029), but not between 




Similar results were seen at time point WK4-2 and a post-hoc Bonferroni 
analysis showed that the significant difference was between the CC and the 
CT values. The reason for the significant difference at these 2 time points is 
unclear but given it is seen in the CT genotype but not the TT genotype then 
it is less likely to be truly significant and may represent an outlier at these 2 
time points.    
 
Figure 4.7 below shows the 3 different genotypes of ABCB1 C3435T in 
relation to tacrolimus dose at all time points for both the recipient and the 
donors.  Both recipient and donor graphs show very little difference in 




Figure 4.7 Tacrolimus dose requirements relative to ABCB1 genotype for 
both the donor and recipient genotype at each time point. * signifies 





4.3.20 ABCB1 Recipient Genotype in Relation to Tac Trough Levels 
 
Similar to the findings of the tacrolimus dose requirements in relation to 
recipient ABCB1 C3435T genotype, there was no significant differences in 
the tacrolimus trough levels at any of the time points between the CC, CT or 
TT recipient genotypes of ABCB1 in liver transplant patients as shown in 
Figure 4.8 below. 
 
4.3.21 ABCB1 Donor Genotype in Relation to Tac Trough Levels 
 
Similar to the recipient ABCB1 genotype, the donor genotype of ABCB1 
C3435T does not have any influence on the tacrolimus trough levels at any 









Figure 4.8 Tacrolimus trough concentration relative to ABCB1 genotype for 
both the donor and recipient genotype at each time point. * signifies 






4.3.22 ABCB1 Recipient Genotype and Dose Corrected Tac Levels 
 
Given that both the tacrolimus dose and the tacrolimus trough levels were 
not affected by the ABCB1 C3435T single nucleotide polymorphism, it is not 
surprising that the dose corrected tacrolimus levels are not influenced by the 
recipient ABCB1 genotype.  None of the time points show any significant 
difference in the dose corrected levels between the CC, CT or TT genotypes 
of ABCB1 as shown in Figure 4.9 below. 
 
4.3.23 ABCB1 Donor Genotype and Dose Corrected Tac Levels 
 
There are 3 time points where the dose corrected tacrolimus levels (C0/D) 
were significantly different (WK1-3, WK4-2 and 12 months) and were due to 
differences between CT and TT genotypes. 
 
The differences in the C0/D levels at these time points in isolation are 
unlikely to represent a true significant difference and may be due to values 
which are outliers.  Figure 4.9 displays the dose corrected tacrolimus level 
(C0/D) for both recipients and donors at each of the time points and shows 
that ABCB1 C3435T polymorphisms do not significantly affect the dose 




Figure 4.9 Dose corrected tacrolimus trough concentration (C0/D) relative to 
ABCB1 genotype for both the donor and recipient genotype at each time 
point. * signifies significant result p<0.05 
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4.3.24 CYP3A4*22 Recipient Genotype in Relation to Tac Dose  
 
Due to the low allele frequency of the CYP3A4*22 T allele, the genotype for 
CYP3A4*22 is analysed as 2 groups, those who do not express the T allele 
(wild type genotype CC) and those who do express the T allele (CT or TT 
genotype).   
 
There was no significant difference in the tacrolimus dose requirements of 
liver transplant patients based on the recipient CYP3A4*22 genotype at any 
of the time points.  (Figure 4.10) 
 
 
4.3.25 CYP3A4*22 Donor Genotype and Relation to Tacrolimus Dose 
 
The dose of tacrolimus was significantly lower in the CT/TT donor genotype 
group by WK2-3 time point with a mean dose of 5.47±2.91mg for the CC 
genotype and 3.44±1.42 mg for the CT/TT genotype, p=0.042, one-way 
ANOVA. 
 
The dose of tacrolimus was significantly lower at the WK3-1, WK4-1, WK4-2, 
3M, 6M and 12M time points too.   
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Figure 4.10 below demonstrates the tacrolimus dose requirements in relation 
to both the recipient and the donor CYP3A4*22 genotype. The donor 
genotype plays a much more significant role and expression of a T allele 





Figure 4.10 Tacrolimus dose requirements relative to CYP3A4*22 T allele 
expression for both the donor and recipient genotype at each time point. * 





4.3.26 CYP3A4*22 Recipient Genotype Relative to Tac Trough Levels 
   
The recipient CYP3A4*22 genotype has a mixed effect on tacrolimus trough 
levels, with the C0 levels significantly different between the CC and the 
CT/TT groups at some of the time points (WK1-3, WK2-2, WK2-3 and WK4-
2) where the T allele expressers have higher tacrolimus trough levels.   
 
Displaying graphically the mean tacrolimus trough levels of the CYP3A4*22 
CC and CT/TT genotypes (Figure 4.11) does suggest that those individuals 
who carry the CYP3A4*22 T allele have higher tacrolimus levels than the CC 
genotype, but this only reaches statistical significance at certain time points. 
 
4.3.27 Donor CYP3A4*22 Genotype Relative to Tac Trough Levels 
 
There appears to be only minimal impact on tacrolimus trough levels in 
relation to donor CYP3A4*22 genotype with a significant difference seen at 
time points WK3-1 and WK3-2 however this is likely to be an anomaly rather 
than any significant difference. 
 
Figure 4.11 below shows graphically the differences in tacrolimus trough 
levels for both donor and recipient CYP3A4*22 genotypes. 
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Figure 4.11 Tacrolimus trough concentration (C0) relative to CYP3A4*22 T 
allele expression for both the donor and recipient genotype at each time 






4.3.28 Dose-corrected Tac Levels Relative to Recipient CYP3A4*22 
 
 
Recipients who express a T allele do not have any difference in the dose 
corrected tacrolimus levels compared with those of the CC genotype.  The 
only exception noted was at the WK4-2 time point where the dose corrected 
tacrolimus level for the CC genotype was 1.76±1.41 µg/L per mg compared 
with 3.51±2.94 µg/L per mg for the CT/TT genotype, p=0.010, one-way 
ANOVA. 
 
4.3.29 Dose-Corrected Tac Levels Relative to Donor CYP3A4*22  
 
There was a significant difference in the dose corrected tacrolimus levels 
between the donor CC genotype and the CT/TT genotype at multiple time 
points (WK3-1, 3M, 6M and 12M). Patients transplanted with a donor liver 
expressing a T allele have higher dose corrected tacrolimus levels (greater 
tacrolimus exposure) at these time points. 
 
 
Figure 4.12 below displays the dose corrected tacrolimus levels at each of the 
time points in relation to the donor and recipient CYP3A4*22 genotype.  The 
donor genotype appears to have a greater influence leading to greater 
tacrolimus exposure in patients transplanted with donor livers expressing 
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the T allele compared with the CC homozygotes.  While these differences 
only reach statistical significance at a few of the time points, the allele 
frequency of the T allele in this SNP is very low and therefore much larger 
numbers of patients may be required in order to evaluate if there is a truly 
sustained significant difference. 
 
Figure 4.12 Tacrolimus dose corrected trough concentration (C0/D) relative to 
CYP3A4*22 T allele expression for both the donor and recipient genotype at 
each time point. * signifies significant result p<0.05 
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4.3.30 Repeated Measures ANOVA 
 
A potential pitfall of repeatedly measuring the same variables in the same 
subjects over a time period is that patient baseline characteristics may be 
misinterpreted as a true difference and also a regression towards the mean 
effect, whereby a result that may seem significant has, in fact, just followed 
on from an unusually high or unusually low result and the actual mean is not 
significantly different to other subjects. 
 
A repeated measures ANOVA is a multivariate analysis that corrects for this 
and is considered a better statistical test than carrying out an ANOVA 
analysis at each time point.  The repeated measures ANOVA will give an 
overall p value (called Wilks’ lambda) and will also give a significance of the 
within-subject effects and the between-subject effects. 
 
Table 4.3 below outlines the significance overall (Wilks’ lambda) of the mean  
tacrolimus dose, the mean tacrolimus trough concentration and the mean 
dose-corrected trough concentration for both recipient and donor CYP3A5, 
ABCB1 and CYP3A4*22 genotypes.  It also details any significant difference 
of the within-subject effects or between-subject effects for these parameters.   
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In general the results reflect similar findings of the ANOVA univariate 
analyses already presented in this chapter with the donor CYP3A5 genotype 
having the dominant effect on tacrolimus pharmacodynamics. 
 
Table 4.3 Repeated measures ANOVA for donor and recipient CYP3A5, 
ABCB1 and CYP3A4*22 genotype for tacrolimus dose, tacrolimus trough 
concentration and dose corrected tacrolimus trough concentration.  Overall 
multivariate comparison (Wilks’ lambda), within-subject effects and between-
subject effects are shown. 
 
 
Wilks' Lambda p value 
(Multivariate) 
Within-Subject Effects (p 
value) 






Dose Corr Tac 
Dose 










0.048 0.322 0.933 0.007 0.04 0.991 0.014 0.002 0.012 
DONOR 
ABCB1 
0.205 0.337 0.597 0.309 0.273 0.256 0.676 0.068 0.619 
DONOR 
CYP3A4 
0.986 0.095 <0.0001 0.606 0.042 0.259 0.053 0.373 0.275 
RECIPIENT 
CYP3A5 
0.151 0.045 0.655 0.714 0.268 0.993 0.453 0.637 0.375 
RECIPIENT 
ABCB1 
0.359 0.496 0.485 0.111 0.332 0.536 0.026 0.434 0.142 
RECIPIENT 
CYP3A4 
0.195 0.119 0.753 0.72 <0.0001 0.932 0.776 0.647 0.74 
 
 
There are some drawbacks of this type of analysis, however, which make its 
application to this retrospective analysis somewhat difficult.  This analysis 
requires each field between subjects and within a subject to be filled, in short 
it only analyses results where every value is recorded between the subjects 
and cannot analyse missing data.  The result is far fewer subjects where an 
entirely full dataset is available.  A retrospective study of this kind will 
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almost always have some missing data therefore this analysis is likely to be 
underpowered as the dataset is much smaller (only 32 subjects analysed for 
donor CYP3A5 genotype relative to tacrolimus dose).  The majority of the 
currently published literature performs a standard univariate method of 
analysing the difference of the means (ANOVA or t-test) although more 
complex multivariate models are now appearing in literature.  Given the 
limitations of this repeated measures analysis with our dataset the 
remainder of analysis in this thesis are performed with univariate ANOVA, 
accepting the limitations of that statistical test. 
 
4.3.31 Time to Reach Therapeutic Tacrolimus Levels  
 
Following liver transplantation it is important that patients achieve a 
therapeutic tacrolimus trough level as soon as possible to ensure adequate 
immunosuppression to prevent allograft rejection.  In our centre the 
minimum level at which tacrolimus whole blood concentration trough level 
is considered therapeutic is 5µg/L.  We investigated the time taken for each 
patient to reach a therapeutic level and correlated this with the recipient and 




4.3.32 CYP3A5 Recipient and Donor Genotypes  
 
Recipients who were non-expressers of CYP3A5 (GG or *3/*3 genotype) had 
a significantly shorter mean time before reaching a therapeutic tacrolimus 
level compared to recipients who were expressers of CYP3A5 (GA *3/*1 or 
AA *1/*1 genotype) [5.188±1.2491 days (0 – 21 days) vs 8.088±6.0679 days (0 
– 23 days), p=0.014, one-way ANOVA].  The trend was similar for the donor 
genotype however it did not reach statistical significance, [5.671±5.4260 
days (0 – 34 days) compared with 7.474±5.2400 days (0 – 21 days), p=0.170, 
one-way ANOVA].  Figure 4.13 below displays the time taken to reach the 
therapeutic tacrolimus trough level relative to recipient and donor 
expression of CYP3A5. 
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Figure 4.13 Time taken to reach a therapeutic tacrolimus trough 







4.3.33 CYP3A5 Donor and Recipient Grouped Genotypes 
 
The time to reach therapeutic tacrolimus level for (RnE/DnE) patients was 
5.03±4.23 days (0 – 21 days). Where the recipient was an expresser of 
CYP3A5 but the donor liver was not (RE/DnE), a therapeutic level was 
reached in 7.034±5.83 (0 – 23 days).  When the recipient was a non-expresser 
of CYP3A5 but was transplanted with a CYP3A5 expresser liver (RnE/DE), 
the mean time to reaching a therapeutic tacrolimus level was 7.39±4.78 days 
(0 – 14 days). There were only two patients in the RE/DE group (both 
recipient and donor expressers of CYP3A5) and the mean time to therapeutic 
level was 8.50±0.71 days (8 – 9 days).  None of these times were statistically 
different, p=0.128, one-way ANOVA. 
 
Figure 4.14 below displays the time taken to reach a therapeutic tacrolimus 






Figure 4.14 Time taken to reach a therapeutic tacrolimus trough 
concentration (C0) relative to CYP3A5 grouped genotype in both the liver 
donor and recipient.  (RE = recipient expresser, RnE = recipient non-




4.3.34 ABCB1 Recipient and Donor Genotypes 
 
 
There was no difference in the time to reaching therapeutic tacrolimus levels 
between any of the recipient genotypes of ABCB1 [5.17±4.27 days for CC 
genotype, 5.48±3.90 days for CT genotype and 6.18±5.67 days for the TT 
genotype, (p=0.604, one-way ANOVA). 
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Similar results were seen for the liver donor ABCB1 genotype [5.68±5.05 days 
for the CC genotype, 5.59±5.18 days for the CT donor genotype and 
7.00±6.66 days for the TT donor genotype, (p=0.370, one-way ANOVA).   
Figure 4.15 below shows the mean time taken until a therapeutic level of 




Figure 4.15 Time taken to reach a therapeutic tacrolimus trough 








4.3.35 CYP3A4*22 Recipient and Donor Genotypes 
 
Liver transplant recipients who expressed a T allele of CYP3A4*22 appeared 
to reach a therapeutic tacrolimus level slightly earlier than those who did 
not express a T allele although this did not reach statistical significance 
[3.818±2.8220 days (1 – 11days) for the CT/TT genotype compared to 
5.712±4.6768 days (0 – 23 days) for the CC genotype, (p=0.189 one-way 
ANOVA)]. 
 
In contrast, there were no differences according to the expression of a donor 
T allele of CYP3A4*22 [5.914±5.7060 days (0 – 34 days) for the CC genotype 
compared with 5.947±4.5151 days (1 – 19 days) for the CT/TT genotype, 
(p=0.980, one-way ANOVA)].  Figure 4.16 below shows the time to reach 
therapeutic tacrolimus level for both donor and recipient genotypes of 
CYP3A4*22. 
 
Only recipient expressers of CYP3A5 take a significantly longer time to 
therapeutic tacrolimus levels compared with recipient non-expressers of 
CYP3A5.  While there are some trends towards a longer time, the donor 
CYP3A5 genotype and the recipient genotype of CYP3A4*22 have no 
statistically significant impact. 
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Figure 4.16 Time taken to reach a therapeutic tacrolimus trough 
concentration (C0) relative to CYP3A4*22 T allele expression in both the liver 




4.3.36 Biopsy Proven Acute Rejection in Relation to Genotype 
 
While different SNPs can affect the pharmacokinetics of tacrolimus, the 
clinical implications of this are less clearly established. 
 
The recipient CYP3A5 genotype analysis revealed that 30 out of 119 liver 
transplant patients (25.2%) who were GG (*3/*3) genotype [non-expressers 
of CYP3A5] had at least one episode of acute rejection compared with four 
out of 17 patients (23.5%) who were CYP3A5 expressers (GA/AA or 
*3/*1,*1/*1) (p=0.574, Chi-square test).  We also examined the temporal 
relationship of BPAR with the transplant looking at three time points: 30 
days, 90 days and 365 days post transplantation. 
 
At 30 days, there were no differences between CYP3A5 expressers [2 patients 
(11.8%)] and non-expressers [13 patients (10.9%)]. (p=0.918, Chi-square 
test). 
 
Similar findings were noted at 90 days [19 (16.1%) vs 3 (17.6%), p=0.872, 
Chi-square test) and 365 days respectively [29 (24.6%) compared with 3 




Figure 4.17 Biopsy proven acute rejection rate relative to recipient CYP3A5 
expression over the entire study period and at 30, 90 and 365 days. 
 
 
4.3.37 Donor CYP3A5 Expression and Acute Rejection 
 
In contrast to the recipient CYP3A5 genotype, CYP3A5 expression in donor 
livers does appear to have a significant impact on acute rejection in liver 
transplant patients.  Overall 8 (42.1%) out of 19 patients transplanted with a 
CYP3A5 expresser donor liver had at least one episode of biopsy proven 
acute rejection compared with 36 (20.9%) out of 172 patients transplanted 







This difference was not significant at 30 days [2 (10.5%) CYP3A5 expressers 
vs 16 (9.3%) non-expressers, (p=0.862, Chi-square test)] but was clear at 90 
days when 6 out of 19, (31.6%) CYP3A5 expresser liver recipients had BPAR 
compared with 19 out of 171, (11.1%) non-expresser recipients, (p=0.012, 
Chi-square test). 
 
At the 365 day, there was a trend towards higher incidence of BPAR in the 
expresser group, although this did not reach statistical significance [7 
(36.8%) out of 19 expresser recipients compared with 34 (19.9%) out of 171 
non-expresser recipients (p=0.088, Chi-square test). 
 
Figure 4.18 below demonstrates the differences in BPAR between patients 
transplanted with livers from CYP3A5 expressers and non-expressers at each 





Figure 4.18 Biopsy proven acute rejection rate relative to donor CYP3A5 
expression over the entire study period and at 30, 90 and 365 days. 
 
 
4.3.38 ABCB1 Recipient Genotype and Acute Rejection 
 
There was no correlation between any of the three possible recipient 
genotypes of ABCB1 C3435T (CC, CT, TT) and the overall incidence of BPAR 
[12 (33.3%) out of 36 CC genotype recipients, 13 (22.4%) out of 58 CT 
genotype recipients and 10 (23.8%) out of 32 TT genotype recipients 







At 30 days post-transplant, 8 (22.2%) of 36 patients with the CC genotype 
compared with 6 (10.3%) out of 58 patients with the CT genotype and 2 
(4.8%) out of 42 patients with the TT genotype respectively had at least one 
episode of acute rejection, although this not reach statistical difference 
(p=0.053, Chi-square test). The incidence of BPAR was comparable at the 90 






Figure 4.19 Biopsy proven acute rejection rate relative to recipient ABCB1 











4.3.39 Donor ABCB1 Genotype and Acute Rejection 
 
 
Similarly to the recipient genotype of ABCB1, there were no significant 
differences in BPAR between the recipients of CC, CT or TT donor genotype 
livers [10 (27.0%) out of 37 patients for the CC genotype, 21 (21.6%) out of 97 
patients for the CT genotype and 10 (23.8%) out of 42 patients for the TT 






Figure 4.20 Biopsy proven acute rejection rate relative to donor ABCB1 




Overall 30 DAYS 90 DAYS 365 DAYS
CC 27.00% 8.10% 18.90% 27.00%
CT 21.60% 11.30% 12.40% 20.60%
















4.3.40 CYP3A4*22 Recipient Genotype in Relation to Acute Rejection 
 
Due to the low allele frequency of the T allele of CYP3A4*22, patients were 
placed into 2 groups for analysis: CC wild type and those who express either 
one or both T alleles (CT/TT). 
 
Overall, there were no significant differences in acute rejection between the 
two recipient genotypes [33 (26.0%) out of 127 patients with the recipient CC 
genotype compared with 2 (18.2%) out of 11 patients with the CT/TT 





Figure 4.21 Biopsy proven acute rejection rate relative to recipient 
CYP3A4*22 T allele expression over the entire study period and at 30, 90 









4.3.41 Donor CYP3A4*22 Genotype in Relation to Acute Rejection 
 
When the donor genotype was analysed, there was no significant difference 
between the overall and individual time point BPAR incidence according to 
the 2 genotypes of CYP3A4*22 [39 (24.5%) out of 159 patients with a donor 
CC genotype compared with 6 (31.6%) out of 19 patients with a CC/CT donor 
liver genotype (p=0.504, Chi-square test)].   Figure 4.22 shows biopsy proven 
acute rejection in relation to donor CYP3A4*22 genotype overall and at the 





Figure 4.22 Biopsy proven acute rejection rate relative to donor CYP3A4*22 





Overall 30 DAYS 90 DAYS 365 DAYS
CC 24.50% 9.40% 13.90% 22.80%
















4.3.42 Cox Regression Multivariate Analysis 
 
Multivariate analysis also showed that donor expression of CYP3A5 was 
associated with increased biopsy proven acute rejection within the first year 
following transplant, p=0.027.  Interestingly CYP3A4*22 donor T allele 
expression was also associated with increased biopsy proven acute rejection 
in multivariate analysis (p=0.006) however this was not seen in a univariate 
analysis.  The T allele frequency is very low in the CYP3A4*22 genotype and 
a much larger study would be needed to further evaluate whether acute 
rejection was associated with T allele expression in the donor. 
 
Table 4.4 Cox regression multivariate analysis for acute rejection 
Variable  P value 
CYP3A5 Recipient Genotype  0.347 
CYP3A5 Donor Genotype 0.027 
ABCB1 Recipient Genotype 0.668 
ABCB1 Donor Genotype 0.612 
CYP3A4*22 Recipient Genotype 0.648 
CYP3A4*22 Donor Genotype 0.006 
Recipient Age 0.689 
MELD 0.952 
Cold Ischaemic Time 0.121 
Donor Type (DBD/DCD) 0.073 
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4.3.43 Graft Survival 
 
There were 7 episodes of graft loss within the first year following 
transplantation giving a 1 year graft survival for this cohort of 96.39%.  
Overall in this study there were 17 episodes of graft loss in the study period, 
equating to graft survival of 91.2% (on a variable time scale from the date of 
transplantation). 
 
4.3.44 CYP3A5 Expression and Graft Loss 
 
There was no significant difference found in graft survival with either 














Figure 4.23 Kaplan-Meier plots of graft survival following liver transplantation 
relative to CYP3A5 expression of both the donor and recipient 
 
A univariate Kaplan-Meier analysis does not demonstrate any significant 
difference in graft survival between recipient CYP3A5 expression (Log-Rank 
p = 0.791) and donor CYP3A5 expression (Log-Rank p = 0.193). 
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4.3.45 Grouped Genotype Analysis of CYP3A5 and Graft Survival 
 
There was similarly no significant difference in graft survival between any of 
the donor/recipient combination genotypes of CYP3A5. 
 
 
Figure 4.24 Kaplan-Meier plot of graft survival following liver transplantation 
relative to CYP3A5 donor/recipient grouped genotypes. (RnE = recipient non-
expresser, RE = recipient expresser, DnE = donor non-expresser, DE = 
donor expresser) 
Log rank test RnE/DnE RE/DnE RnE/DE RE/DE 
RnE/DnE  0.828 0.380 0.720 
RE/DnE 0.828  0.337 0.695 
RnE/DE 0.380 0.337  x 
RE/DE 0.720 0.695 x  
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4.3.46 Graft Loss Relative to ABCB1 Genotype 
 
There was no significant difference in graft survival between any of the 3 
different genotypes of ABCB1 for either the recipient or donor genotypes.  
The tables below show the different p values for the Log-rank test between 
the three different recipient and donor genotypes shown in the Kaplan-
Meier survival curves that follow in Figure	4.25	below.	
	
Recipient Genotypes CC CT TT 
CC  0.854 0.308 
CT 0.854  0.211 
TT 0.308 0.211  
 
Donor Genotypes CC CT TT 
CC  0.576 0.606 
CT 0.576  0.215 





Figure 4.25 Graft survival following liver transplantation relative to ABCB1 
genotype for both donor and recipient.   
 
 
A univariate Kaplan-Meier analysis did not show any significant difference 
in graft survival between the 3 different genotypes of ABCB1 for either the 
recipient or donor. 
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4.3.47 Graft Survival Relative to CYP3A4*22 Genotype 
 
There was no significant difference in graft survival due to either the 
recipient or donor genotype of CYP3A4*22 on univariate Kaplan-Meier 
curves with Log-rank analysis as shown in	Figure	4.26	below. 
 
This study did not find that any of the different genotypes of the 3 SNPs had 

















Figure 4.26 Graft survival following liver transplantation relative to 
CYP3A4*22 T allele expression of both donor and recipient 
 
 
A univariate Kaplan-Meier analysis does not demonstrate any significant 
difference in graft survival between recipient CYP3A4*22 expression (Log-
Rank p = 0.382) and donor CYP3A4*22 expression (Log-Rank p = 0.543). 
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4.3.48 Cox Regression Multivariate Analysis 
 
Multivariate analysis did not demonstrate any significant difference in graft 
loss between any of the genotypes of the 3 SNPs in this study. This was the 
same for both the recipient and donor genotypes.  There were no variables in 
the analysis that significantly increased graft loss. 
 
Table 4.5 Cox regression multivariate analysis graft survival 
Variable p value 
CYP3A5 Recipient Genotype 0.983 
CYP3A5 Donor Genotype 0.990 
ABCB1 Recipient Genotype 0.466 
ABCB1 Donor Genotype 0.467 
CYP3A4*22 Recipient Genotype 0.995 
CYP3A4*22 Donor Genotype 0.993 
Recipient Age 0.382 
Recipient Gender 0.572 
Donor Age 0.530 
MELD 0.384 
Cold Ischaemic Time 0.809 
BPAR 0.976 
Donor Type (DBD/DCD) 0.254 
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4.3.49 Patient Survival 
 
There were 3 patient deaths within the first 12 months of transplantation 
giving a 1 year patient survival rate of 98.45%.  Overall there were 9 deaths 
during this study period giving an overall patient survival rate of 95.4% (on a 
varying time scale from the point of transplantation). 
 
4.3.50 Patient Survival Relative to CYP3A5 Genotype 
 
There was no significant difference in patient survival relative to either the 














Figure 4.27 Patient survival following liver transplantation relative to CYP3A5 
genotype of both donor and recipient 
  
 
A univariate Kaplan-Meier analysis does not demonstrate any significant 
difference in patient survival between recipient CYP3A5 expression (Log-
Rank p = 0.878) and donor CYP3A5 expression (Log-Rank p = 0.289)
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4.3.51 Grouped Genotype Analysis of CYP3A5 and Patient Survival 
 
There was no significant difference seen between any of the CYP3A5 
expresser/non-expresser combinations of donor or recipient genotype and 
patient survival as shown in Figure 4.28 below. 
 
Figure 4.28 Patient survival following liver transplantation relative to 
combined CYP3A5 genotype of both donor and recipient. (RnE = recipient 
non-expresser, RE = recipient expresser, DnE = donor non-expresser, DE = 
donor expresser) 
Log rank RnE/DnE RE/DnE RnE/DE RE/DE 
RnE/DnE - 0.685 0.440 0.706 
RE/DnE 0.685 - 0.337 0.695 
RnE/DE 0.440 0.337 - - 
RE/DE 0.706 0.695   
 
 220 
4.3.52 Patient Survival Relative to Recipient and Donor ABCB1  
 
There was no significant difference in patient survival relative to the 
recipient genotype of ABCB1 or the donor genotype of ABCB1.    The tables 
below show the different p values for the Log-rank test between the three 
different recipient and donor genotypes shown in the Kaplan-Meier survival 
curves that follow. (Figure	4.29)	
 
Recipient Genotypes CC CT TT 
CC - 0.521 0.458 
CT 0.521 - 0.976 
TT 0.458 0.976 - 
 
Donor Genotypes CC CT TT 
CC - 0.561 0.530 
CT 0.561 - 0.176 




Figure 4.29 Patient survival following liver transplantation relative to ABCB1 
genotype of both the donor and the recipient. 
 
 
A univariate Kaplan-Meier analysis did not show any significant difference 
in patient survival between the 3 different genotypes of ABCB1 for either the 
recipient or donor.
 222 
4.3.53 Recipient and Donor CYP3A4*22 and Patient Survival 
 
There was no significant difference in patient survival due to either the 
recipient or donor genotype of CYP3A4*22 on univariate Kaplan-Meier 




Figure 4.30 Patient survival following liver transplantation relative to 






This study did not find that any of the different genotypes of the 3 SNPs had 
a significant impact on patient survival on univariate analysis.
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4.3.54 Cox Regression Multivariate Analysis for Patient Survival 
 
Cox regression survival analysis did not reveal any significant difference in 
patient survival for any of the genotypes of the 3 SNPs.  None of the 
variables in the analysis demonstrated a significant impact on patient 
survival as shown below. 
Table 4.6 Cox regression analysis for patient survival following liver 
transplantation 
Variable  p value 
CYP3A5 Recipient Genotype 0.958 
CYP3A5 Donor Genotype 0.376 
ABCB1 Recipient Genotype 0.559 
ABCB1 Donor Genotype 0.413 
CYP3A4*22 Recipient Genotype 0.883 
CYP3A4*22 Donor Genotype 0.900 
Recipient Age 0.245 
Recipient Gender 0.541 
Donor Age 0.249 
Donor Type (DBD/DCD) 0.185 
MELD 0.985 
BPAR 0.131 
Diabetes After Transplantation 0.129 
Myocardial Infarction 0.107 
Cerebrovascular Accident 0.686 
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Many factors affect patient survival and with a relatively short follow up 
time and few events, further larger studies are much better placed to 
evaluate post liver transplant survival. 
 
This study has found no evidence that variation in expression of the 
genotype of CYP3A5, ABCB1 or CYP3A4*22 affects graft or patient survival 
when taking into account the genotype of both the donor and the recipient 
of a liver transplant patient. 
 
4.3.55 Power of The Study 
 
Given that there are no significant differences in graft or patient survival in 
the univariate analysis for donor or recipient and in the multivariate 
analysis, factors that are known to be independent risk factors for graft loss 
such as donor age, did not reveal a significant result, the power of this study 
is worth considering.  Given that this is a retrospective analysis, a 
prospective power calculation is not possible however it is feasible to 
calculate, retrospectively, the power of the study.  Some statistical purists 
consider this a meaningless exercise however it can inform in a very broad 
sense whether the study was large enough to detect a true difference. 
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A retrospective power calculation was undertaken for the recipient and 
donor CYP3A5 expressers for graft and patient survival. 
 
Table 4.7 Retrospective power calculation for graft and patient survival 
relative to CYP3A5 expression with assumed alpha value of 0.05.   
 Graft Survival Power Patient Survival Power 
Donor CYP3A5 2.5% 0.9% 
Recipient CYP3A5 2.8% 7.2% 
 
The standard minimum power for a study is 80% therefore we should 
consider this study underpowered to detect a true difference in graft or 
patient survival relative to different genotypes.  A power calculation was not 
carried out for the other chapters or different SNPs for graft and patient 
survival as it is highly likely they are all equally underpowered to detect 
these differences, given the results are similar to the liver recipients and 
their CYP3A5 genotype. 
 
4.4 Chapter Summary 
 
The data presented in this chapter have shown that CYP3A5 expression has 
the most significant impact on tacrolimus metabolism requiring significantly 
higher doses compared with patients in whom CYP3A5 expression is absent.  
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As CYP3A5 is made primarily in liver tissue, the donor genotype of CYP3A5 
had a greater influence than that of the recipient.  In addition to the higher 
dose requirements, it also took longer for both the donor and recipient 
expressers of CYP3A5 to reach a therapeutic level compared with non-
expressers.  Biopsy proven acute rejection was significantly higher in those 
patients who received a liver transplant from a donor who was a CYP3A5 
expresser in both univariate and multivariate analyses.  Recipient expression 
of CYP3A5 did not influence acute rejection.  Both graft and patient survival 
was unaffected by CYP3A5 expression from either the donor or the recipient.   
 
The 3 different genotypes of ABCB1 appear to play little role in the 
metabolism and pharmacodynamics of tacrolimus.  There was no significant 
difference in tacrolimus dose requirements or trough levels between any of 
the 3 possible genotypes of ABCB1 for either the donor or the recipient 
genotype.  ABCB1 expression did not seem to have any impact on the time 
taken to reach a therapeutic level nor did it have any influence on biopsy 
proven acute rejection, all the results were comparable between the different 
genotypes for both donor and recipient.  Patient and graft survival were 
unaffected by ABCB1 genotype.  These findings for ABCB1 are similar to 
those found in the more extensively studied renal transplant population in 
the current literature. 
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To accurately ascertain the impact of T allele expression of CYP3A4*22 in 
relation to tacrolimus metabolism and pharmacodynamics is somewhat 
difficult due to the infrequency of which a T allele is expressed.  This study 
showed that donor T allele expression of CYP3A4*22 showed a trend towards 
lower tacrolimus dose requirements although there was less of an impact 
seen on the trough levels.  The lower dose requirement is more subtle than 
the difference in the increased dose requirement seen in donor CYP3A5 
expressers.  This would be in keeping with previously published literature on 
renal transplantation which reports an approximate 50% reduction in 
tacrolimus dose requirement for individuals that express a T allele of 
CYP3A4*22 [180].  There was no increase in acute rejection on univariate 
analysis of T allele expressers however on multivariate analysis this became 
significant if the donor was a T allele expresser.  Further studies with larger 
patient numbers are required to determine if this phenomenon is reproduced 
in other cohorts of liver transplant patients.  CYP3A4*22 expression in either 
the donor or recipient had no impact on graft or patient survival. 
 
The influence of CYP3A5 in renal transplantation has been established for 
some time now however the impact this polymorphism has on tacrolimus in 
liver transplantation is only just beginning to emerge.  It seems that donor 
expression carries the greater influence than native genotype and it may well 
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have more clinical implications with acute rejection which has not been seen 
in studies of renal transplant patients. 
 
Early studies of acute rejection following liver transplantation found that it 
was a common event arising in up to 65 % of liver transplant patients within 
the first year, the majority of which occurred in the first 3 months [201].   
Another review of 18 studies reported acute rejection rates of between 24 – 
80% (mean 49%) [202].  In liver transplantation the clinical impact of acute 
rejection on graft and patient survival is thought to be minimal as it is easily 
reversible with steroid boluses in the majority of cases.  While there are 
some more recent studies that suggest acute cellular rejection in liver 
transplant patients may, in fact, negatively impact graft and patient survival 
[203] the majority of the current evidence does not support this. 
 
This study found that CYP3A5 expression in donor livers was associated with 
significantly higher rates of acute rejection, however this appeared to 
happen late after transplantation rather than within the first 3 months as 
one might expect.  Acute rejection which occurs late has been shown to 
negatively impact on graft and patient survival [204, 205].  There could be 
several reasons for late rejection but a favoured opinion is that it occurs due 
to changes in immunosuppression, either the stopping of steroids, the 
reduction of CNIs or both.  Other independent risk factors that have been 
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reported are a young age, female gender and an autoimmune pathology prior 
to liver transplantation [206].  A detailed multivariate analysis is out with 
the remit of this study however these factors should be borne in mind when 
interpreting the results of increased late acute rejection in the patients 































In renal transplantation, careful HLA matching alongside a robust 
immunosuppressant regimen is required to minimise the risk of organ 
rejection.  Calcineurin inhibitors (CNI) have been the backbone of 
immunosuppression for renal transplant patients and currently Tacrolimus 
is the most commonly used agent. 
 
Given the narrow therapeutic index of Tacrolimus, therapeutic drug 
monitoring (TDM) reduces the risk of a patient developing tacrolimus 
toxicity or being inadequately immunosuppressed. However, there is 
considerable variability between individual patients as well as within an 
individual recipient, making a standard dosing protocol somewhat 
problematic, some individuals requiring significantly higher doses in order 
to achieve the pre-determined therapeutic levels of tacrolimus.  This 
phenomenon was noted more frequently in black patients prompting 
investigation into a genetic basis for the increased dose requirements [100].  
Several genetic polymorphisms including single nucleotide polymorphism of 
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the cytochrome CYP3A5, ABCB1 and CYP3A4*22 genes have been reported 
to influence tacrolimus pharmacokinetics   [100] [124]  [105, 207]. 
 
This chapter will examine the effect of the expression of SNPs of CYP3A5 
(6898 A>G), ABCB1 (3435C>T) and CYP3A4*22 (15389 C>T) on tacrolimus 
dose requirements and trough levels in a cohort of Scottish renal transplant 
patients with particular emphasis on clinical impact in terms of acute 
rejection, delayed graft function, renal function and in graft and patient 
survival.  A smaller cohort of simultaneous pancreas-kidney (SPK) patients 
has also been genotyped for these 3 SNPs and the correlations with 
tacrolimus dose requirements, trough levels and clinical end points 
explored. 
 
5.2 Chapter Methodology 
 
 
185 renal transplants and 32 SPK transplants with stored frozen DNA 
samples available for genotyping were included in this study.  DNA samples 
were genotyped for the CYP3A5 A6986G transition (rs776746), the ABCB1 
C3435T transition (rs1045642) and the CYP3A4*22 C15389T transition 
(rs35599367) using the Taqman® genotyping assay and real-time polymerase 
chain reaction (RT-PCR) technique as described in the methods chapter.  
 234 
Clinical data were collected from a variety of sources including medical case 
notes, electronic medical records and donor information records.  This 
included gender, age, ethnic group, height, weight, BMI, renal disease 
diagnosis, medical co-morbidities, blood group, number of transplant, and 
virology status (HCV/HBV/HIV/CMV).  Donor information included gender, 
age, ethnic group, height, weight, BMI, blood group, donor type 
(DBD/DCD/LIVE), cause of death, region, co-morbidities, renal function and 
virology status (HCV/HBV/HIV/CMV).  Transplant information included the 
cold ischaemic time (CIT) and the HLA mismatch.   
 
Tacrolimus dose and trough levels (C0) were collected at a total of 14 time 
points: 3 time points in weeks 1-3, 2 time points in the 4th week and then at 
3, 6 and 12 months. The time to reach the therapeutic C0 tacrolimus level was 
recorded. In addition, renal function (MDRD creatinine) was recorded at 
each of the time points.  Biopsy proven acute rejection episodes, graft 
survival and patient survival were recorded and significant post operative 







5.3 Chapter Results 
 
5.3.1 Renal Transplant Recipient Demographics 
 
59 female renal transplant recipients (31.9%) and 126 male recipients 
(68.1%) were included in this study.  The majority of the recipients were 
Caucasian with 174 patients (94.1%) of the White – Scottish ethnic group, 5 
patients (2.7%) of the White – other ethnic group, 5 patients (2.7%) of the 
Asian – Indian ethnic group and 1 patient (0.5%) of the Asian – Chinese 
ethnic group.  The mean age of the renal transplant recipients was 
47.20±13.42 years (range 18 – 78 years) with a mean height of 1.727±0.105 
metres (range 1.49 – 1.93 meters) and a mean weight of 76.90±14.91 kg 
(range 42.20 – 111.30 kg).   
 
For the majority of the patients this was their first renal transplant, 153 
(82.7%). There were 26 patients (14.1%) receiving their second kidney, 5 
patients (2.7%) receiving their 3rd kidney transplant and a single patient 
(0.5%) who received their 4th renal transplant.  All patients were 





5.3.2 Renal Disease 
 
There was considerable variation in the disease processes that led to end 
stage renal disease.  The most common cause of end stage renal disease was 
IgA nephropathy [38 out of 185 patients (20.5%)] followed by adult 
polycystic kidney disease [27 patients (14.6%)].  The causes of renal failure in 

















Table 5.1 Renal disease diagnosis in kidney transplant patients in this cohort 




Uncertain aetiology 14 7.60% 
Focal segmental glomerulosclerosis with 
nephrotic syndrome 
6 3.20% 
Adult polycystic kidney disease 27 14.60% 
Alport's syndrome 2 1.10% 
IgA nephropathy 38 20.50% 
Alagille (prune belly) syndrome 1 0.50% 
Pyelonephritis with vesicoureteric reflux 14 7.60% 
Congenital obstructive vesicoureteric reflux 6 3.20% 
Glomerulonephritis 10 5.40% 
Diabetic glomerulosclerosis/nephropathy 13 7% 
Interstitial nephritis 2 1.10% 
Crescentric glomerulonephritis 1 0.50% 
Pseudomembranous glomerulonephritis 1 0.50% 
Hypertensive renal vascular disease 6 3.20% 
Recurrent pyelonephritis 5 2.70% 
Polyarteritis 2 1.10% 
Congenital renal hypoplasia 5 2.70% 
Drug induced renal failure 2 1.10% 
Laurence Moon Biedl Syndrome 1 0.50% 
Haemolytic uraemic syndrome 2 1.10% 
Goodpasture's syndrome 2 1.10% 
Wegner's granulomatosis 2 1.10% 
Familial nephropathy 1 0.50% 
Neurogenic bladder and reflux nephropathy 4 2.20% 
Microscopic polyangitis 1 0.50% 
Chronic pyelonephritis 6 3.20% 
ANCA positive glomerulonephritis 2 1.10% 
Bilateral hydronephrosis 1 0.50% 
Lupus erythematosis 2 1.10% 
Membrano-proliferative glomerulonephritis 2 1.10% 
Fibrillary glomerulonephritis 1 0.50% 
Mesangiocapillary glomerulonephritis 2 1.10% 
Medullary cystic disease 1 0.50% 






Sixteen patients (8.6%) underwent pre-emptive renal transplantation whilst 
all other patients were on dialysis [111 patients (60.0%) on haemodialysis, 43 
patients (23.2%) on peritoneal dialysis]. 
 
5.3.3 HLA Mis-matching 
 
In the United Kingdom kidneys are allocated based on an assigned mismatch 
level of HLA antigens at the A, B and DR loci (as well as many other clinical 
factors).  The mismatch level is 1-4 with a level 1 mismatch equal to a 000 
mismatch for the 3 HLA antigens.  Therefore, the best matched kidneys are 
level 1 and the worst are level 4.   
The table below summarises the mismatch levels for the patients in this 
cohort. 
Table 5.2 HLA mis-match level 
HLA mismatch 
level 
Number of patients Percentage 
1 29 15.8% 
2 37 20.1% 
3 95 51.6% 
4 23 12.5% 
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5.3.4 Donor Demographics 
 
The mean donor age was 48.16±15.31 years. There were 97 female donors 
(52.4%) and 87 male donors (47.0%). Donors were classified as locally 
retrieved (by the Scottish Organ Retrieval Team or a live donor) or imported 
from elsewhere in the UK.  Accordingly, there were 96 locally retrieved 
kidneys (51.9%) and 89 imported kidneys (48.1%).  88 donors (47.6%) 
donated following brain stem death (DBD), 35 donors (18.9%) donated 
following circulatory death (DCD) and 62 were live donors (33.5%).   
 
5.3.5 Ischaemic times 
 
The mean cold ischaemic time (CIT) was 09:45±05:55 (hh:mm) [range: 
00:44-23:04].  The mean anastomosis time (also known as the second warm 
ischaemic time [SWIT]) was 00:39±00:14 [ranging from 00:18 to 02:02] 
 
5.3.6 Recipient and donor Virology status 
 
72 (38.9%) recipients had CMV positive virology.  All recipients were 
hepatitis C virus (HCV) negative, human immunodeficiency virus (HIV) 
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negative and HBV surface antigen negative.  There were 89 donors who were 
CMV positive (48.1%).  All donors were HCV, HIV and HBV negative.  
 
5.3.7 CYP3A5 Genotype in Renal Transplant Recipients 
 
149 patients (80.5%) who were of the GG genotype (*3/*3).  36 patients made 
functional CYP3A5 [30 patients (16.2%) were heterozygotes and 6 patients 
(3.2%) were wild type homozygotes expressing the AA genotype (*1/*1)]. 
 
5.3.8 Tacrolimus Dose Requirements Related to CYP3A5 Genotype 
 
Initially both CYP3A5 expressers (GA/AA, *3/*1 or *1/*1) and non-expressers 
(GG, *3/*3) were prescribed comparable doses of tacrolimus 6.23±2.167 vs 
6.59±2.327 mg (p=0.436, one-way ANOVA). However, after this initial dose, 
the non-expressers (GG, *3/*3) achieved a therapeutic tacrolimus level 
straight away (8.60±4.942 µg/L) compared with the CYP3A5 expressers (GA, 
*3/*1 or AA, *1/*1) who achieved a lower tacrolimus trough level (4.18±2.463 
µg/L), p<0.0001, one-way ANOVA. The dose requirements during the 12 
months are illustrated in Figure 5.1 below. In order to reach target levels, 
CYP3A5 expresser group requires a significantly higher dose (8.03±2.50 mg) 
compared with the non-expresser group (7.08±2.14 mg), p=0.034, one-way 
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ANOVA as early as the second dose and that as time passes there is a clear 
difference between the two groups in terms of dose requirement. 
 
 
Figure 5.1 Tacrolimus dose requirements following kidney transplantation 
relative to CYP3A5 expression at each study time point.  * denotes a 
significant result p<0.05. 
 
5.3.9 Tacrolimus Levels Relative to CYP3A5 Expression 
 
The tacrolimus trough level in CYP3A5 expressers was significantly lower 
immediately post transplant and remained sub-therapeutic (despite an 
increase in the dose) until the start of the 3rd week following transplantation 
(GG 9.28±3.33 vs GA/AA 7.78±4.61 µg/L, p=0.061, one-way ANOVA).  The 
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Figure 5.2 Tacrolimus trough concentration (C0) following kidney 
transplantation relative to CYP3A5 expression at each study time point.          
* denotes a significant result p<0.05. 
 
 
5.3.10 Dose-corrected trough levels Relative to CYP3A5  
 
CYP3A5 expresser patients had significantly lower dose corrected tacrolimus 
levels compared with non-expressers immediately post-transplant 
(0.68±0.387 vs 1.39±0.817 µg/L per mg, p <0.0001, one-way ANOVA) and 
throughout the first 12 months following transplantation.  This sustained 
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difference suggests that individuals who are expressers of CYP3A5 will have 
increased tacrolimus clearance compared to non-expressers thus having 




Figure 5.3 Dose corrected tacrolimus trough concentration (C0/D) relative to 








5.3.11 Renal Function Relative to CYP3A5  
 
Given that CYP3A5 expression leads to significantly higher doses to achieve 
a therapeutic level, it is important to assess if this has a detrimental impact 
on the renal function. 
 
The creatinine was comparable for both expressers and non-expressers of 
CYP3A5 at each of the time points. (Figure 5.4) 
 
The initial eGFR differed significantly with a lower initial post transplant 
eGFR in the CYP3A5 expressers (15.31±11.79 ml/min/1.73m2) compared with 
22.65±17.91 ml/min/1.73m2 in the non-expressers p=0.023, one-way 
ANOVA).  However, all subsequent measurements remained comparable 
throughout the duration of the follow-up.  The corresponding eGFR at 12 
months was comparable between both groups [46.20±15.89 ml/min/1.73m2 in 
the expressers and 48.73 ml/min/1.73m2 in the non-expresser, p=0.520, one-





Figure 5.4 Creatinine at each time point relative to CYP3A5 expression 




Figure 5.5 eGFR at each time point relative to CYP3A5 expression following 
kidney transplantation. * denotes significant result p<0.05 
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5.3.12 ABCB1 Genotype in Relation to Renal Transplant Patients 
 
ABCB1 genotypes were more evenly distributed with 34 patients (18.4%) 
expressing the CC genotype, 85 patients (45.9%) heterozygotes with a CT 
genotype and 65 patients (35.1%) who expressed the TT genotype.  There 
was a single patient where the genotype was not identified. 
 
5.3.13 Tacrolimus Dose Requirements in Relation to ABCB1  
 
All transplant recipients were prescribed comparable doses of tacrolimus 
initially with those of the CC genotype prescribed 6.54±2.51 mg, those of the 
CT genotype prescribed 6.56±2.40 mg and those patients of the TT genotype 
prescribed 6.45±2.07 mg. (p=0.990, one-way ANOVA).  
There was no significant difference in tacrolimus dose between the three 
genotypes of ABCB1at any of the time points from the time of 
transplantation up to the 12 month time point where the tacrolimus dose 
was comparable between all 3 genotypes [ 5.23±3.38 mg for the CC genotype, 
5.48±2.78 mg for the CT genotype and 5.47±3.91 mg for the TT genotype, 
p=0.966, one-way ANOVA]. 
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Figure 5.6 below shows the dose requirements for the three different 




Figure 5.6 Tacrolimus dose requirements relative to ABCB1 genotype 




5.3.14 Tacrolimus Trough Levels in Relation to ABCB1 
 
There was no difference between the tacrolimus trough levels for any of the 
three genotypes of ABCB1 at any time point during follow-up.  The initial 
tacrolimus trough level in recipients of the CC genotype following 
 248 
transplantation was 7.70±4.33 µg/L, for patients of the CT genotype it was 
7.57±4.50 µg/L and for patients of the TT genotype it was 8.00±5.68 µg/L 
(p=0.958, one-way ANOVA).   
At 12 months following transplantation the tacrolimus trough levels 





Figure 5.7 Tacrolimus trough concentration (C0) following kidney 
transplantation relative to ABCB1 genotype at each time point. * denotes a 





5.3.15 Dose Corrected Tacrolimus Level in Relation to ABCB1  
 
Given that there was no significant difference in dose or trough level 
between any of the three genotypes, the dose corrected level of tacrolimus 
was comparable across the 3 genotypes of ABCB1.  Figure 5.8 below shows 
the dose corrected tacrolimus level relative to ABCB1 genotype for each of 




Figure 5.8 Dose corrected tacrolimus trough concentration (C0/D) following 
kidney transplantation relative ABCB1 genotype at each time point.                
* denotes a significant result p<0.05 
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5.3.16 Renal Function in Relation to ABCB1 Genotype 
 
Given the lack of differences between the genotype in terms of drug 
exposure, renal function (creatinine) was comparable between these patients 
at all time points during the study apart from at 12 months where the CC 




Figure 5.9 Creatinine at each time point following kidney transplantation 





The only difference noted in eGFR was at 6 and 12 months when the eGFR of 
the CC genotype patients was lower compared with the other two genotypes 
[39.83±14.53 ml/min/1.73m2, vs 47.48±11.38 ml/min/1.73m2 (CT) and 
50.62±11.64 ml/min/1.73m2 (TT), p=0.030, one-way ANOVA and respectively 
40.08±19.84 ml/min/1.73m2 vs 47.15±11.31 ml/min/1.73m2 (CT) and 
52.73±12.71 ml/min/1.73m2 (TT) p=0.017, one-way ANOVA].  While the 
difference in renal function of the CC genotype appeared to be statistically 
significant, the clinical significance is less certain.  The eGFR at each of the 




Figure 5.10 eGFR following kidney transplantation at each time point relative 
to ABCB1 genotype. * denotes a significant result p<0.05 
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5.3.17 CYP3A4*22 in Relation to Renal Transplant Patients 
 
171 patients (92.4%) had the CC genotype for CYP3A4*22, 12 patients (6.5%) 
were of the CT genotype and a single patient (0.5%) was of the TT genotype.  
There was one patient in the group where the CYP3A4*22 genotype was not 
determined.  Due to the very low allele frequency of the T allele, those with 
one copy of the T allele (CT genotype) and both copies of the T allele (TT 
genotype) were analysed together as a single group and named T allele 
expressers, [n=13 (7.03%)].   
 
5.3.18 Dose Requirements in Relation to CYP3A4*22  
 
The initial dose of tacrolimus was similar for both the T allele expresser 
group and the non-T allele expresser group (CC genotype) (p=0.403, one-way 
ANOVA).  However, by the end of the second week patients who expressed a 
T allele tended to have a lower dose requirement although, with the 
exception of the 3 month time point, this never reached statistical 




Figure 5.11 Tacrolimus dose requirements following kidney transplantation at 
each time point relative to CYP3A4*22 T allele expression at each time point.  
* denotes a significant result p<0.05 
 
 
5.3.19 Tacrolimus Trough Levels in Relation to CYP3A4*22  
 
Despite the slight difference in the dose requirements, the tacrolimus trough 




Figure 5.12 Tacrolimus trough concentration (C0) at each time point following 
kidney transplantation relative to CYP3A4*22 T allele expression. * denotes a 
significant result p<0.05 
 
 
5.3.20 Dose Corrected Tacrolimus Level Relative to CYP3A4*22  
 
Similarly, the dose corrected tacrolimus levels showed no significant 
difference between those individuals who expressed a T allele of CYP3A4*22 
(CT/TT) and those who did not (CC) (p=0.471 one-way ANOVA).  The slightly 
higher dose corrected level seen after transplantation in the CT/TT genotype 
group was maintained throughout but it was not statistically significant with 
the exception of the 12 month time point where the dose corrected level in 
the CC genotype group was 1.63±0.99 µg/L per mg and the CT/TT genotype 
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was 3.49±3.83µg/L per mg, p<0.0001, one-way ANOVA.  Although most of 
the dose corrected levels for the CYP3A4*22 T allele expressers were slightly 
higher, there is no obvious reason for the difference at 12 months and 
therefore, this result should be interpreted with caution.  Figure 5.13 below 
shows the dose corrected tacrolimus level at each of the time points relative 




Figure 5.13 Dose corrected tacrolimus trough concentration (C0/D) at each 
time point following kidney transplantation relative to CYP3A4*22 T allele 
expression.  * denotes a significant result p<0.05 
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5.3.21 Creatinine and eGFR in Relation to CYP3A4*22  
 
The renal function, measured by the serum creatinine and eGFR, showed 
comparable results between the CYP3A4*22 T allele expresser group and the 
non- expresser group at most of the time points.  The notable exceptions 
were at the WK3-1, WK3-2 and WK3-3 time points where the creatinine was 
significantly higher in the non-expresser group than the T allele expresser 
group at each of these time points. (WK3-1 CC 210.42±163.79 vs CT/TT 
142.78±65.58 µmol/L, p=0.014, WK3-2 CC 197.62±153.09 vs CT/TT 
137.20±47.72 µmol/L, p<0.0001 and WK3-3 CC 165.27±94.60 vs CT/TT 
139.20±52.78 µmol/L, p<0.0001, one-way ANOVA).  The reason for this 
significant difference at these specific time points is unclear however given 
the low number of recipients who express a T allele (n=10), this may be a 
statistical anomaly rather than clinically relevant given that the 
corresponding eGFR values at the same time points were comparable (WK3-
1 CC, 38.69±1.63 vs CT/TT 43.75±16.24 ml/min/1.73m2, p=0.165, WK3-2 CC, 
40.21±16.91 vs CT/TT 46.30±14.78 ml/min/1.73m2, p=0.190 and WK3-3 CC, 
43.06±15.17 vs CT/TT 45.60±15.31 ml/min/1.73m2, p=0.056, one-way 
ANOVA.   
 
Figure 5.14 below details the creatinine levels at each of the time points and 




Figure 5.14 Creatinine at each time point following kidney transplantation 





Figure 5.15 eGFR at each time point following kidney transplantation relative 




5.3.22 Time to Reach Therapeutic Tac Levels and Genotype 
 
The time taken to reach a therapeutic tacrolimus trough level does not 
necessarily in itself represent a detrimental clinical end point but 
nonetheless a delay in reaching a therapeutic tacrolimus level could pose a 
significant risk of acute rejection due to sub-therapeutic tacrolimus levels 
for a prolonged period of time in the immediate post-transplant period. 
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To that end, the number of days until the first therapeutic trough level of 
tacrolimus was reached for each patient was recorded with a therapeutic 
level being 5 µg/L or greater. 
 
5.3.23 CYP3A5 Genotype and Time to Therapeutic Level  
 
Renal transplant recipients of the CYP3A5 GG (*3/*3) genotype took 
3.17±2.84 days to reach a therapeutic tacrolimus trough level compared with 
7.94±5.26 days of the CYP3A5 GA/AA (*3/*1 or *1/*1) genotype (p<0.0001, 
one-way ANOVA) (Figure 5.16 below). 
 
 
Figure 5.16 Time taken in days following kidney transplantation to reach a 
therapeutic trough concentration (C0) relative to CYP3A5 expression. 
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5.3.24 ABCB1 Genotype and Time to Therapeutic Level  
 
In contrast to CYP3A5 expression, there was no difference in the number of 
days until a therapeutic level of tacrolimus was reached between any of the 3 
different genotypes of ABCB1 (3.88±3.96 days for CC genotype vs 4.23±3.94 
days for CT vs 4.13±4.00 for TT genotype, p=0.925, one-way ANOVA) as 




Figure 5.17 Time taken in days following kidney transplantation to reach a 





5.3.25 CYP3A4*22 Genotype and Time to Therapeutic Level  
 
Similar to the results of the ABCB1 genotype, there was no difference in the 
time taken to reach a therapeutic tacrolimus trough level between patients 
who expressed a T allele of CYP3A4*22 (CC genotype) and those who did not 
(CT/TT genotype), 4.17±3.99 days for the CC genotype compared with 
3.62±3.45 days for CT/TT genotype, p=0.770, one-way ANOVA as shown in 
Figure 5.18 below. 
 
 
Figure 5.18 Time taken in days following kidney transplantation to reach a 






5.3.26  Acute Rejection Relative to Genotype Expression 
 
With CYP3A5 expression resulting in a significantly longer time until a 
therapeutic tacrolimus level is reached, there is potential that renal 
transplant patients who express CYP3A5 could be at a higher risk of acute 
rejection due to under immunosuppression.  To investigate whether this was 
the case, and whether any of the different genotypes of the 3 SNPs had an 
impact on the incidence of biopsy proven acute rejection (BPAR), data was 
recorded for each patient on the incidence of biopsy proven acute rejection 
and at what time this occurred following transplantation.  The incidence of 
BPAR was compared by the different genotypes of each of the 3 SNPs. 
 
5.3.27 Acute Rejection Relative to the CYP3A5 Genotype 
 
The overall rate of BPAR in the entire cohort irrespective of genotype was 27 
patients out of 185 giving a rate of 14.6%.  Looking specifically at the 
distribution relative to CYP3A5 genotype, there was no significant difference 
observed between CYP3A5 non-expressers (22/149 [14.8%]) and the 
expressers (5/36 [13.9%]), p=0.894, Chi-Square test.  Biopsy proven acute 
rejection within 30 days of transplant was more common in the CYP3A5 
non-expresser group (17/149 [11.4%]) compared with the expresser group 
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(2/36 [5.6%]) but this was not statistically significant, p=0.299, Chi-Square 
test. 
 
There was no significant difference in the rate of BPAR at 90 days post 






Figure 5.19 Percentage of patients who develop biopsy proven acute 
rejection following kidney transplantation overall and at 30, 90 and 365 days 




Overall 30 DAYS 90 DAYS 365 DAYS
NON-EXPRESSER 14.80% 11.40% 12.10% 12.80%

















5.3.28 Acute Rejection Relative to ABCB1 Genotype 
 
The distribution of BPAR across the different genotypes of ABCB1 did not 
show any significant difference overall with 6/34 (17.6%) BPAR in the CC 
genotype group, 10/85 (11.8%) in the CT genotype group and 11/65 (16.9%) 
in the TT genotype group, p=0.740.  There was also no difference in the 
incidence of BPAR across the three genotypes of ABCB1 at 30 days, 90 days 
or 365 days following transplantation as shown in Figure 5.20 below. 
 
 
Figure 5.20 Percentage of patients who develop biopsy proven acute 
rejection following kidney transplantation overall and at 30, 90 and 365 days 
relative to ABCB1 genotype. 
 
 
Overall 30 DAYS 90 DAYS 365 DAYS
CC 17.60% 8.80% 8.80% 8.80%
CT 11.80% 8.20% 9.40% 11.80%



















5.3.29 Acute Rejection Relative to CYP3A4*22 Genotype 
 
Biopsy proven acute rejection in relation to CYP3A4*22 T allele expression is 
somewhat interesting as none of the patients who expressed a T allele (CT or 
TT genotype) had any episodes of BPAR.  Indeed, all of the episodes of BPAR 
occurred in the CC genotype group with 27/171 in the CC genotype group 
(15.8%) having an episode of BPAR while 0/13 (0.0%) in the CT/TT group had 
BPAR.  The very small numbers in the T allele expresser group compared to 
the whole cohort means this figure is not statistically significant with a p 
value of 0.274, Chi-Square test.   The incidence of BPAR overall and at 30 




Figure 5.21 Percentage of patients who develop biopsy proven acute 
rejection following kidney transplantation overall and at 30, 90 and 365 days 
relative to CYP3A4*22 T allele expression. 
Overall 30 DAYS 90 DAYS 365 DAYS
CC 15.80% 11.10% 11.70% 13.50%













5.3.30 Post Operative Complications Relative to Genotype 
 
Given the correlation with trough levels, we evaluated the incidence of some 
of the complications according to the SNP of CYP3A5, ABCB1 and 
CYP3A4*22. 
 
5.3.31 Delayed Graft Function 
 
The overall incidence of delayed graft function in this cohort was 33.2%. 
There was no difference in the rate of DGF in the CYP3A5 genotype group 
between the non-expressers (49/149, 32.9%) and the expressers (12/35, 
34.3%), p=0.874 Chi-Square test.  The incidence of DGF was also comparable 
between the 3 different genotypes of ABCB1 [CC genotype DGF incidence of 
13/33 (39.4%), CT genotype incidence 27/85 (31.8%) and the TT genotype 
incidence 20/65 (30.8%), p=0.417 Chi-Square test].  DGF was also similar 
across the different genotypes of CYP3A4*22 with a 56/170 (32.9%) 
incidence in the CC genotype group and 4/13 (30.8%) in the CT/TT group, 




5.3.32 New Onset Diabetes After Transplantation (NODAT) 
 
The diabetogenic effects of immunosuppressive agents such as prednisolone 
and tacrolimus are well known therefore some patients will go on to develop 
diabetes following renal transplantation.  New Onset Diabetes After 
Transplantation (NODAT) is defined as the development of Type II diabetes 
requiring medical pharmacotherapy with oral antihyperglycaemic 
medication or insulin after solid organ transplantation, where it was not 
present beforehand.  This definition does not include diabetic patients who 
were controlled with oral antihyperglycaemic agents prior to transplantation 
that then went on to require insulin afterwards.  There was no difference in 
the incidence of NODAT between those patients who were CYP3A5 non-
expressers (8/144, 5.6%) and those who were expressers of which none 
developed NODAT, p=0.154 Chi-Square test.  There were more patients of 
the TT genotype of ABCB1 (6/62, 9.7%) who went on to develop NODAT 
compared with those of the CC genotype (0/32, 0.0%) and those of the CT 
genotype (2/84, 2.4%), p=0.018 Chi-Square test (Linear-by-Linear 
Association).  There were no patients with the CT/TT genotype of 
CYP3A4*22 who went on to develop NODAT and 8/166 (4.8%) of the CC 




5.3.33 Post Operative Infection 
 
Immunosuppression increases the risk of infection in all transplant patients 
in the perioperative period and in the long term due to reduced T cell 
activity.  The incidence of post-operative bacterial infections, primarily 
urinary, wound, and respiratory infections (excluding viral infections such as 
CMV and BK virus) was recorded.  The incidence of post-operative infection 
was evaluated for each genotype of the 3 different SNPs examined in this 
study.  The overall incidence of post operative infection was 29.2% 
irrespective of genotype.  There was no difference in the incidence of post-
operative infection between non-expressers of CYP3A5 (44/149, 29.5%) and 
the expressers of CYP3A5 (10/36, 27.8%), p=0.836, Chi-Square test.  
Similarly, the rate of post-operative infection between the 3 genotypes of 
ABCB1 were comparable between CC genotype [10/34 (29.4%)], CT genotype 
[23/85 (27.1%)] and TT genotype [20/65 (30.8%)], p=0.442, Chi-Square test.  
There was also no difference in the rate of post-operative infection between 
the different genotypes of CYP3A4*22 with 50/171 (29.2%) of those with the 
CC genotype and 4/13 (30.8%) of those with the CT/TT genotype having a 
post-operative infection, p=0.807 Chi-Square test. 
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5.3.34 Cardiovascular events 
 
We also examined the correlation between the different SNPs and the 
incidence of cardiovascular events including myocardial infarction, acute 
stroke, pulmonary embolus, cardiac arrhythmias, pulmonary oedema and 
unstable angina. Genotype expression appears to make no difference to the 
incidence of any of these post- operative complications. 
 
The only correlation identified was a slightly higher incidence of NODAT in 
patients with the TT genotype of ABCB1.  The reason for this difference is 
not clear and would require further evaluation before it could be determined 
if it was truly clinically relevant.  The post operative complications are 




Table 5.3 Post transplant complications relative to different genotypes of CYP3A5, ABCB1 and CYP3A4*22. * denotes a 








CYP3A5 GG 32.90% 5.60% 29.50% 1.40% 1.40% 2.10% 2.10% 1.40% 1.40% 
 GA/AA  34.30% 0.00% 27.80% 2.90% 2.90% 5.90% 0.00% 2.90% 0.00% 
           
ABCB1 CC 39.40% 0.00% 29.40% 3.10% 0.00% 3.20% 0.00% 3.20% 0.00% 
 CT 31.80% 2.40% 27.10% 0.00% 1.20% 3.60% 3.60% 1.20% 1.20% 
 TT 30.80% *9.70% 30.80% 3.20% 3.20% 1.70% 0.00% 1.70% 1.70% 
           
CYP3A4*22 CC 32.90% 4.80% 29.20% 1.80% 1.20% 2.50% 1.80% 1.80% 1.20% 
 CT/TT 30.80% 0.00% 30.80% 0.00% 7.70% 7.70% 0.00% 0.00% 0.00% 
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5.3.35 Graft Survival relative to CYP3A5 genotype 
 
There was no significant difference in graft survival between the CYP3A5 
expressers and non-expressers as shown in the Kaplan-Meier graph below, 














5.3.36 Graft survival relative to ABCB1 genotype 
 
There was significantly more graft loss on univariate analysis for the CC 
genotype of ABCB1 when compared with the CT and the TT genotype. 
 
 
Figure 5.23 Kaplan-Meier plot for graft survival following kidney 
transplantation relative to ABCB1 genotype 
 
Log Rank Test CC CT TT 
CC - p = 0.003 p = 0.017 
CT p = 0.003 - p = 0.702 
TT p = 0.017 p = 0.702 - 
 
 273 
5.3.37 Graft Survival Relative to CYP3A4*22 Genotype 
 
There was no significant difference in graft survival between the T allele 





Figure 5.24 Kaplan-Meier plot for graft survival following kidney 





5.3.38 Cox Regression Multivariate Analysis of Graft Survival 
 
Multivariate analysis was carried out and demonstrated no significant 
difference in graft survival between any of the genotypes of the 3 SNPs.  The 
only 2 significant values in graft survival was a DCD donor, p=0.021, and 
recipient age which was just statistically significant at p=0.047, Cox-
regression. 
 
Table 5.4 Cox regression multivariate analysis graft survival following kidney 
transplantation. 
Variable  p value 
CYP3A5 Genotype 0.996 
ABCB1 Genotype 0.237 
CYP3A4*22 Genotype 0.995 
Delayed Graft Function 0.400 
BPAR 0.179 
Recipient Gender 0.390 
Recipient Age 0.047 
Donor Age 0.360 
DCD Donor 0.021 
Mis-match Level 0.154 
Cold Ischaemic Time 0.124 
Days Until Therapeutic Level  0.378 
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5.3.39 Patient Survival Relative to CYP3A5 Genotype 
 
There was no significant difference seen in patient survival between the 
expressers and non-expressers of CYP3A5 as shown in the Kaplan-Meier plot 
below, Log-rank p = 0.416. 
 
 
Figure 5.25 Kaplan-Meier plot for patient survival following kidney 







5.3.40 Patient Survival Relative to ABCB1 Genotype 
 
Similarly there was no difference in patient survival between the 3 different 
genotypes of ABCB1 as shown in the Kaplan-Meier curve below. 
 
 
Figure 5.26 Kaplan-Meier plot for patient survival following kidney 
transplantation relative to ABCB1 genotype. 
 
 
Log Rank Test CC CT TT 
CC - p = 0.270 p = 0.209 
CT p = 0.270 - p = 0.722 
TT p = 0.209 p = 0.722 - 
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5.3.41 Patient Survival Relative to CYP3A4*22 Genotype 
 
There was no significant difference in patient survival between the T allele 
expressers of CYP3A4*22 and those patients that did not express the T allele 
as shown in the Kaplan-Meier curve below.  Log-rank p = 0.519. 
 
 






5.3.42 Cox Regression Multivariate Survival Analysis 
 
There was no significant difference in patient survival between any of the 
genotypes of the 3 SNPs in the Cox Regression analysis.  There was no 
significant variable that was included in the analysis that significantly 
affected patient survival.  These data should be interpreted within the 
context of a small sample size over a relatively short follow up period.  To 
best evaluate patient survival in renal transplant patients, a much larger 













Table 5.5 Cox regression multivariate analysis for patient survival following 
kidney transplantation. 
Variable p-value 
CYP3A5 Genotype 0.997 
ABCB1 Genotype 0.999 
CYP3A4*22 Genotype 0.990 
Recipient Gender 0.954 
Donor Gender 0.992 
Recipient Age 0.916 
Donor Age 0.927 
Diabetes After Transplant 0.908 
Myocardial Infarction 0.668 
Cerebrovascular Accident 0.532 
Malignancy 0.939 
Delayed Graft Function 0.893 
Graft Loss 0.954 
Post Operative Infection 0.956 
 
These results are in keeping with other studies of CYP3A5, ABCB1 and 
CYP3A4*22 expression in renal transplantation where there has not been 
any link established between genotype expression of any of these SNPs and 




5.4 Simultaneous Pancreas-Kidney Patients 
 
While there is now a substantial body of literature examining the role of 
CYP3A5 A6989G, ABCB1 C3435T and, to a lesser extent the CYP3A4*22 
intron 6 polymorphism in renal transplant recipients, there is no published 
data looking solely at simultaneous pancreas-kidney (SPK) transplant 
recipients.  It may be reasonable to assume that SPK transplant patients are 
not any different from the kidney transplant patients with regards to these 
genetic polymorphisms and therefore the data accrued from the kidney 
studies can be extrapolated to the SPK patients.  Nevertheless, some SPK 
patients do have some important clinical differences to renal transplant 
recipients, such as the presence of autonomic neuropathy and gastroparesis, 
which has the potential to impact on the gut absorption and 
pharmacokinetics of tacrolimus [208]. 
 
In order to evaluate the impact of polymorphisms of CYP3A5, ABCB1 and 
CYP3A4*22 on tacrolimus dose requirements, trough levels and clinical 
outcome in SPK patients, a cohort of 32 SPK patients were genotyped for the 
same SNPs of CYP3A5, ABCB1 and CYP3A4*22 as the renal transplant 
cohort.  The tacrolimus dose, trough level, dose-corrected level, creatinine 
and eGFR were recorded at the same time points within the first year 
following transplantation.  In addition, the HbA1c was recorded at 3 months 
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and 12 months and the glucose level noted on discharge.  Insulin 
independence was evaluated at discharge, 3 and 12 months.  Biopsy proven 
acute rejection and graft and patient survival were also evaluated. 
 
5.4.1 Patient Demographics 
 
There were 20 male (62.5%) patients and 12 (37.5%) female patients with a 
mean age of 39.84±6.96 years (range 28 – 55 years). The mean weight of the 
recipients in this cohort was 69.59±13.55 kg (range 45.5 – 99.0 kg) with a 
corresponding mean BMI of 24.01±3.54, (range 19.0 – 31.6).  All patients in 
this cohort were of the White-Scottish ethnic group.   
 
5.4.2 Donor Demographics 
 
All donors donated after brain death. There were 11 male donors (34.4%) and 
20 female donors (62.5%).  The mean donor age was 36.31±13.63 years 
(range 14 – 57 years).  The mean donor BMI was 23.04±3.14 (range 16.50 – 
29.73).  15 donors (46.9%) were blood group O, 13 donors (40.6%) blood 
group A, 3 donors (9.4%) blood group B and a single AB donor (3.1%).  
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The mean cold ischaemic time for the pancreas was 11:47±02:41 (hh:mm) 
(range 06:36 – 16:48) and the mean cold ischaemic time for the kidney was 
12:19±03:24 (range 06:21 – 19:51). 
 
5.4.3 Genotype Distribution 
 
In the SPK cohort there were 25 patients (78.1%) who had the GG (*3/*3) 
genotype for CYP3A5.  The remaining seven patients (21.9%) had the GA 
(*3/*1) genotype of CYP3A5 and made functional CYP3A5 protein.  
16 patients (50.0%) had the CT genotype for ABCB1, whilst 9 patients 
(28.1%) were of the TT genotype and seven patients (21.9%) had the CC 
genotype of ABCB1,  
28 patients (87.5%) expressed the CC genotype of CYP3A4*22 and 3 patients 
(9.4%) had the CT genotype.   
 
5.4.4 Tacrolimus Dose Requirements Relative to CYP3A5  
 
With the caveat of a small number of patients and even smaller number of 
expressers, there were significant differences in the dose of tacrolimus in the 
non-expresser group (10.22±3.36 mg) and the expresser group (18.67±5.60 
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mg0, p<0.0001, one-way ANOVA.  There was a statistically significant higher 
dose requirement at time points WK3-3, 1M, 2M, and 12M.   
 
 
Figure 5.28 Tacrolimus dose requirements following SPK transplantation at 




5.4.5 Tacrolimus Trough Levels Relative to CYP3A5  
 
The initial tacrolimus trough level was lower in the CYP3A5 expresser group 
(6.40±2.66 µg/L) compared to the non-expresser group (11.08±4.94 µg/L), 
p=0.033, one-way ANOVA.  From the 2nd time point (WK1-2) there was no 
significant difference in the tacrolimus trough levels with the exception of 
the WK2-2 time point and the 6M time point where the trough level were 
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lower in the CYP3A5 expresser group compared with the non-expresser 




Figure 5.29 Tacrolimus trough concentration (C0) at each time point following 




There appears to be considerable fluctuation within the CYP3A5 expresser 
group however the non-expresser group appears to have a steadier level, but 





5.4.6 Dose Corrected Tacrolimus Levels Relative to CYP3A5 
 
The general trend appears to show that the dose-corrected tacrolimus level 
runs slightly lower in the CYP3A5 expresser group, although very few of 





Figure 5.30 Dose corrected tacrolimus trough concentration (C0/D) at each 
time point following SPK transplantation relative to CYP3A5 expression.  * 






5.4.7 Renal Function in SPK Patients Relative to CYP3A5  
 
There is very little difference in renal function between CYP3A5 expressers 
and non-expressers in SPK patients.  The starting creatinine is similar for 
both groups, (450.04±238.83 µmol/L for non-expressers compared with 
438.00±211.61 µmol/L in the CYP3A5 expresser group).  The creatinine is 
comparable at all time points other than WK3-1.  Although this is the only 
time point where there is a statistically significant difference in the 
creatinine, Figure 5.31 below shows that the trend of slightly higher 




Figure 5.31 Creatinine for each time point following SPK transplantation 
relative to CYP3A5 expression. *denotes a significant difference p<0.05 
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The eGFR follows a similar pattern to the creatinine in the CYP3A5 non-
expresser and expresser groups as is shown in Figure 5.32 below with no real 
difference throughout the study. 
 
 
Figure 5.32 eGFR at each time point following SPK transplantation relative to 












5.4.8 Tacrolimus Dose Requirements Relative to ABCB1  
 
The mean tacrolimus dose was comparable between all 3 genotypes of 
ABCB1 at all time points up to and including the 12 month time point as 




Figure 5.33 Tacrolimus dose requirements at each time point following SPK 







5.4.9 Tacrolimus Trough Levels Relative to ABCB1  
 
Similarly, the tacrolimus trough levels were comparable between all three 
genotypes of ABCB1 at all time points up to and including 12 months as 





Figure 5.34 Tacrolimus trough concentration (C0) at each time point following 







5.4.10 Dose Corrected Tacrolimus Levels Relative to ABCB1 
The dose Corrected Tacrolimus Level relative to the ABCB1 genotype was 




Figure 5.35 Dose corrected tacrolimus trough concentration (C0/D) at each 




5.4.11 Renal Function in Relative to ABCB1 
 
Immediately after transplantation patients of the CT genotype had a 
significantly lower creatinine level (331.94±212.93 µmol/L) compared with 
those of the CC genotype (585.14±193.78 µmol/L) and also the TT genotype 
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(546.89±196.84 µmol/L), p=0.012, one-way ANOVA.  The corresponding 
eGFR immediately post transplant was significantly higher in the CT 
genotype (25.38±16.34 ml/min/1.73m2) when compared with both the CC 
genotype (8.86±3.44 ml/min/1.73m2) and the TT genotype (12.67±12.17 
ml/min/1.73m2), p=0.017, one-way ANOVA.   
 
This apparent improved renal function in those SPK patients of the CT 
genotype of ABCB1 disappears by the 3rd week following transplantation 
where the results are 49.00±12.19 ml/min/1.73m2 for the CC genotype, 
53.20±10.30 ml/min/1.73m2 for the CT genotype and 56.25±7.50 
ml/min/1.73m2 for the TT genotype, p=0.611, one-way ANOVA. 
 
The creatinine levels for the different genotypes of ABCB1 are shown in 
Figure 5.36 below and the corresponding eGFR at each of the time points is 




Figure 5.36 Creatinine at each time point following SPK transplantation 
relative to ABCB1 genotype. * denotes a significant difference p<0.05 
 
 
Figure 5.37 eGFR at each time point following SPK transplantation relative to 




5.4.12 Delayed Graft Function Across the ABCB1 Genotypes 
 
The reason for the improved renal function in the ABCB1 CT genotype is not 
immediately apparent based on genotype alone, particularly given that this 
particular polymorphism does not appear to have any significant impact on 
tacrolimus dose requirements or trough levels.  The fact that the renal 
function became comparable between the three genotypes after the first few 
weeks, with those in the CC and TT genotype groups reaching the same renal 
function as those in the CT group, suggested that perhaps delayed graft 
function played a role. Delayed graft function was indeed significantly lower 
in the CT genotype group with only 4/16 patients (25.0%) experiencing 
delayed graft function compared with 5/7 patients in the CC genotype group 
(71.4%) and 6/9 patients (66.7%) in the TT genotype group, p=0.045, Chi-
Square test. 
 
There was no difference in the pancreatic graft function in relation to ABCB1 
genotype. The HbA1c values were similar at 3 months and remained 
comparable at 12 months with a level of 7.57±4.02% for the CC genotype, 
5.80±1.33% for the CT genotype and 5.44±0.44% for the TT genotype, 




5.4.13 Tacrolimus Dose Requirements Relative to CYP3A4*22  
 
Despite comparable initial tacrolimus doses, the dose requirement for those 
who expressed a T allele of CYP3A4*22 (CT genotype) tended to be lower 
after the second week after transplant.  The tacrolimus dose was 
significantly different at WK3-3 (CC 11.18±4.87 mg vs CT 6.00±1.41 mg, 
p=0.004), 1 month (CC 12.17±4.05 mg vs CT 6.25±2.47 mg, p=0.001) and the 
2 month time point (CC 10.59±3.68 mg vs 6.00 mg, p=0.001, one-way 
ANOVA).  The combination of a small cohort size, missing tacrolimus doses 
and the very low allele frequency of the T allele of CYP3A4*22 makes it 
difficult to draw firm conclusions regarding this dataset, particularly when, 
on occasion, there is a single value for mean dose in the CT genotype.  Figure 





Figure 5.38 SPK Tacrolimus dose requirement at each time point following 
SPK transplantation relative to CYP3A4*22 T allele expression.  * signifies a 
significant difference p<0.05 
 
 
5.4.14 Tacrolimus Trough Level Relative to CYP3A4*22  
 
The tacrolimus trough levels tended to be slightly higher in the CYP3A4*22 
CT genotype group initially (15.20±4.15 µg/L) compared with the CC 
genotype (9.69±4.84 µg/L) however this was not statistically significant, 
p=0.184 (Figure 5.39). The low T allele frequency of CYP3A4*22 combined 




Figure 5.39 Tacrolimus trough concentration (C0) at each time point following 
SPK transplantation relative to CYP3A4*22 T allele expression.  * denotes a 
significant difference p<0.05. 
 
 
5.4.15 Dose Corrected Tacrolimus Level Relative to CYP3A4*22 
 
Initially after transplantation there was no difference in the dose corrected 
tacrolimus level between the CYP3A4*22 CC genotype (1.71±0.87 µg/L per 
mg) and the CT genotype (1.84±0.17 µg/L per mg), p=0.842.  After the first 
week the CT genotype appeared to have slightly higher tacrolimus dose-
corrected level although this only reached statistical significance at WK3-3 
(CC 0.74±0.40 µg/L per mg vs CT 2.04±1.36 µg/L per mg, p=0.006, one-way 
 297 
ANOVA) and at 1 month (CC 0.94±0.372 µg/L per mg vs CT 1.84±1.39 µg/L 
per mg, p=0.025, one-way ANOVA). 
 
While there is no real significant difference demonstrated between the CC 
and the CT genotype relative to the dose-corrected tacrolimus trough level, 




Figure 5.40 Dose corrected tacrolimus trough concentration (C0/D) at each 
time point following SPK transplantation relative to CYP3A4*22 T allele 





5.4.16 Renal Function in SPK Patients Relative to CYP3A4*22  
 
There was no significant difference in the creatinine according to the 
CYP3A4*22 genotype with the exception of the WK3-1 time point where the 
creatinine in the CT group is significantly higher (322.00±341.27 µmol/L) 
compared with the CC group (175.04±153.55 µmol/L, p=0.025 one-way 
ANOVA).  Figure 5.41 below shows the creatinine for each genotype at each 




Figure 5.41 Creatinine at each time point following SPK transplantation 




The eGFR was comparable at all of the time points for both the CC and the 
CT genotype of CYP3A4*22 up to and including the 12 month time point 
where the eGFR of the CC genotype was 52.06±10.21 ml/min/1.73m2 
compared with 60.00 ml/min/1.73m2 of the CT genotype, p=0.595, one-way 
ANOVA.  
 
The eGFR relative to CYP3A4*22 genotype is shown in Figure 5.42 below. 
 
 
Figure 5.42 eGFR at each time point following SPK transplantation relative to 





5.4.17 Time Until Therapeutic Tacrolimus Trough Level Reached 
 
There was no significant difference in the number of days taken to reach a 
therapeutic tacrolimus trough level between the genotypes of any of the 3 
SNPs.  In the CYP3A5 genotype the non-expresser group had a mean of 
3.04±1.43 days until a therapeutic level of tacrolimus was reached compared 
with 3.00±0.894 days in the expresser group, p=0.950 one-way ANOVA.  The 
time taken to reach a therapeutic tacrolimus level was also comparable 
across the three genotypes of ABCB1 (CC 2.86±0.69 days, CT 2.94±1.24 days 
and TT 3.33±1.87 days), p=0.731 one-way ANOVA.  Similarly, for the 
CYP3A4*22 there was also no difference in the time taken to reach a 
therapeutic tacrolimus level with 3.04±1.35 days for the CC genotype and 
3.00±1.73 days for the CT genotype, p=0.999, one-way ANOVA. 
 
5.4.18 Delayed Graft Function 
 
All of the pancreatic grafts had primary function apart from one graft which 
was removed due to primary non-function.  The overall incidence of delayed 
graft (renal) function in this cohort was 15/32 (46.9%).  There was no 
significant difference in the incidence of delayed graft function (DGF) 
between the CYP3A5 non-expresser genotype (46.2%) and the CYP3A5 
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expresser group (50.0%), p=0.608, Chi-Square test.  When patients were 
grouped by ABCB1 genotype there was significantly lower DGF in the CT 
genotype group (25.0%) compared with the CC genotype group (71.4%) and 
the TT genotype group (66.7%), p=0.045, Chi-Square test.  There was no 
significant difference in incidence of DGF when patients were grouped by 
their CYP3A4*22 genotype with 46.4% in the CC genotype group and 33.3% 
in the CT genotype group, p=0.508, Chi-Square Test.  The incidence of DGF 




Figure 5.43 Percentage of delayed graft function in the renal allograft 
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5.4.19 Biopsy Proven Acute Rejection 
 
The overall incidence of biopsy proven acute rejection (BPAR) in this cohort 
of patients was 7/32 (21.9%).  There was a significantly higher incidence of 
BPAR in the CYP3A5 expresser group (66.7%) when compared with the 
CYP3A5 non-expresser group where the incidence was 11.5%, p=0.012, Chi-
Square Test.  There was no significant difference in the incidence of BPAR in 
relation to the ABCB1 or the CYP3A4*22 genotypes.  The incidence of BPAR 




Figure 5.44 Percentage of biopsy proven acute rejection in the renal allograft 
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5.4.20 Other Post-Operative Complications 
 
Post operative infection was a very common reported complication following 
an SPK transplant with 18/32 (56.3%) of patients experience some form of 
post operative infection.  There was no difference in the incidence of post 
operative infections in relation to the genotypes expressed by the patients 
for any of the 3 SNPs.  The infections were wide ranging and included 
Klebsiella urinary sepsis, Streptococcal urinary sepsis, pneumonia, intra-
abdominal sepsis, wound infections, vancomycin resistant enterococcus 
diarrhoea, C. difficile infection and duodenal candida. 
 
5.5 Chapter Summary 
 
The data from the renal transplant cohort supports previously reported 
findings in relation to CYP3A5 expression where those individuals who 
expressed CYP3A5 required approximately double the dose of tacrolimus in 
order to achieve a therapeutic level compared with those patients who did 
not express functional CYP3A5.  Consequently, those who were CYP3A5 
expressers had initially lower tacrolimus trough levels and also had 
significantly higher number of days until a therapeutic level was reached 
compared with the non-expressers.  In the renal transplant cohort this did 
not, however, translate into increased rejection or delayed graft function and 
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renal function did not differ between the expressers and non-expressers of 
CYP3A5. 
 
This study did not reveal any significant impact of the different genotypes of 
ABCB1 on tacrolimus dose requirements, tacrolimus trough levels, renal 
function or time until a therapeutic trough level was reached in the renal 
transplant cohort.  A patient’s ABCB1 genotype also had no significant 
bearing on renal function, delayed graft function or biopsy proven acute 
rejection.  These findings are in keeping with most of the recent studies that 
have examined the role of ABCB1 on tacrolimus pharmacokinetics. However 
some earlier studies had suggested that ABCB1 could influence tacrolimus 
dose requirements. 
 
This study did show significantly reduced graft survival in patients who 
carried the ABCB1 CC genotype compared with the CT or TT genotypes.  One 
possible mechanism for this relates to the discrepancy between whole blood 
concentrations of tacrolimus and the intra-lymphocyte concentration.  
Approximately 80% of the measured whole blood concentration of 
tacrolimus relates to concentration within erythrocytes, which are not 
thought to contribute significantly to the immune response and therefore 
the concentration within circulating peripheral blood lymphocytes may 
better reflect the immunosuppressive effect [209].  ABCB1 is present on the 
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cell membrane of many cells, including lymphocytes, and may play a role in 
the intracellular concentration of tacrolimus [210].  Indeed Capron et al 
reported higher intra-lymphocyte concentrations of tacrolimus in kidney 
transplant patients who carry the T allele of 3435 C>T in the ABCB1 gene 
[211] which may explain the increased graft loss seen in this study.  The role 
of intra lymphocyte tacrolimus concentration in acute and chronic rejection 
needs further work to determine if the ABCB1 may yet prove significant. 
 
CYP3A4*22 has been less widely studied but published data does suggest 
that patients require lower doses of tacrolimus if they are either 
heterozygotes or homozygotes for the T allele of CYP3A4*22.  This study has 
not shown statistically significant differences in the dosing requirements or 
tacrolimus trough levels in the renal transplant cohort. However, there was a 
tendency for those with the CYP3A4*22 CT/TT genotype to run slightly 
lower tacrolimus dose requirements. The very low allele frequency of the T 
allele means that quite a large sample of patients is required before even a 
small number of patients of the CT/TT genotype are available to compare 
and this may be why this study has not shown a convincing impact of T allele 
expression of CYP3A4*22.  Similarly, CYP3A4*22 had no impact on renal 
function, DGF, BPAR or any other clinical outcome. 
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Multi-variate analysis in this study did not show any significant difference in 
graft survival or patient survival relative to any of the different SNPs studied, 
however it also did not reveal any impact on graft survival of donor age, a 
factor that has been shown time and time again to be an independent risk 
factor for graft loss, suggesting that this study may be underpowered for an 
analysis of graft or patient survival.  A larger, prospective, adequately 
powered study is required for evaluate the impact of these SNPs on graft and 
patient survival. 
 
The SPK group of patients showed different results from the renal transplant 
group yet the small number of patients in the cohort makes it difficult to 
interpret if these differences are genuine or determined by the small sample 
size.  Furthermore, the almost complete absence of any published data in an 
isolated SPK cohort means there is a paucity of data to compare with the 
results of this study. 
 
The SPK patients who expressed CYP3A5 had a similar dose requirements 
trend to the renal transplant cohort, expressers requiring higher doses of 
tacrolimus. However, this was not as marked as in the renal transplant 
cohort and was statistically significant at only a few of the time points.  It is 
likely that due to small numbers in the expresser group, the difference is not 
as convincing as in the renal transplant cohort which had many more 
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patients.  There was no noticeable difference in the time taken to reach a 
therapeutic tacrolimus level in the SPK group, however those CYP3A5 
expresser patients did have a significantly higher incidence of BPAR. 
 
ABCB1 genotype did not appear to influence the dose requirements or 
trough levels in the SPK cohort much the same as the renal transplant group 
however there was significantly less DGF in patients who expressed the CT 
genotype.  It is difficult to conceive that this is a genuinely ‘protective’ 
genotype and is more likely due to the fact that the majority of patients are 
of the CT genotype and so those few who have DGF of the CC or the TT 
genotype will likely form a larger percentage of that group.   
 
The T allele frequency of CYP3A4*22 is so low that in a cohort of only 32 
patients, there are instances where only one result is available to represent 
CT genotype and that makes it almost impossible to draw any conclusions 
other than to say that the CYP3A4*22 genotype did not appear to 
significantly affect dose, trough level, renal function or other clinical 
outcomes in this small cohort of patients.  A much larger number of patients 
is required (both for renal and SPK transplant recipients) to try and better 
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6 GENETIC POLYMORPHISMS AND VARIABILITY 




Tacrolimus, although highly effective in preventing allograft rejection, is 
complicated by considerable variation in pharmacokinetics between 
individual patients and a narrow therapeutic index which requires close 
monitoring of the trough levels. Patients exposed to excessive 
immunosuppression are at risk of neurological and cardiovascular side 
effects and graft loss due to drug toxicity [212], whilst under-exposure leads 
to a higher risk of immune mediated rejection and graft loss with an 
associated increased risk of mortality [213]. Patient variability in the 
pharmacokinetics of tacrolimus is associated with many different factors, 
including but not limited to, weight, ethnic group, cytochrome P450 3A5 
gene expression and patient adherence.  
  
There have been suggestions that high intra-patient variability may be 
associated with increased graft loss [49, 214] and although the cause remains 
poorly understood, patient adherence is thought to play a significant role 
[215].  Furthermore, current studies suggest that cytochrome P450 3A5 
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(CYP3A5) expression affects inter-patient variability but does not 
significantly influence tacrolimus variability within individual patients [61, 
216]. 
The two available formulations of tacrolimus [twice-daily (Tac-BD) and 
modified-release once-daily (Tac-QD)] have slightly different 
pharmacokinetics.  Furthermore, it is perceived that once-daily medications 
are better adhered to than twice-daily (although the evidence for this is 
somewhat variable) raising the possibility that medication adherence may 
play a role in reducing intra-individual variability.   
The aim of this study, therefore, was to evaluate if there are any differences 
in the intra-patient variability before and after conversion from Tac-BD to 
Tac-QD in renal transplant patients and to examine the impact of tacrolimus 
variability on graft survival.   
The secondary aim is to examine to what extent the different genotypes of 
CYP3A5, ABCB1 and CYP3A4*22 have on tacrolimus dose requirements and 
trough levels following conversion to Tac-QD (modified release once daily).  
It is feasible that given the expression of CYP3A5 in particular is associated 
with lower exposure of tacrolimus, it could influence tacrolimus variability 
however there is little evidence currently to evaluate this. 
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6.2 Chapter Methodology 
 
 
All renal transplant recipients attending our centre who had been converted 
from Tac-BD (Prograf®) preparation of tacrolimus to Tac-QD (Advagraf®) 
preparation between September 2008 and December 2011 were included.  
Clinical data was collected on 103 renal transplant patients converted from 
Tac-BD to Tac-QD.  Patients were converted at the discretion of the 
transplant clinician.   
To calculate tacrolimus intra-individual variability we used a method 
previously described by Borra et al [49].    A value of percentage variability is 
derived for each individual patient, which describes the percentage by which 
their dose corrected tacrolimus levels vary from their own mean.  It is 
calculated using the formula {[( χ mean – χ 1) + (χ mean – χ 2)...... + (χ mean – χ n)]/n} / χ 
mean * 100   = intra individual variability (%) where χ mean is the mean dose 
corrected tacrolimus level (tac C0/dose) and χn are each of the dose corrected 
tacrolimus levels for that patient.  All available dose corrected tacrolimus 
levels for 12 months prior to conversion (Tac-BD) and 12 months after 
conversion (Tac-QD) were used and a percentage variability value calculated 
for each patient before and after conversion.   
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Patients in the study were categorised as either high or low variability 
depending on whether their percentage variability was higher or lower than 
the median value both before and after conversion to Tac-QD. The overall 
tacrolimus variability in the 12 months before conversion (Tac-BD) was 
compared with the tacrolimus variability in the 12 months after conversion 
to Tac-QD. In addition, 4 separate groups were defined, taking into account 
the pre and post conversion variability percentage:  Low-low (LL), low-to-
high (LH), high-to-low (HL), high-high (HH). Graft and patient survival as well 
as the serum creatinine up to 12 months after conversion to Tac-QD were 
evaluated for these groups. The tacrolimus variability for both preparations 
was compared between patients converted to Tac-QD within the first 12 
months following transplantation and those converted beyond 12 months 
after transplantation to investigate whether time to conversion from 
transplant had an impact on tacrolimus variability.   
A smaller sub-cohort of these patients who were converted to Tac-QD had 
stored frozen DNA available (n=43) which was then genotyped as described 
in the laboratory methodology chapter for CYP3A5, ABCB1 and CYP3A4*22.  
The tacrolimus dose requirement and the trough level was measured prior to 
conversion and then at 1, 2, 3, 6 and 12 months after conversion to Tac-QD. 
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6.3 Chapter Results 
 
6.3.1 Patient demographics 
 
103 patients (67 male and 36 female) were converted from Tac-BD to Tac-QD 
with a mean time to conversion of 41.50 ± 45.61 months after transplant 
(range 0 – 155 months).  Patient demographic data is shown in Table 6.1 
below.  Forty-two patients (40.78%) were converted to Tac-QD within the 
first 12 months of transplantation at a mean time of 4.00 ± 3.20 months 
(range 0 – 11 months) and 61 patients (59.22%) were converted greater than 
12 months after transplantation at a mean time of 67.31 ± 43.21 months 
(range 13 – 155 months). 
 
Table 6.1 Patients demographics of renal transplant patients converted to 
once-daily modified release tacrolimus 
Patient Demographics Values Column3 Column4 
Male:Female 67 (65.0%) 36 (35.0%)  
Transplant 1st:2nd:>2nd 85 (82.5%) 11 (10.7%) 7 (6.8%) 
DBD:DCD:Live Donor 69 (67.0%) 10 (9.7%) 24 (23.3%) 
Age (mean±SD) (years) 48.96±13.15   
Weight (mean±SD) (kg) 76.65±16.71   
Converted 0-12 months:>12 
months 





6.3.2 Conversion to Tac-QD 
60 patients (58.3%) were converted to Tac-QD on a mg:mg basis, 26 patients 
(25.3%) were converted to a Tac-QD dose ± 1 mg of the Tac-BD dose and 17 
patients (16.5%) were converted to a Tac-QD dose greater than ± 2 mg. The 
mean dose of Tac-BD prescribed prior to conversion was 6.27±4.81 mg (1-26 
mg) and the mean starting dose of Tac-QD was 6.21±4.77 mg (1-27 mg). 
 
6.3.3 Tacrolimus Variability 
Overall tacrolimus variability was higher for the Tac-BD formulation in the 
12 months prior to conversion compared with the Tac-QD formulation in the 
12 months following conversion (25.23±14.63% compared to 21.68±12.62%, 
p=0.043, paired samples t-test) (Figure 6.1 below) 
 
Figure 6.1 Overall tacrolimus variability for both the twice-daily (BD) and 
once-daily (QD) preparations in this kidney transplant cohort. 
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There was a significant difference in variability for the Tac-BD formulation 
up to the point of conversion between patients converted early and those 
converted beyond 12 months following transplantation, [30.59±16.61% 
(n=42) versus 21.55±11.89% (n=61), p=0.002, t-test].  Once patients were 
converted to Tac-QD, intra-patient variability was comparable irrespective 
of the time of conversion [24.17±12.22% (<12 months) vs 19.97±12.70% (> 12 
months), p=0.097 t-test].  
There was a significant improvement in intra-patient variability upon 
conversion from Tac-BD (30.59±16.61%) to Tac-QD (24.17±12.22%) 
(p=0.038, T-test) in those converted within the first 12 months post-
transplant.  However, there was no difference between the variability of Tac-
BD (21.55±11.89%) and Tac-QD (19.97±12.70%) in patients converted 





Figure 6.2 Tacrolimus variability for patients converted before and after 12 
months demonstrating a significant reduction in variability if converted before 
12 months but those converted after 12 months did not have significantly 
reduced variability between the Tac-BD and Tac-QD preparations. 
 
6.3.4 Variability Change after Conversion to Tac-QD 
To determine whether tacrolimus variability had a clinical impact, patients 
were compared according to the percentage variability before and after 
conversion: Low-low (LL), low-to-high (LH), high-to-low (HL), high-high (HH).  
In the LL group the percentage variability for Tac-BD was 14.92 ± 5.45% and 
for Tac-QD 11.57 ± 5.02% (n=32).  The variability in the LH group was 13.72 ± 
6.77% for Tac-BD and 29.90 ± 7.83% for Tac-QD (n=19).  In the HL group the 
variability was 36.03 ± 14.05% for Tac-BD and 13.12 ± 4.61% for Tac-QD 
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(n=20).  The variability in the HH group was 35.64 ± 12.19% for Tac-BD and 
32.26 ± 11.86% for Tac-QD (n=32). 
 
Table 6.2 Change  in variability in each group for Tac-BD prior to conversion 
and Tac-QD after conversion 
 Tac-BD %Variability Tac-QD %Variability 
Low to Low (LL) 14.92 ± 5.45% 11.57 ± 5.02% 
Low to High (LH) 13.72 ± 6.77% 29.90 ± 7.83% 
High to Low (HL) 36.03 ± 14.05% 13.12 ± 4.61% 
High to High (HH) 35.64 ± 12.19% 32.26 ± 11.86% 
 
 
6.3.5 Acute Rejection 
Overall, 21 patients (20.4%) experienced acute rejection episodes but there 
was no difference between the groups (Chi-square test p=0.953).  There were 
3 episodes of acute rejection that occurred after conversion to Tac-QD, 1 in 
the LL group and 2 in the HH group, with no significant difference between 




6.3.6 Renal Function 
 
There was no significant difference in renal function between the four 
groups and the serum creatinine levels were comparable when measured 




Figure 6.3 Creatinine immediately prior to conversion and at each time point 
post conversion to Tac-QD for each of the variability groupings with no 





6.3.7 Graft Survival and Patient Survival 
 
Four patients (12.5%) lost their grafts in the HH group, more compared with 
all other groups. Kaplan-Meier survival analysis showed a poorer graft 
survival in the HH (87.5%) group compared with the LL group (100%), 
(p=0.011 log-rank test) with no difference between the other groups.  There 






Figure 6.4 Kaplan-Meier survival curves for each variability group following 
conversion from Tac-BD to Tac-QD.  No difference in patient survival is seen 
however significantly greater graft loss seen in the HH group compared with 
the LL group, p=0.011 Log-rank test.
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6.3.8 Impact of Genetic Polymorphisms on Tac-QD and Variability 
 
43 patients converted from Tac-BD to Tac-QD had stored frozen DNA that 
was available for genotyping.  These patients had their DNA genotyped for 
polymorphisms of CYP3A5, ABCB1 and CYP3A4*22 as previously described 




There were 36 patients (83.7%) of the GG (*3/*3) genotype of CYP3A5, 6 
patients (14.0%) of the GA (*3/*1) and a single patient (2.3%) of the AA 
(*1/*1) genotype meaning there were 36 non-expressers of CYP3A5 (83.7%) 




There were 11 patients (25.6%) who expressed the CC genotype of ABCB1, 15 






There were 37 patients (86.0%) who expressed the CC genotype, 5 (11.6%) 
who expressed the CT genotype and a single patient (2.3%) who expressed 
the TT genotype of CYP3A4*22.  This means there were 6 T allele expressers 
of CYP3A4*22 (14.0%). 
 
6.3.12 Tacrolimus Variability Relative to Genotype 
 
Tacrolimus variability was comparable between CYP3A5 expressers 
(24.52±8.43%) and non-expressers (30.80±18.49%) for the Tac-BD 
preparation, p=0.388, one-way ANOVA and similarly for the Tac-QD 
preparation where the variability for CYP3A5 expressers was 23.37±6.27% 
compared with 23.51±11.62% for the non-expressers, p=0.977, one-way 
ANOVA. 
The variability for Tac-BD (Prograf) was significantly higher in patients of 
the CC genotype of ABCB1 (41.78±19.53%) when compared with the CT 
genotype (21.52±14.12%), p=0.011, one-way ANOVA.  The variability was 
lower for those of the TT genotype (29.40±14.81%) compared with the CC 
genotype but it did not reach statistical significance, p=0.171 one-way 
ANOVA.   
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For the Tac-QD preparation of tacrolimus the variability did not differ 
between any of the 3 genotype groups of ABCB1 and was 24.91±13.65% for 
the CC genotype, 21.28±11.37% for the CT genotype and 24.38±8.59% for the 
TT genotype, p=0.653, one-way ANOVA for the combined groups. 
It is not clear why the CC genotype should have significantly higher 
variability in the Tac-BD group alone and requires further evaluation in a 
much larger study before any conclusions can be drawn. 
Tacrolimus variability relative to CYP3A4*22 genotype did not show any 
significant difference between those of the CC genotype (30.43±17.72%), or 
the CT/TT genotype (25.63±15.05%), p=0.536, one-way ANOVA, for the Tac-
BD preparation.  There was similarly no difference when patients were 
converted to the Tac-QD preparation in variability between the CC genotype 
(23.34±10.46%) or the CT/TT genotype (24.34±14.12%), p=0.838, one-way 
ANOVA. 
 
6.3.13 Tacrolimus Dose and Trough Levels Relative to Genotype 
 
The smaller cohort of 43 patients who had been converted to Tac-QD and 
who had their genotype of CYP3A5, ABCB1 and CYP3A4 available had their 
tacrolimus dose and trough levels measured at various time points up to 12 
months after conversion to Tac-QD. 
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6.3.14 CYP3A5 and Tac-QD 
 
Patients who were expressers of CYP3A5 had a similar 2-fold increase in 
dose requirement in order to achieve therapeutic levels as patients taking 
the twice-daily Tac-BD preparation. The increased Tac-QD requirement was 
sustained throughout the 12 months follow up period after conversion and 
was highly significant (p<0.0001) at every time point, one-way ANOVA.  
(Figure 6.5 below) 
 
 
Figure 6.5 Tacrolimus dose requirement at each time point relative to 
CYP3A5 expression.  The dose requirement is significantly higher at each 




6.3.15 Tacrolimus Trough Levels and CYP3A5 Genotype 
 
The patients in this study were converted at different time points following 
transplant, therefore many will have been transplanted some time ago and 
have stable levels.  There was no significant difference in tacrolimus trough 
levels between the expressers and non-expressers of CYP3A5 following 
conversion to Tac-QD. (Figure 6.6) 
 
 
Figure 6.6 Tacrolimus trough concentration (C0) at each time point relative to 




6.3.16 ABCB1 and Tac-QD 
 
There was no significant difference between the Tac-QD dose requirement at 
any of the time points between the different genotypes of ABCB1 (Figure 
6.7). Correspondingly there was also no significant difference between the 
tacrolimus trough levels of any of the different genotypes of ABCB1 at any of 
the time points following conversion to Tac-QD (Figure 6.8). 
 
 





Figure 6.8 Tacrolimus trough concentrations (C0) at each time point relative 
to ABCB1 genotype. 
 
 
6.3.17 CYP3A4*22 and Tac-QD 
 
The dose requirement of Tac-QD was slightly lower at each time point for 
those individuals who expressed a T allele of CYP3A4*22 although it did not 
reach statistical significance at any of the time points.  The trend towards a 
lower dose requirement for individuals who express a T allele of CYP3A4*22 





Figure 6.9 Tacrolimus dose requirement at each time point relative to 
CYP3A4*22 T allele expression. 
 
6.3.18 Tac Trough Levels and Tac-QD Relative to CYP3A4*22 
 
There was no difference in the trough levels of tacrolimus following 
conversion to Tac-QD at any of the time points, similar to the Tac-BD 





Figure 6.10 Tacrolimus trough concentration (C0) at each time point relative 
to CYP3A4*22 T allele expression. 
 
6.4 Chapter Summary 
 
 
Kidney transplantation is considered the best treatment for end stage renal 
disease and modern surgical techniques along with advances in 
immunosuppression have transformed renal transplantation into a routine, 
cost-effective and highly successful treatment.  Despite these successes 
there remain a proportion of patients who will lose their transplant during 
the follow up.  While undoubtedly the reasons for graft loss are multi-
factorial, a study by Borra et al has shown that high intra-individual 
variability of tacrolimus trough concentrations is one of the contributing 
factors to increased graft loss [49].  Following this report, some 
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consideration has been given as to whether the once-daily modified release 
formulation of tacrolimus (Tac-QD or Advagraf®) could result in lower intra-
individual variability, given its different pharmacokinetic profile. Wu et al in 
2011 suggested that this may be the case [217] whilst Stifft et al [62] 
presented supportive evidence that once-daily modified release tacrolimus 
leads to reduced variability although the follow up period was rather short, 
over the course of 16 weeks. 
In this study the variability was calculated before and after conversion to 
Tac-QD by taking a minimum of 3 trough concentrations in the year prior to 
conversion and a minimum of 3 trough concentrations in the year following 
conversion.  It is important to note that variability does tend to reduce over 
time anyway for both the Tac-BD and Tac-QD preparations and thus 
interpretation of the results can be clouded by this.  This may be one reason 
why different studies have reported that conversion to Tac-QD both does 
and does not affect variability.  The results of this study should be 
interpreted with that caveat in mind. 
In our study, we found that first of all, the twice daily formulation of 
tacrolimus is associated with a higher intra-individual variability of trough 
levels however this is only apparent in the first 12 months following 
transplantation. The exact mechanism for this is unclear however it is 
generally accepted that much variation in dose and tacrolimus levels will 
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occur within the first year after transplantation and in particular during the 
first 3 months. Some of this variation is undoubtedly due to changes in the 
prescribed dose which are more numerous early after transplantation. 
Following conversion to a once daily formulation, the intra-patient 
variability reduced significantly, but only in those patients converted within 
the first 12 months following transplantation. It may be that during this time 
the once-daily preparation of tacrolimus leads to a different profile of the 
area under the curve and therefore reduces some of the variability, but long 
term there are no differences between the two preparations.  A paper by 
Shuker et al, Ther Drug Monit, 2015 describes a phenomenon of ‘regression to 
the mean’ which may account for the reduction in IPV reported by some 
other studies [218].  Regression to the mean (RTM) is a statistical 
phenomenon that can result when the same subjects are sampled repeatedly 
and can make natural variation appear as if it is real change.  This can occur 
when an unusually large or small value is then followed by a measurement 
that is closer to the true mean.  Shuker et al adjusted their IPV values based 
on a corrected for RTM and reported that 98% of the reduction in the IPV 
following conversion to Tac-QD was due to RTM rather than a true change.  
While it is not possible to determine if other studies change in IPV is simply 
as a result of RTM rather than a true reduction, it must be considered a real 
possibility, particularly in retrospective and non-randomized studies.  We 
did not correct for RTM in this study and therefore must apply caution in 
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interpreting the result of a modest reduction in IPV seen in patients 
converted within the first 12 months after transplant. 
Patients who have a high intra-individual variability, irrespective of the 
tacrolimus formulation, have an increased risk of graft loss. Current 
evidence has not shown that once-daily tacrolimus started early after 
transplantation or de novo reduces the risk of acute rejection. As this study 
only shows a significant reduction in intra-patient variability in patients 
converted to Tac-QD within the first year after transplant, we cannot 
conclude that there is any significant benefit of early conversion in terms of 
patient outcome.  Our data does suggest that persistently high intra-patient 
variability, irrespective of the preparation of tacrolimus taken, leads to 
increased graft loss. One of the questions that needs to be addressed is why 
some patients have high intra-patient variability.  While this question was 
outside the scope of this study, two factors have been proposed as potential 
explanations: patient adherence with medication and genetic 
polymorphisms that may influence tacrolimus pharmacokinetics.  Patient 
adherence is known to influence the outcome of renal transplantation in 
both adult and paediatric patients [219-221].  Currently, there is limited 
published data linking non-adherence with increased tacrolimus variability, 
as an accurate measurement of adherence is difficult to obtain. However 
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further evaluation of a direct link between adherence and tacrolimus 
variability would be of value [222]. 
Genetic polymorphisms of cytochrome P450 are well known to influence the 
pharmacokinetics and dose requirements of tacrolimus [152, 223]. More 
recently it has been hypothesised that the expression of CYP3A5 
polymorphisms may contribute to the intra-individual variability of 
tacrolimus, although the supportive evidence is contradictory. Ro et al [61, 
214, 216] supports a role for CYP3A5 polymorphism in the intra-individual 
variability of tacrolimus whilst Spierings et al [61, 214, 216] and Pashaee et al 
[61, 214, 216] suggest  that CYP3A5 polymorphisms have no influence at all 
on tacrolimus variability.  Therefore, the potential impact of genetic 
polymorphisms on the variability of tacrolimus is yet to be fully ascertained. 
This study is limited by the fact that most conversions were at the discretion 
of the treating physician rather that part of a robust conversion protocol and 
it is, therefore, conceivable that other patients who were not converted may 
exhibit a different intra-patient variability profile and have different 
outcomes that were not captured in this analysis. The non-protocolised 
conversion strategy utilised in this study is a significant limitation when 
drawing conclusions about the effectiveness of switching from Tac-BD to 
Tac-QD as a means of reducing tacrolimus variability.  Additionally, our 
study cohort is not randomized in this retrospective analysis which reduces 
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the ability to draw firm conclusions from out dataset.  While we acknowledge 
these limitations, this study does provide some preliminary data which adds 
to the growing evidence that increased tacrolimus variability appears to 
increase the risk of graft loss in renal transplantation.   
Conversion from Tac-BD to Tac-QD appears to be beneficial in reducing 
intra-patient variability if the patient is converted within the first 12 months 
however this effect is absent in patients converted after the first year.  
Increased variability, for both twice-daily and once-daily preparations of 
tacrolimus has a detrimental effect on graft function and further prospective 
randomized studies are required to investigate this phenomenon robustly 




























Scotland’s multi-organ transplant unit in Edinburgh presented a good 
opportunity to study the impact of genetic polymorphisms on tacrolimus 
metabolism and pharmacodynamics across 3 different abdominal organ 
transplants and to evaluate any differences.  The Generation Scotland Bio 
Resource allowed for a large sample of the population to be genotyped for 
the genetic polymorphisms of interest in this study and to determine their 
distribution in a healthy Scottish population.  By bringing these two 
elements together, it was possible to build a picture of how these drug 
metabolism genetic polymorphisms impact on organ transplantation in a 
Scottish population and to what extent the distribution of these genetic 
polymorphisms in the transplant patients are reflected in the healthy 
Scottish population. 
 
The studies in this thesis add to the existing published data, primarily in 
renal transplantation, on the impact of SNPs of CYP3A5, ABCB1 and 
CYP3A4*22 on tacrolimus drug metabolism and support the findings that 
CYP3A5 expression, in particular, is associated with increased tacrolimus 
dose requirements and initially reduced trough levels, resulting in a longer 
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time to reach a steady state blood level post-transplant [119, 123, 125-128, 
130, 152, 163]. 
 
This study also adds to the emerging data on liver transplant patients 
demonstrating that donor liver CYP3A5 expression leads to an increased 
tacrolimus dose requirement to achieve therapeutic levels but also, crucially, 
results in increased acute rejection of liver allografts and a longer time to 
reach a therapeutic trough level.  These findings re in keeping with more 
recent publications [224, 225]. 
 
It is thought that in Caucasians genetic polymorphisms, primarily of CYP3A5 
and CYP3A4, account for about 20% of the variation in tacrolimus dose and 
trough levels. While there is good evidence to support the influence of 
genetic polymorphisms on tacrolimus pharmacokinetics, there are many 
other factors which can influence the tacrolimus dose requirements and 
trough levels.  These factors are often difficult to adjust for and include 
concomitant medication, variations in haematocrit level and weight, patient 
adherence and whether the medication is taken alongside food.   
Tacrolimus trough concentrations can vary significantly from person to 
person (inter-patient variability) and also within individual patients between 
repeated measurements of the trough level (intra-patient variability).  Inter-
patient variability is likely influenced by the expressed genotype of CYP3A5 
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and CYP3A4, alongside some newer polymorphisms such as POR*28 [226].  
Intra-patient variability is possibly more significant, however, as evidence is 
now emerging that patients with high variability tacrolimus trough levels 
have poorer long-term graft survival compared with those with stable levels.   
This study also explored whether a change from a twice-daily preparation of 
tacrolimus to once-daily tacrolimus in renal transplant recipients would 
reduce the intra-patient variability and found an improvement if conversion 
happened within the first 12 months following transplantation with little 
effect beyond that.  Additionally, it was found that patients who had high 
intra-patient variability for both twice-daily and once-daily tacrolimus had 
significantly greater graft loss when compared with patients with low intra-
patient variability. This study also found that in a small sub-set of patients, 
where genomic DNA was available for genotyping, SNPs of CYP3A5, 









7.1 Distribution of Polymorphisms in a Scottish Population 
 
 
The first question set out in the introduction of this thesis sought to answer 
how the SNPs of CYP3A5, ABCB1 and CYP3A4*22 were distributed in a 
Scottish population and how they compared with other similar Caucasian 
populations as well as noting differences to other ethnic groups.  
 
This chapter explored the distribution of the three SNPs of interest in this 
study (CYP3A5, ABCB1 and CYP3A4*22) in a large control group of the 
Scottish population, with more than 5000 subjects tested. This allowed a 
confident description of the distribution of these polymorphisms in the 
Scottish population, a fairly homogeneous ethnic population previously not 
genotyped for these SNPs. This analysis allowed a direct comparison with 
the cohort of transplant patients. 
 
This study demonstrates a similar expression of CYP3A5 in White – Scottish 
subjects as reported in other studies with Caucasian subjects in the UK 
(86.6%) [152]  or Europe [124, 227, 228].  World-wide the GG (*3/*3) 
genotype of CYP3A5s seen in 75 – 90% Caucasians.   
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The distribution of ABCB1 was also found to be similar to previously studied 
populations and in this instance there was another Scottish cohort of 
inflammatory bowel disease patients to compare against [229].  In this paper 
a control group of 370 individuals, the distribution of the different 
genotypes of ABCB1 C3435T was CC 22.2%, CT 51.3% and TT 26.5%, similar 
to that seen in the Generation Scotland subjects in this thesis (CC 20.6%, CT 
49.4%, TT 30.0%).  Other studies have described the distribution of the 
ABCB1 C3435T genotype in Caucasian subjects and have reported similar 
results  [104, 124, 227, 230, 231].   
 
The T allele of CYP3A4*22 has  a very low allele frequency in Caucasians, as 
was the case with this study, and almost completely absent in other non-
Caucasian ethnic groups [105]. 
 
Examining a large section of the healthy Scottish population and 
establishing the distribution of the different genotypes of CYP3A5, ABCB1 
and CYP3A4*22 gave a robust control group for the next stage of the study 
where different cohorts of transplant recipients (as well as organ donors) 
were genotyped for the same SNPs.  This study has shown a consistent 
distribution of the 3 different SNPs across the different organ transplant 
groups, compared with the sample from the healthy Scottish blood donors.   
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7.2 Genomics and Liver Transplantation 
 
The impact of the investigated SNPs on liver transplantation has been 
scarcely examined to date and the next question in the thesis was to explore 
if the CYP3A5, ABCB1 and CYP3A4*22 polymorphisms had the same effect 
on tacrolimus pharmacodynamics in liver transplant patients as they had 
been shown to have in many renal transplant cohorts. 
 
Given that CYP3A5 is a cytochrome p450 enzyme expressed predominantly 
in liver tissue, it was important to take the donor’s genotype into 
consideration, as we hypothesised that the donor genotype rather than 
recipient’s own genotype plays the prime role in metabolising tacrolimus.   
 
This study did show that the donor expression of CYP3A5 had a significant 
impact on the tacrolimus dose requirements of liver transplant patients. 
Significantly higher doses were required to achieve the same therapeutic 
level as those with livers from CYP3A5 non-expressers.  Donor expression 
had a greater influence than recipient genotype, although recipient 
expression had a cumulative effect leading to highest tacrolimus dose 




The CYP3A4*22 genotype has not been extensively studied in liver 
transplantation.  This study showed a trend toward lower tacrolimus dose 
requirements, particularly in the CYP3A4*22 T allele expressers in the liver 
donors.  This finding again supported the idea that the donor genotype 
played a more significant role in determining the cytochrome P450 activity 
than the recipient genotype alone.  
 
There was no significant influence of the C3435T polymorphism of ABCB1 
from either the donor or recipient in terms of tacrolimus pharmacodynamics 
or clinical outcome in this study. 
 
The interaction of these genetic polymorphisms with tacrolimus dose 
requirements and exposure is of scientific interest and furthers the 
understanding of drug metabolism and pharmacokinetics, however the 
translation into clinical relevance for solid organ transplant recipients has 
been difficult to establish.  Theoretically patients who have either a higher 
or lower exposure to tacrolimus could be at risk of adverse clinical events 
related to either toxicity or inadequate immunosuppression however these 
links have not been well established in current literature. 
 
This study did, however, find that only donor expression of CYP3A5 resulted 
in increased acute cellular rejection in liver transplant patients compared 
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with the non-expressers.  Whilst this could be anticipated given that the 
donor CYP3A5 expression results in significantly reduced tacrolimus 
exposure, this is at odds with the results in renal transplantation where 
there was no increase in acute rejection.  
 
One possible explanation to consider is that the tacrolimus level measured 
in these studies represents the whole blood concentration trough level which 
does not necessarily reflect the intracellular concentration of tacrolimus 
within the hepatocytes.  Given that liver donors who express CYP3A5 will 
metabolise and clear tacrolimus more extensively than the CYP3A5 non-
expressers, it is conceivable that the tacrolimus concentration within the 
liver itself is lower than the whole blood concentration, falsely reassuring 
the clinician that the tacrolimus levels are adequate.  In a renal transplant 
scenario however, if the recipient is a CYP3A5 expresser, they will need a 
higher dose to reach a therapeutic level but the whole blood trough levels 
are likely to be representative of the intra-parenchymal concentration of 
tacrolimus in the kidney. 
 
If the intrahepatic concentration of tacrolimus were (hypothetically) lower 
the next thing to consider is whether this would actually increase the risk of 
rejection within the graft.  T cell activity is suppressed by calcineurin 
inhibitors, and therefore circulating T cells should be adequately suppressed 
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with a therapeutic whole blood trough level of tacrolimus.  It seems 
theoretically possible, however, that T cells within the liver graft could be 
more active if the environment within the liver itself were more favourable, 
with a lower concentration of tacrolimus.  While this is speculative in the 
context of this study, a paper by Capron et al in 2007 examined the 
correlation between hepatic tissue concentration of tacrolimus post liver 
transplant and acute cellular rejection [232].  They found that the tissue 
concentration had a more accurate association with acute rejection than the 
systemic concentration and derived a cut off value of less than 30 pg/mg 
which was highly sensitive and specific for clinically relevant acute rejection. 
 
Although this study did not evaluate cytochrome P450 genetic polymorphism 
expression, it revealed that the systemic concentration and the intrahepatic 
concentration of tacrolimus are not necessarily equivalent and that the 
intrahepatic concentration appears to be more closely associated with acute 







7.3 Genomics and Renal Transplantation 
 
 
The role of polymorphisms of genes related to drug metabolism of 
tacrolimus are most widely described in renal transplantation, where the 
three SNPs evaluated here are most widely published.  The influence of 
CYP3A5, in particular, which increases the tacrolimus dose requirements 
approximately two-fold to achieve a therapeutic trough level, is widely 
established in the current literature and has led to the pursuit of other 
possible genetic polymorphisms which may also influence tacrolimus 
pharmacokinetics.   
 
The next question this thesis sought to address was whether the distribution 
of the genetic polymorphisms in a Scottish renal transplant cohort was 
similar to those described in other renal transplant studies and whether the 
influence of these polymorphisms on tacrolimus pharmacodynamics and 
clinical outcome was similar to those described previously. 
 
Since the first publication of preliminary studies around 15 years ago there 
has been a plethora of evidence in renal transplantation exploring the 
relationship between genetic polymorphisms related to drug metabolism 
enzymes and tacrolimus [111, 154, 162, 209].  
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In this study, we found that CYP3A5 expression results in an approximately 
two-fold increase in the dose requirement to achieve a therapeutic level, 
similar to previously published data. In contrast, the ABCB1 C3435T SNP 
had no discernible impact on tacrolimus dose requirements. 
 
The results of the CYP3A4*22 assay in renal transplant recipients in this 
study supported recently published works by Elens et al where those who 
expressed the T – variant allele had a lower tacrolimus dose requirement and 
greater tacrolimus exposure.  This reduction in dose requirement is more 
subtle than the higher dose required by the CYP3A5 expressers and 
represents around a 50% reduction from the CC wild type homozygotes of 
CYP3A4*22.   
 
This study did not find any significant impact on clinical outcomes such as 
renal function, acute rejection, graft or patient survival in the renal 
transplant cohort that was related to the genetic polymorphisms of CYP3A5 
and CYP3A4*22.  However, there appeared to be significantly greater graft 
loss associated with patients of the CC genotype of ABCB1.  There have been 
reports of different genotypes of ABCB1 conferring an increased risk of renal 
allograft loss, however the reports have not been consistent.  A large study 
by Moore et al in 2012 demonstrated increased graft loss in patients who 
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received a kidney from a donor, rather than recipient of the CC genotype 
[233].  A smaller study by Woillard et al in 2010 found that, in fact, the TT 
genotype of the donor was associated with increased graft loss however 
patients were taking ciclosporin instead of tacrolimus [234].  In our study, it 
was the recipients only who were genotyped and while the CC genotype of 
renal transplant patients had greater graft loss, this was only found in 
univariate analysis. 
 
7.4 Genomics and SPK Transplantation 
 
There is little data about tacrolimus pharmacogenomics in an SPK 
population and the next question we set to investigate was whether or not 
SPK patients behaved in the same way as the much better established renal 
transplant population relative to SNP expression and tacrolimus 
pharmacodynamics.  
 
While it may seem likely that SPK patients would have similar findings to 
renal transplant patients, SPK patients could metabolise tacrolimus 
differently due to a high incidence of autonomic neuropathy and, in 
particular, gastroparesis and gut dysmotility.   
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This study found a trend towards an association between CYP3A5 expression 
and higher doses of tacrolimus for SPK patients, however the results were 
less clear cut than the kidney alone cohort.  One of the potential 
explanations is the considerably smaller number of patients in the SPK 
cohort.  Similarly, there were no clear significant differences seen in the 
CYP3A4*22 group, again likely due to small numbers as well as the very low 
allele frequency of the T-variant allele of this polymorphism.   
 
In the case of SPK transplantation, it seemed plausible that the ABCB1 
polymorphism of the 3435 C>T transition may play a greater role than seen 
in either renal or liver transplantation.  The reason for this relates to the gut 
dysmotility seen in SPK patients, as the distribution of p-glycoprotein varies 
along the length of the GI tract and these influence changes in the function 
of the gut, how much tacrolimus is absorbed and crucially, where exactly in 
the GI tract the tacrolimus is absorbed. 
 
In this cohort of SPK patients, however, there was no difference seen 
between any of the genotypes of the ABCB1 polymorphism and tacrolimus 
exposure.  However, we did not investigate the gut expression of the 








The studies undertaken have shown that CYP3A5 expression has the greatest 
impact on tacrolimus dose requirements and early trough levels and that 
patients who are CYP3A5 expressers have significantly lower tacrolimus 
exposure compared to non-expressers on a comparable dose.  This influence 
was seen in the renal transplant cohort as well as the liver transplant cohort. 
In the liver cohort, the donor genotype has the greatest significance.  A 
similar trend was seen in the SPK patients however the results were not 
statistically significant, most likely due to a smaller sample size, and 
therefore this requires further evaluation. 
 
ABCB1 appeared to have very little, if any, impact on the tacrolimus dosing 
requirements and tacrolimus exposure.  It seems to be a polymorphism 
included in a lot of studies due to the fact that some early papers appeared to 
suggest an effect.  Subsequent studies have not supported those results and 
the findings in this thesis would strengthen the conclusion that the effect on 
tacrolimus dose requirements in any abdominal solid organ transplant is 
negligible.  It is, however, worth noting that CYP3A5 expression reduces 
tacrolimus exposure so significantly that it may mask the smaller effect of 
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other polymorphisms.  ABCB1 and CYP3A4*22 certainly have a smaller 
impact and an analysis looking only at CYP3A5 non-expressers to tease out 
the influence of other SNPs may be relevant. 
 
The effect of the T allele expression of CYP3A4*22 results in lower 
tacrolimus dose requirements and a greater systemic exposure to tacrolimus 
compared with those patients of the CC wild-type genotype.  This effect is 
seen in renal and liver transplant patients and suggested in the SPK patients 
but the lower numbers compounded with a very low allele frequency mean 
the results do not reach statistical significance at most time points. 
 
The clinical impact, in terms of significant graft or patient level events, 
related to different drug metabolising genetic polymorphisms has been 
minimal.  The only clinical outcome which has been influenced by 
expression of a particular genetic polymorphism is an increased acute 
cellular rejection in liver transplant patients where the donor was a CYP3A5 
expresser. 
 
7.6 Tailored Dosing of Tacrolimus Based on Genotype 
 
The current clinical practice in determining the initial dose of tacrolimus is 
based on the weight of the patient, and the dose is then adjusted based on 
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therapeutic drug monitoring trough levels.  This method, while crude, is 
fairly reliable for most transplant recipients and will lead to effective 
immunosuppression in a timely fashion minimising the risk of acute 
rejection.  There will be, however, in a Caucasian population 15 – 20% of 
individuals who will express at least one copy of the CYP3A5 A (*1) allele, 
making functional CYP3A5. For these patients, a weight based dose 
calculation alone may be inadequate, exposing them to a risk of under-
immunosuppression in the first week or so after transplantation [103].  It 
therefore seems sensible to consider individualising the dose of tacrolimus 
based on the CYP3A5 genotype.  There is little evidence either from this 
study or elsewhere in the literature to justify using ABCB1 genotype in 
determining the optimal dose of tacrolimus and while T allele expression of 
CYP3A4*22 may well have an influence on dose requirements, the allele 
frequency is so low that it is unlikely to have a practical implication in any 
one transplant unit.   
 
In 2010, Thervet et al, published a randomized controlled trial where patients 
undergoing renal transplantation were randomized to receive standard dose 
tacrolimus according to weight or a dose based on CYP3A5 expression.  They 
found that at day 10 the patients in the CYP3A5 based dosing were more 
likely to be in the target C0 compared with the control group [235].  This 
paper demonstrated that peri-transplant genotyping is both feasible and 
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effective in achieving a therapeutic C0 level more rapidly in CYP3A5 
expressers but failed to demonstrate any real clinical benefit from this as the 
rejection rates and eGFR were similar between the two groups.  Furthermore, 
patients in this study were low immunological risk (most receiving their first 
transplant), but despite that were significantly immunosuppressed, 82% 
received induction with rabbit antithymocyte globulin (ATG) which in UK 
practice is reserved for the higher immunological risk transplants.   
 
It is conceivable that higher immunological risk patients such as those who 
are highly sensitised, those with a less well-matched graft or HLA/ABO 
incompatible transplants may benefit more from targeted dosing of 
tacrolimus based on the CYP3A5 genotype but this remains to be evaluated. 
 
In 2011 Passey et al described a dosing model that considered both genetic 
and clinical factors found to be important in predicting the tacrolimus 
clearance of individual patients [236].  In addition to CYP3A5 expression 
they found that transplantation at a steroid sparing centre, patient’s age, 
time from transplant and concomitant use of a calcium channel blocker 
influenced the dose of tacrolimus required to achieve a therapeutic trough 
level.  This equation is complex and would be difficult for every day clinical 
use (although an electronic calculator in a spreadsheet would be easy 
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enough to develop) and also requires the pre-emptive genotyping of all 
potential recipients for CYP3A5 to identify expressers.   
 
It is clear that genetic polymorphism expression is not the only variable 
which explains the inter-patient variability of tacrolimus clearance, and 
studies have shown that the haematocrit level, steroid use, drugs such as 
fluconazole and patient’s age, can influence the required dose in order to 
achieve a therapeutic trough level.  Nevertheless, despite these other 
influences on tacrolimus metabolism, repeated studies have shown that 
CYP3A5 expression appears to have the largest impact of any one single 
variable.  What has not been shown convincingly is a significant impact of 
CYP3A5 expression on major clinical outcomes. 
 
7.7 Variability, Genetic Polymorphisms and Tac-QD 
 
The final question in this thesis was to explore a more recent phenomenon 
that has been described and may significantly impact on graft survival; high 
intra-patient variability of tacrolimus levels.  This is not a description of the 
different tacrolimus levels between different patients (which may or may not 
be related to genetic polymorphisms) but rather describes the variation of 
tacrolimus trough levels within an individual.  We also set out to explore 
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whether or not there was a relationship between intra-patient variability and 
the 3 genetic polymorphisms of interest in this study. 
 
A seminal paper by Borra et al in 2010 described intra-patient variability 
(IPV) by calculating the percentage by which any individual patient deviates 
from their own mean tacrolimus trough levels.  By taking the median value 
patients were either in a high or low variability group. The authors reported 
an increased graft loss in patients in the high IPV group [49].   
 
In this study we examined a subgroup of renal transplant patients who had 
been converted from a twice-daily tacrolimus standard release preparation 
(Prografâ, Tac-BD) to a once-daily modified release preparation (Advagrafâ, 
Tac-QD) and evaluated the impact of the 3 SNPs on the dose requirements 
and tacrolimus trough levels.  In addition, we calculated the IPV before and 
after conversion to once-daily tacrolimus and related this to clinical 
outcome.   
 
This study found that IPV was reduced by conversion to a modified release 
once-daily tacrolimus (Tac-QD) however this effect was only seen if the 
conversion took place within the first 12 months after transplantation given 
that the first year after transplantation is the most dynamic period for 
tacrolimus levels and dose changes [237].   
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There are some studies that have suggested a more significant impact on IPV 
from converting to Tac-QD. Wu et al, 2011 [59] found that in stable kidney 
transplant patients, conversion to once-daily tacrolimus still reduced the 
IPV.  The impact of once-daily tacrolimus on IPV remains controversial as 
other studies found that a conversion to the modified release preparation did 
not have any impact on IPV [218].  The studies investigating this issue were 
small and therefore were unable to account for all the potential variables 
which could influence the variability of tacrolimus (many difficult to 
measure).  Regression towards the mean (RTM) is a statistical phenomenon 
seen when repeated measures of the same subjects can suggest an effect of 
an intervention when, in fact, the difference is merely natural variation.  
RTM can be corrected for, in terms of IPV, however very few studies do this 
and their results are perhaps misinterpreted as a result.  Until a carefully 
designed and adequately powered multi-centred study is undertaken, the 
smaller studies (this one included) will struggle to answer the question 
definitively. 
 
An aspect of IPV that is far less controversial is the impact of a high IPV on 
long term graft survival.  This study found that patients who had a high IPV 
both before and after conversion to once-daily Tac-QD had significantly 
higher graft loss than those patients who had low IPV before and after 
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conversion.  High IPV has been consistently shown in several studies to 
negatively impact renal allograft survival [49, 238, 239] however these 
studies are all limited by the fact that they are retrospective and it is difficult 
to tease out the many factors and in particular non-adherence.  
Nevertheless, they provide some convincing evidence that high IPV 
(whatever the cause) has a deleterious impact on graft survival. 
 
We then went on to explore whether there was a relationship between 
CYP3A5 expression and tacrolimus dose requirements between those renal 
transplant patients who were taking the standard twice-daily preparation of 
tacrolimus (Tac-BD) and those taking the modified release once-daily 
preparation (Tac-QD).  Those who were CYP3A5 expressers had consistently 
higher dose requirements than those who did not express CYP3A5.  We also 
found that there was no impact on the clinical outcomes. 
 
The impact of the CYP3A4*22 SNP on once-daily tacrolimus 
pharmacodynamics was also similar to renal transplant patients taking Tac-
QD with a trend clearly seen towards lower dose requirements for T-variant 
allele expressers, although again not statistically significant.  There were 
similarly no differences seen in the clinical outcome of renal transplant 
patients, relative to CYP3A4*22 genotype. 
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It is not surprising that the influence of CYP3A5 and CYP3A4*22 is similar in 
the modified release once-daily tacrolimus as it is in the standard twice-
daily preparation. Although the rate of absorption will be different, the 
overall amount of tacrolimus exposure will be similar and therefore the 
impact from cytochrome P450 enzymes in terms of dose requirements and 
levels are likely to be the same.  
 
In terms of ABCB1 SNP influences, this is where modified release tacrolimus 
and the distribution of P-gp in the gut may have been more likely to interact.  
Tac-QD is absorbed more distally in the gut than the immediate release 
formulation Tac-BD.  Given that T allele expression of ABCB1 C3435T 
decreases the expression of P-gp which is most abundant in the distal gut 
(colon) then it seemed plausible that ABCB1 may have a greater impact on 
the pharmacodynamics of once-daily Tac-QD compared with Tac-BD.  This 
was not the case in this study as there was no difference in the dose 
requirements or trough levels between the CC, CT or TT genotype.   
This finding suggests that the expression of P-gp relative to the ABCB1 
C3435T polymorphism has very little impact on the pharmacodynamics of 
tacrolimus, particularly when both the immediate release and modified 




The final part of this study was to try and bring these 2 elements of IPV and 
genotype expression together and explore whether there was an association 
between CYP3A5, CYP3A4*22 or ABCB1 genotype and IPV.   In this smaller 
cohort of patients, we did not find any significant association between the 
different genotypes of CYP3A5, CYP3A4*22 or ABCB1 and IPV.  Although 
there was a higher variability for those who were CYP3A5 expressers, this did 
not reach statistical significance.  There have been conflicting data regarding 
the influence of CYP3A5 on IPV with some studies suggesting there is an 
association with CYP3A5 genotype [60] while others have found no link 
between CYP3A5 genotype and IPV [61]. 
For the patients converted from twice-daily Tac-BD to once-daily Tac-QD in 
this study, a large number were converted some time out from 
transplantation and therefore at steady state in terms of their tacrolimus 
dosing and trough levels reducing the likelihood that variability was due to 
multiple dose adjustments as seen in the early post transplant period.   
 
The reasons for increased IPV are certainly multifactorial and almost 





7.8 Limitations of This Thesis 
 
This study was undertaken carefully and diligently to ensure the data and 
results presented were as accurate as possible.  Nevertheless there are 
several limitations that could significantly impact on the results.  Firstly this 
study is retrospective and so all the data collected was done as part of 
routine clinical care and not with a study in mind.  As such there are missing 
data, variation in how the data was collected, and adjustment to doses that 
were made as part of clinical interpretation of results rather than a rigid 
study protocol.  Without randomisation, a proper control group that is 
matched on demographics is not possible and thus can introduce bias into 
the results. 
 
This study is underpowered to detect 2 major clinical outcomes of graft loss 
and patient survival.  As a result, the impact of genetic polymorphisms on 
graft and patient survival cannot be fully evaluated and a much larger study 
with adequate follow up is required in order to answer that question 
definitively. 
 
This study had only a small number of patients in the SPK cohort and 
therefore the impact of the SNPs was less pronounced.  A larger cohort of 
SPK patients would be desirable to evaluate whether there were any 
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differences in SPK transplant patients compared with the standard renal 
transplant cohort. 
 
Where patients were converted from Tac-BD to Tac-QD this was done at 
clinician discretion rather than as part of a protocol which introduces the 
potential for bias, particularly as it was not possible to ascertain why these 
patients were chosen to switch from Tac-BD to Tac-QD.  This study did not 
correct for a regression to the mean when measuring IPV so the reduction in 
IPV seen by converting from Tac-BD to Tac-QD if converted within the first 




This thesis describes the distribution of certain genetic polymorphisms in 
Scotland which are relevant to transplant patients and their 
immunosuppression medication and explores the impact on the clinical 
outcomes.  We took one of the largest samples of a single population ever 
studied in this particular area and found the that the distribution of 
polymorphisms of CYP3A5, ABCB1 and CYP3A4*22 were similar to other 
Caucasian groups.   
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The studies in this thesis confirmed the impact of CYP3A5 expression on 
renal transplant patients and produced one of the first studies of this kind in 
a cohort of simultaneous pancreas-kidney transplant patients, finding 
similar results to renal transplant patients.  In addition, one of the studies in 
this thesis revealed that in liver transplant patients, the donor genotype is of 
a greater influence than the recipient’s own genotype.   Furthermore, donor 
expression of CYP3A5 led to increased acute rejection compared with the 
non-expressers, although variations in these polymorphisms had no impact 
on graft or patient survival. 
 
The final part of this thesis examined a subset of renal transplant patients 
who had been converted to once-daily tacrolimus (Advagrafâ) and showed 
that the genetic polymorphisms of CYP3A5, CYP3A4*22 and ABCB1 
influenced the once-daily preparation in a similar way to the standard twice-
daily (Prografâ).   
 
In addition, this subset of patients converted to once-daily tacrolimus had 
reduced IPV if converted within the first 12 months following 
transplantation however this effect was not seen if conversion took place 
beyond 12 months.  Finally, patients with high IPV both pre and post 
conversion to once-daily tacrolimus had significantly greater graft loss 
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compared to those patients with low IPV pre and post conversion to once-
daily tacrolimus. 
 
Careful maintenance of a therapeutic but non-toxic tacrolimus level is 
crucial for long term graft survival and it is clear many factors can influence 
the pharmacodynamics and pharmacokinetics.  Individually tailored dosing 
which incorporates CYP3A5 genotype is an approach which is gaining 
interest within the transplant community however its impact on long term 
graft function is yet to be fully evaluated. While CYP3A5 genotype would be 
a powerful tool in predicting the dose requirements of tacrolimus in 
transplant patients, it does not seem to influence clinical outcome in a 
particularly meaningful way and it may be that other indicators such as IPV 
are more relevant. 
 
As the long term sequelae of immunosuppression begins to emerge, 
alongside the increasing evidence of the detrimental impact of high IPV, 
strategies to minimise CNI exposure and individually tailor 
immunosuppression to each patient are becoming desirable.  Genotyping of 
recipients and donors may well become part of this strategy to better tailor 
doses to individual patients.  Genotyping alone is unlikely to have a 
significant clinical impact however as part of a wider strategy, including 
measurement of IPV, it may provide a useful adjunct to delivering a 
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personalised immunosuppression regimen to each patient.  To date CYP3A5 
expression has been the most influential SNP discovered relative to 
tacrolimus pharmacodynamics and I think it is the only one that will have 
any significant clinical impact as part of a personalised dosing strategy.  
While CYP3A5 expression undoubtedly has an impact on the dose 
requirements of tacrolimus in transplant patients, the clinical impact is 
much weaker and it may be that the extra time and expense to genotype 
patients cannot be justified.  IPV appears to have a much greater clinical 
impact and would not require any additional testing, but it cannot be 
determined pre-transplant and it is not yet clear why some people have high 
IPV compared with others, which makes the development of a useful 
intervention difficult to implement. 
 
Further prospective studies in these areas are required to better inform 
clinicians of ways of improving tacrolimus dosing and monitoring in the 
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9.1 Data Tables for Chapter 3 
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GG (*3/*3) GA (*3/*1) AA (*1/*1) UNDETERMINED
Count 3726 495 14 82
Percentage 86.3% 11.5% .3% 1.9%
Count 392 61 1 9
Percentage 84.7% 13.2% .2% 1.9%
Count 40 4 1 2
Percentage 85.1% 8.5% 2.1% 4.3%
Count 31 4 0 2
Percentage 83.8% 10.8% 0.0% 5.4%
Count 12 3 0 0
Percentage 80.0% 20.0% 0.0% 0.0%
Count 2 1 0 0
Percentage 66.7% 33.3% 0.0% 0.0%
Count 2 1 0 0
Percentage 66.7% 33.3% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 3 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 9 1 0 0
Percentage 90.0% 10.0% 0.0% 0.0%
Count 4218 570 16 95
Percentage 86.1% 11.6% .3% 1.9%
Count 232 43 7 7
Percentage 80.3% 14.9% 2.4% 2.4%
Count 5 2 0 0
Percentage 71.4% 28.6% 0.0% 0.0%
Count 3 3 2 0
Percentage 37.5% 37.5% 25.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 241 48 9 7
Percentage 79.0% 15.7% 3.0% 2.3%
Count 36 8 1 2
Percentage 76.6% 17.0% 2.1% 4.3%
Count 0 1 0 0
Percentage 0.0% 100.0% 0.0% 0.0%
Count 36 9 1 2
Percentage 75.0% 18.8% 2.1% 4.2%
Count 214 26 0 5
Percentage 87.3% 10.6% 0.0% 2.0%
Count 4 1 1 0
Percentage 66.7% 16.7% 16.7% 0.0%
Count 0 0 1 0
Percentage 0.0% 0.0% 100.0% 0.0%
Count 218 27 2 5
Percentage 86.5% 10.7% .8% 2.0%
Count 98 10 0 2
Percentage 89.1% 9.1% 0.0% 1.8%
Count 108 13 0 6
Percentage 85.0% 10.2% 0.0% 4.7%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 117 23 0 5
Percentage 80.7% 15.9% 0.0% 3.4%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 0 1 0 0
Percentage 0.0% 100.0% 0.0% 0.0%
Count 325 47 0 13
Percentage 84.4% 12.2% 0.0% 3.4%
Count 4306 582 22 98
Percentage 86.0% 11.6% .4% 2.0%
Count 500 74 1 15
Percentage 84.7% 12.5% .2% 2.5%
Count 41 4 1 2
Percentage 85.4% 8.3% 2.1% 4.2%
Count 153 29 0 7
Percentage 81.0% 15.3% 0.0% 3.7%
Count 12 3 0 0
Percentage 80.0% 20.0% 0.0% 0.0%
Count 10 6 3 0
Percentage 52.6% 31.6% 15.8% 0.0%
Count 0 0 1 0
Percentage 0.0% 0.0% 100.0% 0.0%
Count 3 2 0 0
Percentage 60.0% 40.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 3 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 9 1 0 0
Percentage 90.0% 10.0% 0.0% 0.0%
Count 5038 701 28 122
Percentage 85.5% 11.9% .5% 2.1%
SUBJECT TYPE
CYP3A5
GENERATION SCOTLAND WHITE - SCOTTISH











SPK TRANSPLANT WHITE - SCOTTISH
ASIAN - INDIAN
TOTAL
KIDNEY TRANSPLANT WHITE - SCOTTISH
WHITE - OTHER
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ORGAN DONOR WHITE - SCOTTISH










OVERALL COHORT WHITE - SCOTTISH








Table 9.2 ABCB1 genotypes full cohort 
 
 
CC CT TT UNDETERMINED
Count 881 2044 1236 156
Percentage 20.4% 47.3% 28.6% 3.6%
Count 78 232 137 16
Percentage 16.8% 50.1% 29.6% 3.5%
Count 4 19 24 0
Percentage 8.5% 40.4% 51.1% 0.0%
Count 8 18 9 2
Percentage 21.6% 48.6% 24.3% 5.4%
Count 2 9 4 0
Percentage 13.3% 60.0% 26.7% 0.0%
Count 0 2 1 0
Percentage 0.0% 66.7% 33.3% 0.0%
Count 1 1 1 0
Percentage 33.3% 33.3% 33.3% 0.0%
Count 0 0 1 0
Percentage 0.0% 0.0% 100.0% 0.0%
Count 0 3 0 0
Percentage 0.0% 100.0% 0.0% 0.0%
Count 0 6 4 0
Percentage 0.0% 60.0% 40.0% 0.0%
Count 974 2334 1417 174
Percentage 19.9% 47.6% 28.9% 3.6%
Count 56 137 94 2
Percentage 19.4% 47.4% 32.5% .7%
Count 3 3 1 0
Percentage 42.9% 42.9% 14.3% 0.0%
Count 3 3 2 0
Percentage 37.5% 37.5% 25.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 63 143 97 2
Percentage 20.7% 46.9% 31.8% .7%
Count 9 24 14 0
Percentage 19.1% 51.1% 29.8% 0.0%
Count 0 0 1 0
Percentage 0.0% 0.0% 100.0% 0.0%
Count 9 24 15 0
Percentage 18.8% 50.0% 31.3% 0.0%
Count 57 105 74 9
Percentage 23.3% 42.9% 30.2% 3.7%
Count 1 3 2 0
Percentage 16.7% 50.0% 33.3% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 59 108 76 9
Percentage 23.4% 42.9% 30.2% 3.6%
Count 18 62 25 5
Percentage 16.4% 56.4% 22.7% 4.5%
Count 29 60 31 7
Percentage 22.8% 47.2% 24.4% 5.5%
Count 0 1 0 0
Percentage 0.0% 100.0% 0.0% 0.0%
Count 29 64 40 12
Percentage 20.0% 44.1% 27.6% 8.3%
Count 0 0 0 1
Percentage 0.0% 0.0% 0.0% 100.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 77 187 96 25
Percentage 20.0% 48.6% 24.9% 6.5%
Count 1021 2372 1443 172
Percentage 20.4% 47.4% 28.8% 3.4%
Count 107 292 168 23
Percentage 18.1% 49.5% 28.5% 3.9%
Count 4 20 24 0
Percentage 8.3% 41.7% 50.0% 0.0%
Count 40 85 50 14
Percentage 21.2% 45.0% 26.5% 7.4%
Count 2 9 4 0
Percentage 13.3% 60.0% 26.7% 0.0%
Count 4 8 6 1
Percentage 21.1% 42.1% 31.6% 5.3%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 3 1 1 0
Percentage 60.0% 20.0% 20.0% 0.0%
Count 0 0 1 0
Percentage 0.0% 0.0% 100.0% 0.0%
Count 0 3 0 0
Percentage 0.0% 100.0% 0.0% 0.0%
Count 0 6 4 0
Percentage 0.0% 60.0% 40.0% 0.0%
Count 1182 2796 1701 210
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Table 9.3 CYP3A4*22 genotype full cohort 
 
 
CC CT TT UNDETERMINED
Count 3801 414 7 95
Percentage 88.0% 9.6% .2% 2.2%
Count 404 48 4 7
Percentage 87.3% 10.4% .9% 1.5%
Count 44 3 0 0
Percentage 93.6% 6.4% 0.0% 0.0%
Count 32 4 0 1
Percentage 86.5% 10.8% 0.0% 2.7%
Count 15 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 3 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 3 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 2 1 0 0
Percentage 66.7% 33.3% 0.0% 0.0%
Count 8 2 0 0
Percentage 80.0% 20.0% 0.0% 0.0%
Count 4313 472 11 103
Percentage 88.0% 9.6% 0.2% 2.1%
Count 260 25 2 2
Percentage 90.0% 8.7% 0.7% 0.7%
Count 7 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 8 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 276 25 2 2
Percentage 90.5% 8.2% 0.7% 0.7%
Count 43 3 0 1
Percentage 91.5% 6.4% 0.0% 2.1%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 44 3 0 1
Percentage 91.7% 6.3% 0.0% 2.1%
Count 218 16 0 11
Percentage 89.0% 6.5% 0.0% 4.5%
Count 6 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 225 16 0 11
Percentage 89.3% 6.3% 0.0% 4.4%
Count 88 14 0 8
Percentage 80.0% 12.7% 0.0% 7.3%
Count 110 9 1 7
Percentage 86.6% 7.1% 0.8% 5.5%
Count 0 1 0 0
Percentage 0.0% 100.0% 0.0% 0.0%
Count 127 14 0 4
Percentage 87.6% 9.7% 0.0% 2.8%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 327 38 1 19
Percentage 84.9% 9.9% 0.3% 4.9%
Count 4410 472 9 117
Percentage 88.1% 9.4% 0.2% 2.3%
Count 514 57 5 14
Percentage 87.1% 9.7% 0.8% 2.4%
Count 44 4 0 0
Percentage 91.7% 8.3% 0.0% 0.0%
Count 166 18 0 5
Percentage 87.8% 9.5% 0.0% 2.6%
Count 15 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 19 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 5 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 1 0 0 0
Percentage 100.0% 0.0% 0.0% 0.0%
Count 2 1 0 0
Percentage 66.7% 33.3% 0.0% 0.0%
Count 8 2 0 0
Percentage 80.0% 20.0% 0.0% 0.0%
Count 5185 554 14 136
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9.2 Data tables for Chapter 4 
 
Table 9.4 CYP3A5 recipient dose requirement 
 CYP3A5 GG (*3/*3) 
– non expresser (R) 




 Mean Dose (mg) n Mean Dose (mg) n p 
WK1-1 3.4714 105 3.8235 17 0.363 
WK1-2 4.0194 103 4.7647 15 0.086 
WK1-3 4.5000 93 5.8235 17 0.015 
WK2-1 4.7794 102 6.5588 17 0.003 
WK2-2 4.9813 80 6.8929 14 0.009 
WK2-3 4.9375 64 6.4500 10 0.113 
WK3-1 5.2525 101 7.2500 14 0.002 
WK3-2 5.2823 62 7.0000 10 0.043 
WK3-3 5.7436 37 7.0000 7 0.342 
WK4-1 5.3564 101 7.7813 16 0.001 
WK4-2 5.2174 69 7.4500 10  0.020 
3 M 4.3535 99 6.0667 15 0.010 
6 M 4.2684 95 5.2667 15 0.135 
12 M 4.2391 92 4.1333 15 0.868 
 
Table 9.5 CYP3A5 donor dose requirement 
 Donor CYP3A5 GG 
(*3/*3) 
 Donor CYP3A5 GA/AA 
(*3/*1 - *1/*1) 
  
 Mean Dose (mg) n Mean Dose (mg) n p value 
WK1-1 3.3938 160 3.9688 16 0.106 
WK1-2 3.9399 157 4.7667 16 0.045 
WK1-3 4.3542 144 6.1667 16 <0.0001 
WK2-1 4.6818 154 7.0625 16 <0.0001 
WK2-2 4.9837 123 7.6786 14 <0.0001 
WK2-3 4.7526 97 8.3571 14 <0.0001 
WK3-1 5.1074 149 9.0000 16 <0.0001 
WK3-2 5.2000 100 7.6111 9 0.003 
WK3-3 5.1491 57 9.1818 11 <0.0001 
WK4-1 5.0900 150 9.5833 18 <0.0001 
WK4-2 4.8960 101 9.9167 12 <0.0001 
3 M 4.1301 146 7.8438 16 <0.0001 
6 M 4.0324 142 7.0313 16 <0.0001 
12 M 3.9961 128 6.2857 14 <0.0001 
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Table 9.6 CYP3A5 recipient trough levels 
 Recipient CYP3A5 
GG (*3/*3) 
 Recipient CYP3A5 
GA/AA (*3/*1 - *1/*1) 
  
 Mean C0 (µg/L) n Mean C0 (µg/L) n p value 
WK1-1 4.86440 118 3.3600 15 0.116 
WK1-2 6.55000 116 5.0562 16 0.125 
WK1-3 7.25470 106 5.7000 17 0.149 
WK2-1 7.27810 114 6.4412 17 0.409 
WK2-2 6.76410 92 6.8643 14 0.901 
WK2-3 6.51970 76 6.0600 10 0.700 
WK3-1 7.39910 108 7.2500 14 0.898 
WK3-2 7.29710 69 6.7545 11 0.556 
WK3-3 7.22227 44 7.1857 7 0.976 
WK4-1 7.80100 105 8.2500 16 0.617 
WK4-2 8.40820 73 6.5200 10 0.140 
3 M 7.74810 104 8.7438 16 0.228 
6 M 5.86430 98 6.2250 16 0.581 
12 M 6.69460 92 6.8250 16 0.896 
 
 
Table 9.7 CYP3A5 donor trough levels 
 Donor CYP3A5 GG 
(*3/*3) 
 Donor CYP3A5 GA/AA 
(*3/*1 - *1/*1) 
  
 Mean C0 (µg/L) n Mean C0 (µg/L) n p value 
WK1-1 4.9565 168 3.1526 19 0.036 
WK1-2 6.5655 158 3.6889 18 0.003 
WK1-3 7.1293 157 4.3000 18 0.003 
WK2-1 7.2596 166 5.4444 18 0.047 
WK2-2 6.9692 133 5.6625 14 0.084 
WK2-3 6.6899 109 4.4750 16 0.007 
WK3-1 7.3186 156 5.4353 17 0.053 
WK3-2 7.4283 106 5.1769 13 0.003 
WK3-3 7.8115 61 6.9727 11 0.419 
WK4-1 7.8902 153 7.1167 18 0.333 
WK4-2 8.3952 105 7.8167 12 0.652 
3 M 7.6960 151 8.5056 18 0.287 
6 M 6.0232 142 6.1056 18 0.896 




Table 9.8 CYP3A5 recipient dose corrected levels 
 Recipient CYP3A5 
GG (*3/*3) 
 Recipient CYP3A5 
GA/AA (*3/*1 - *1/*1) 
  
 Mean C0/D (µg/L 
per mg) 
n Mean C0/D (µg/L per 
mg) 
n p value 
WK1-1 1.55300 105 1.0033 15 0.097 
WK1-2 1.94920 103 1.3785 16 0.191 
WK1-3 2.11010 93 1.6398 17 0.492 
WK2-1 2.01740 102 1.0736 17 0.086 
WK2-2 1.80340 79 1.0942 14 0.081 
WK2-3 1.87560 63 1.0746 10 0.194 
WK3-1 1.73760 100 0.9834 14 0.027 
WK3-2 1.73730 62 0.9823 14 0.065 
WK3-3 1.80580 37 1.0664 7 0.276 
WK4-1 1.95340 100 1.0833 16 0.158 
WK4-2 2.10140 69 0.9179 10 0.036 
3 M 2.50190 104 1.4695 16 0.102 
6 M 1.90200 98 1.3165 16 0.168 
12 M 2.07300 92 1.6078 16 0.214 
 
 
Table 9.9 CYP3A5 donor dose corrected levels 
 Donor CYP3A5 GG 
(*3/*3) 
 Donor CYP3A5 GA/AA 
(*3/*1 - *1/*1) 
  
 Mean C0/D (µg/L 
per mg) 
n Mean C0/D (µg/L per 
mg) 
n p value 
WK1-1 1.5480 157 0.9047 16 0.031 
WK1-2 1.9035 157 0.8127 15 0.006 
WK1-3 2.1717 144 0.7639 15 0.036 
WK2-1 2.0300 154 0.8579 16 0.035 
WK2-2 1.7794 120 0.8776 14 0.016 
WK2-3 1.9463 97 0.6512 14 0.011 
WK3-1 1.7781 148 0.6645 16 0.002 
WK3-2 1.7889 99 0.6264 12 0.003 
WK3-3 1.9879 55 0.8155 11 0.028 
WK4-1 1.9883 148 0.8121 18 0.022 
WK4-2 2.1026 101 0.8341 12 0.009 
3 M 2.5260 151 1.0853 18 0.009 
6 M 1.9834 142 0.9361 18 0.011 
12 M 2.0843 128 1.1950 16 0.009 
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n P value 
WK1-
1 
3.3647 85 3.8462 13 4.0909 11 3.500 2 0.389 
WK1-
2 
3.8869 84 4.9231 13 4.9000 10 4.500 2 0.074 
WK1-
3 
4.3108 74 5.8846 13 6.3000 10 5.750 2 0.004 
WK2-
1 
4.5854 82 6.3077 13 6.9545 11 7.750 2 <0.0001 
WK2-
2 
4.6825 63 6.5909 11 7.5500 10 8.000 2 0.001 
WK2-
3 
4.2917 48 5.9375 8 8.3000 10 8.500 2 <0.0001 
WK3-
1 
4.8110 82 7.3182 11 8.7273 11 10.000 2 <0.0001 
WK3-
2 
4.8125 48 6.8750 8 8.0625 8 8.000 1 0.001 
WK3-
3 
4.4259 27 6.5000 6 9.5625 8 10.000 1 <0.0001 
WK4-
1 
4.6750 80 7.6538 13 9.6667 12 9.000 2 <0.0001 
WK4-
2 
4.3113 53 7.0625 8 10.000 9 9.000 2 <0.0001 
3 
MTHS 
3.8846 78 6.0000 13 7.2917 12 6.000 1 <0.0001 
6 
MTHS 
3.8243 74 4.8462 13 6.5000 12 8.000 1 0.001 
12  
MTHS 
3.7254 71 4.0000 13 6.2083 12 2.000 1 0.003 
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 RnE / 
DnE 
 RE / 
DnE 
 RnE / 
DE 













n p value 
WK1-
1 5.0695 95 3.7909 11 3.0923 13 2.0500 2 0.121 
WK1-
2 6.7298 94 5.6833 12 3.5250 12 3.3500 2 0.017 
WK1-
3 7.5440 84 6.1462 13 4.7333 12 4.4500 2 0.101 
WK2-
1 7.6261 92 6.4769 13 5.5583 12 6.2500 2 0.297 
WK2-
2 6.8903 72 7.3273 11 6.0909 11 5.0500 2 0.602 
WK2-
3 6.6103 58 6.8500 8 5.3000 11 2.9000 2 0.252 
WK3-
1 7.7000 87 7.1000 11 5.5273 11 8.4500 2 0.404 
WK3-
2 7.6365 52 6.9250 8 6.2889 9 5.5500 2 0.396 
WK3-
3 7.4833 30 7.1667 6 6.5875 8 7.3000 1 0.910 
WK4-
1 7.7393 84 8.6308 13 7.6250 12 6.5000 2 0.748 
WK4-
2 8.5018 57 6.8125 8 7.5333 9 5.3500 2 0.428 
3 
MTHS 7.7349 83 8.6538 13 8.1250 12 9.5500 2 0.650 
6 
MTHS 6.0104 77 6.1462 13 5.0750 12 6.7000 2 0.599 
12 
MTHS 7.0000 71 6.1538 13 4.9917 12 10.150 2 0.167 
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 RnE / 
DnE 
 RE / 
DnE 
 RnE / 
DE 

















n p value 
WK1-
1 1.6428 85 1.1545 11 0.8629 11 0.6000 2 0.100 
WK1-
2 2.0510 84 1.5810 12 0.7200 10 0.7917 2 0.071 
WK1-
3 2.2713 74 1.8997 13 0.8003 10 0.8558 2 0.385 
WK2-
1 2.1353 82 1.1460 13 0.8911 11 0.7845 2 0.114 
WK2-
2 1.9194 62 1.2225 11 0.9607 10 0.5983 2 0.079 
WK2-
3 2.1174 48 1.2531 8 0.7716 10 0.3607 2 0.084 
WK3-
1 1.9266 81 1.0221 11 0.6934 11 0.7979 2 0.002 
WK3-
2 2.0406 47 1.0585 8 0.7291 9 0.6113 2 0.006 
WK3-
3 2.2980 25 1.1224 6 0.7299 8 0.7300 1 0.074 
WK4-
1 2.1575 79 1.1441 13 0.8574 12 0.7438 2 0.173 
WK4-
2 2.3876 53 0.9949 8 0.8041 9 0.6100 2 0.010 
3 
MTHS 2.7512 83 1.5479 13 1.1968 12 1.6167 1 0.096 
6 
MTHS 2.1077 77 1.4641 13 0.9689 12 0.5500 1 0.076 
12 
MTHS 2.3560 71 1.5955 13 1.0437 12 2.3000 1 0.012 
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Table 9.13 ABCB1 recipient dose requirements 
 CC  CT  TT   
 Mean 
Dose (mg) 




n p value 
WK1-1 3.6406 32 3.7455 55 3.1286 35 0.144 
WK1-2 4.2500 32 4.2909 55 3.8485 33 0.449 
WK1-3 5.0862 29 4.8137 51 4.3500 30 0.388 
WK2-1 5.3485 33 5.1887 51 4.7424 33 0.539 
WK2-2 5.8478 23 5.3488 43 5.0517 29 0.535 
WK2-3 6.2222 18 5.3919 37 4.4000 20 0.145 
WK3-1 6.1406 32 5.8000 50 5.1212 33 0.335 
WK3-2 6.2188 16 5.9333 30 5.0200 25 0.246 
WK3-3 7.6538 13 5.7368 19 4.9286 14 0.439 
WK4-1 6.0313 32 6.0700 50 5.2714 35 0.390 
WK4-2 6.1364 22 5.9028 36 4.5000 20 0.133 
3 M 4.8548 31 4.6304 46 4.6528 36 0.919 
6 M 4.8000 30 4.0814 43 4.9644 36 0.370 
12 M 4.7833 30 3.7381 42 4.4853 34 0.127 
 
 
Table 9.14 ABCB1 donor dose requirements 
 CC  CT  TT   
 Mean 
Dose (mg) 




n p value 
WK1-1 3.5441 34 3.41670 90 3.4079 38 0.883 
WK1-2 4.2188 32 4.01120 89 3.9079 38 0.703 
WK1-3 4.7931 29 4.64460 83 4.2361 36 0.474 
WK2-1 4.9355 31 5.03890 90 4.7568 37 0.811 
WK2-2 5.5536 28 5.17610 71 5.2586 29 0.790 
WK2-3 5.3696 26 6.99000 60 6.8241 29 0.916 
WK3-1 6.0833 30 5.33150 89 5.3824 34 0.422 
WK3-2 6.2174 23 5.24550 55 5.2800 25 0.228 
WK3-3 7.0000 17 5.71430 28 5.2222 18 0.183 
WK4-1 6.6613 31 5.16480 88 5.8971 34 0.028 
WK4-2 6.7500 24 4.90520 58 5.5217 23 0.023 
3 M 4.5333 30 4.38510 87 4.9063 32 0.605 
6 M 4.2679 28 4.12050 83 4.3357 32 0.219 




Table 9.15 ABCB1 recipient trough levels 
 CC  CT  TT   
 Mean C0 
Level (µg/L) 
n Mean C0 
Level (µg/L) 
n Mean C0 
Level 
(µg/L) 
n p value 
WK1-1 4.5229 35 4.7368 57 4.5927 41 0.957 
WK1-2 6.6229 35 6.4737 57 6.2625 40 0.916 
WK1-3 6.2719 32 7.2574 54 7.4784 37 0.436 
WK2-1 7.0857 35 7.0732 56 7.5875 40 0.803 
WK2-2 6.7731 26 6.7646 48 6.6152 33 0.968 
WK2-3 8.1316 19 5.7512 41 6.5269 26 0.051 
WK3-1 8.3500 32 6.9755 53 7.1189 37 0.284 
WK3-2 6.7778 18 7.2629 35 7.3963 27 0.742 
WK3-3 7.8769 13 6.5850 20 7.4167 18 0.439 
WK4-1 8.3152 33 7.4863 51 7.7757 37 0.532 
WK4-2 9.0682 22 7.5892 37 7.8696 23 0.316 
3 M 8.4576 33 8.0940 50 7.2811 37 0.246 
6 M 5.6613 31 6.4457 46 5.6162 37 0.206 
12 M 
6.2207 29 6.8841 44 6.8857 35 0.705 
 
 
Table 9.16 ABCB1 donor trough levels 
 CC  CT  TT   
 Mean C0 
Level (µg/L) 
n Mean C0 
Level (µg/L) 
n Mean C0 
Level 
(µg/L) 
n p value 
WK1-1 5.0432 37 4.79370 95 4.5341 41 0.823 
WK1-2 5.6229 35 6.05370 95 7.2244 41 0.164 
WK1-3 8.1438 32 6.34040 89 6.9650 40 0.083 
WK2-1 7.3412 34 7.51170 94 6.5390 41 0.375 
WK2-2 6.4290 31 7.50270 74 6.3344 32 0.068 
WK2-3 5.3077 26 6.99000 60 6.8241 29 0.060 
WK3-1 6.2875 32 7.91220 90 6.6222 36 0.064 
WK3-2 6.8231 26 7.61720 58 6.9370 27 0.348 
WK3-3 7.0900 20 8.13930 28 8.3778 18 0.386 
WK4-1 8.4303 33 7.78220 90 7.8758 33 0.618 
WK4-2 7.5654 26 8.49670 60 8.8522 23 0.529 
3 M 7.4806 31 7.91210 91 8.4294 34 0.455 
6 M 5.8966 29 6.10580 86 6.2152 33 0.883 




Table 9.17 ABCB1 recipient dose corrected levels 
 CC  CT  TT   
 Mean C0/D  
(µg/L/mg) 
n Mean C0/D 
(µg/L/mg) 
n Mean C0/D 
(µg/L/mg) 
n p value 
WK1-1 1.3305 32 1.3079 54 1.7759 34 0.155 
WK1-2 1.9467 32 1.7863 54 1.9487 33 0.866 
WK1-3 1.3952 29 2.3802 51 2.0452 30 0.262 
WK2-1 1.7396 33 1.5407 52 2.3280 34 0.195 
WK2-2 1.6887 23 1.4321 43 1.9063 28 0.359 
WK2-3 2.0606 16 1.2379 37 2.2807 20 0.069 
WK3-1 1.6658 31 1.3740 50 1.9070 33 0.131 
WK3-2 1.3372 17 1.3714 32 1.9679 24 0.143 
WK3-3 1.3452 12 1.3692 18 2.3289 14 0.189 
WK4-1 1.6392 32 1.4658 50 2.4139 34 0.157 
WK4-2 1.8739 22 1.5805 36 2.4201 20 0.182 
3 M 2.8313 33 2.0167 49 2.3073 37 0.311 
6 M 1.6771 31 1.9610 45 1.7235 37 0.694 
12 M 1.7228 29 2.1704 43 1.9373 35 0.405 
 
 
Table 9.18 ABCB1 donor dose corrected levels 
 CC  CT  TT   
 Mean C0/D  
(µg/L/mg) 
n Mean C0/D 
(µg/L/mg) 
n Mean C0/D 
(µg/L/mg) 
n p value 
WK1-1 1.5406 34 1.5243 89 1.4041 37 0.848 
WK1-2 1.4868 32 1.7419 89 2.2314 37 0.107 
WK1-3 1.8164 29 1.6566 83 3.0905 36 0.016 
WK2-1 2.2564 31 1.7931 90 2.0936 37 0.542 
WK2-2 1.5266 27 1.7992 70 1.6829 28 0.672 
WK2-3 1.3916 23 1.8084 55 2.2979 28 0.226 
WK3-1 1.2248 30 1.8251 88 1.8583 34 0.107 
WK3-2 1.1132 24 1.8641 56 1.8158 26 0.057 
WK3-3 1.1016 17 2.0860 26 2.1292 18 0.111 
WK4-1 1.3636 31 2.1898 87 1.6624 33 0.143 
WK4-2 1.2928 24 2.2704 58 2.0259 23 0.048 
3 M 2.4904 30 2.4548 91 2.3498 34 0.966 
6 M 1.9114 28 2.0090 86 1.6702 33 0.627 
12 M 1.6969 27 2.2475 74 1.6572 31 0.047 
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Table 9.19 CYP3A4*22 recipient dose requirements 
 Recipient 
CYP3A4*22 CC 
 Recipient CYP3A4*22 
CT/TT 
  
 Mean Dose (mg) n Mean Dose (mg) n p value 
WK1-1 3.5219 114 3.6500 10 0.794 
WK1-2 4.1563 112 3.9000 10 0.640 
WK1-3 4.7379 103 4.6111 9 0.861 
WK2-1 5.0586 111 5.2500 10 0.804 
WK2-2 5.3667 90 5.0000 7 0.715 
WK2-3 5.3239 71 4.5000 5 0.541 
WK3-1 5.6402 107 5.7500 10 0.908 
WK3-2 5.5435 69 6.8750 4 0.302 
WK3-3 6.0114 44 5.8333 3 0.926 
WK4-1 5.7982 109 5.7500 10 0.959 
WK4-2 5.6081 74 5.0833 6 0.670 
3 M 4.7429 105 3.8000 10 0.248 
6 M 4.5396 101 3.5000 10 0.192 
12 M 4.2959 98 3.7000 10 0.431 
 
 
Table 9.20 CYP3A4*22 donor dose requirements 
 Donor CYP3A4*22 
CC 
 Donor CYP3A4*22 
CT/TT 
  
 Mean Dose (mg) n Mean Dose (mg) n p value 
WK1-1 3.4830 147 3.3750 16 0.768 
WK1-2 4.0868 144 3.6250 16 0.258 
WK1-3 4.6617 133 3.7857 14 0.112 
WK2-1 5.0769 143 3.9667 15 0.064 
WK2-2 5.4435 115 4.2727 11 0.136 
WK2-3 5.4728 92 3.4444 9 0.042 
WK3-1 5.7794 136 4.0588 17 0.015 
WK3-2 5.5263 95 4.3571 7 0.220 
WK3-3 6.0339 59 3.8750 4 0.160 
WK4-1 5.8705 139 4.0000 17 0.008 
WK4-2 5.7500 92 3.6538 13 0.010 
3 M 4.7293 133 2.8529 17 0.003 
6 M 4.5155 129 2.9000 15 0.008 




Table 9.21 CYP3A4*22 recipient trough levels 
 Recipient 
CYP3A4*22 CC 
 Recipient CYP3A4*22 
CT/TT 
  
 Mean C0 Level 
(µg/L) 
n Mean C0 Level  (µg/L) n p value 
WK1-1 4.5774 124 6.1273 11 0.165 
WK1-2 6.3862 123 7.2455 11 0.467 
WK1-3 6.7339 115 10.7700 10 0.003 
WK2-1 7.0566 122 9.4909 11 0.053 
WK2-2 6.5560 100 9.3222 9 0.005 
WK2-3 6.1938 81 10.0429 7 0.005 
WK3-1 7.2027 113 8.8636 11 0.194 
WK3-2 7.1325 77 8.7400 5 0.215 
WK3-3 7.0688 48 8.9500 4 0.214 
WK4-1 7.6402 112 9.6455 11 0.053 
WK4-2 7.7104 77 12.5000 7 0.001 
3 M 7.9144 111 7.7636 11 0.876 
6 M 5.9981 106 5.5200 10 0.544 
12 M 6.6596 99 6.8636 11 0.859 
 
 
Table 9.22 CYP3A4*22 donor trough levels 
 Donor CYP3A4*22 
CC 
 Donor      CYP3A4*22 
CT/TT 
  
 Mean C0 Level 
(µg/L) 
n Mean C0 Level  (µg/L) n p value 
WK1-1 4.7667 156 5.62780 18 0.341 
WK1-2 6.2344 154 7.04210 19 0.405 
WK1-3 6.8103 145 6.84120 17 0.976 
WK2-1 6.9941 153 8.33890 18 0.154 
WK2-2 6.5839 124 8.19230 13 0.051 
WK2-3 6.3167 102 7.50910 11 0.226 
WK3-1 7.0482 141 9.00530 19 0.038 
WK3-2 7.0786 103 9.00000 8 0.047 
WK3-3 7.9129 62 8.10000 5 0.899 
WK4-1 7.8411 141 7.82780 18 0.968 
WK4-2 8.0926 95 7.86430 14 0.826 
3 M 7.9633 139 7.81110 18 0.843 
6 M 6.0917 133 6.01880 16 0.914 
12 M 6.8864 118 6.18670 15 0.448 
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Table 9.23 CYP3A4*22 recipient dose corrected level 
 Recipient 
CYP3A4*22 CC 
 Recipient     
CYP3A4*22 CT/TT 
  
 Mean C0/D Level 
(µg/L/mg) 
n Mean C0/D Level  
(µg/L/mg) 
n p value 
WK1-1 1.4339 112 1.9408 10 0.198 
WK1-2 1.8481 111 2.2690 10 0.431 
WK1-3 2.0105 103 2.2656 9 0.776 
WK2-1 1.8869 111 1.7969 10 0.896 
WK2-2 1.6239 89 2.2931 7 0.222 
WK2-3 1.7060 70 2.2578 5 0.509 
WK3-1 1.5805 106 1.9762 10 0.315 
WK3-2 1.5597 71 1.8515 4 0.648 
WK3-3 1.6511 42 1.9038 3 0.797 
WK4-1 1.7734 108 2.0422 10 0.721 
WK4-2 1.7631 74 3.5054 6 0.010 
3 M 2.1815 105 2.6903 10 0.248 
6 M 1.7896 105 2.0563 10 0.609 
12 M 1.9335 98 2.3482 11 0.346 
 
 
Table 9.24 CYP3A4*22 donor dose corrected levels 
 Donor CYP3A4*22 
CC 
 Donor      CYP3A4*22 
CT/TT 
  
 Mean C0/D Level 
(µg/L/mg) 
n Mean C0/D Level  
(µg/L/mg) 
n p value 
WK1-1 1.4954 145 1.6472 15 0.631 
WK1-2 1.7670 143 2.2337 16 0.243 
WK1-3 2.0206 133 2.2052 14 0.799 
WK2-1 1.8644 143 2.6448 15 0.190 
WK2-2 1.5967 112 2.3444 11 0.084 
WK2-3 1.7530 91 2.4211 9 0.311 
WK3-1 1.5896 135 2.4916 17 0.013 
WK3-2 1.6128 97 2.5393 7 0.078 
WK3-3 1.8116 57 2.4454 4 0.469 
WK4-1 1.8101 137 2.3035 17 0.368 
WK4-2 1.8065 92 2.4469 13 0.136 
3 M 2.2086 138 4.0506 18 0.039 
6 M 1.7667 132 2.8488 16 0.015 
12 M 1.8848 117 2.7263 15 0.014 
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9.3 Data tables Chapter 5 
9.3.1 Renal transplant patients 
Table 9.25 CYP3A5 dose requirement 
 
CYP3A5 GG (*3/*3)  
 





Mean Dose (mg) n Mean Dose (mg) n p 
WK1-1 6.5900 121 6.23000 31 0.436 
WK1-2 7.0840 125 8.03230 31 0.034 
WK1-3 7.4360 125 9.79030 31 <0.0001 
WK2-1 7.9152 112 11.8793 29 <0.0001 
WK2-2 8.3619 105 13.2581 31 <0.0001 
WK2-3 8.3606 104 13.0400 25 <0.0001 
WK3-1 8.4592 98 13.7308 26 <0.0001 
WK3-2 8.3138 94 14.0417 24 <0.0001 
WK3-3 8.3011 88 14.1875 24 <0.0001 
1M 8.1105 86 14.2826 23 <0.0001 
2M 7.1944 90 13.3250 20 <0.0001 
3 M 6.4607 89 12.0250 20 <0.0001 
6 M 5.4659 88 10.7647 20 <0.0001 
12 M 4.6131 84 9.52940 17 <0.0001 
 
Table 9.26 CYP3A5 trough levels 
 
CYP3A5 GG (*3/*3)  
 





Mean Tac Level 
(µg/L) 
n Mean Tac Level 
(µg/L) 
n p 
WK1-1 8.6000 149 4.1833 36 <0.0001 
WK1-2 8.3743 148 5.1028 36 <0.0001 
WK1-3 8.1930 143 5.3250 36 <0.0001 
WK2-1 7.8814 129 5.8576 33 0.001 
WK2-2 8.5797 118 6.3750 32 0.002 
WK2-3 9.3973 111 6.8600 25 0.007 
WK3-1 9.2825 103 7.7808 26 0.061 
WK3-2 9.4879 99 7.3333 24 0.005 
WK3-3 10.6110 91 8.9875 24 0.152 
1M 10.1500 90 8.4000 23 0.035 
2M 9.9750 92 8.4200 20 0.082 
3 M 9.3099 91 8.3800 20 0.187 
6 M 8.5798 89 8.4471 17 0.872 
12 M 7.6081 86 6.9235 17 0.556 
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Table 9.27 CYP3A5 dose corrected levels 
 
CYP3A5 GG (*3/*3)  
 





Dose Corrected Tac 
Level  
(µg/L per mg) 
n Dose Corrected Tac 
Level  
(µg/L per mg) 
n p 
WK1-1 1.3876 121 0.6784 31 <0.0001 
WK1-2 1.3311 125 0.6898 31 0.001 
WK1-3 1.2935 122 0.6004 31 <0.0001 
WK2-1 1.1854 112 0.5681 29 <0.0001 
WK2-2 1.1958 105 0.5329 31 <0.0001 
WK2-3 1.3531 103 0.5708 25 <0.0001 
WK3-1 1.3491 98 0.6025 26 <0.0001 
WK3-2 1.4262 94 0.5723 24 <0.0001 
WK3-3 1.6576 88 0.6504 24 <0.0001 
1M 1.5632 86 0.6571 23 <0.0001 
2M 1.8237 90 0.7156 20 <0.0001 
3 M 2.3480 89 0.8023 20 0.124 
6 M 2.0449 87 0.8820 17 0.001 
























Dose (mg) n  Dose (mg) n Dose (mg) n p value 
WK1-1 6.5400 27 6.5600 72 6.4500 52 0.990 
WK1-2 7.3148 27 7.1600 75 7.4340 53 0.852 
WK1-3 8.0385 26 7.8581 74 7.9455 55 0.840 
WK2-1 9.4130 23 8.1591 66 9.2353 51 0.230 
WK2-2 10.6458 24 8.5231 65 10.2717 46 0.068 
WK2-3 10.2800 25 8.5492 61 9.6905 42 0.236 
WK3-1 10.2955 22 9.0259 58 9.7674 43 0.244 
WK3-2 10.2500 22 9.2130 58 9.1585 41 0.072 
WK3-3 10.3056 18 9.4151 53 9.1625 40 0.117 
1 M 10.2500 18 9.2500 52 9.0132 38 0.206 
2 M 8.1667 18 8.0755 53 8.4474 38 0.238 
3 M 7.8889 18 7.3774 53 7.4342 38 0.902 
6 M 5.8750 16 6.0096 52 6.9595 37 0.461 
12 M 5.2333 15 5.4804 51 5.4714 35 0.966 
 











n Tac Level 
(µg/L) 
n Tac Level 
(µg/L) 
n p value 
WK1-1 7.7000 34 7.5729 85 7.9954 65 0.958 
WK1-2 7.9788 33 7.6706 85 7.5923 65 0.423 
WK1-3 7.5781 32 7.6691 81 7.5662 65 0.998 
WK2-1 7.9345 29 7.3918 73 7.3898 59 0.650 
WK2-2 8.3857 28 7.9478 69 8.2596 52 0.596 
WK2-3 10.1000 26 8.1569 65 9.5091 44 0.084 
WK3-1 9.0174 23 8.9250 60 9.1600 45 0.473 
WK3-2 10.1087 23 8.7304 56 8.9116 43 0.383 
WK3-3 12.2474 19 9.6407 54 10.0073 41 0.095 
1 M 10.9474 19 9.8491 53 9.1875 40 0.366 
2 M 9.8389 18 9.2833 54 10.2000 39 0.691 
3 M 9.4211 19 8.6352 54 9.7237 39 0.176 
6 M 9.6294 17 8.1283 53 8.6861 36 0.211 


























n p value 
WK1-1 1.23500 27 1.1979 72 1.3117 52 0.892 
WK1-2 1.18690 27 1.2329 75 1.1486 53 0.616 
WK1-3 1.02450 26 1.1020 72 1.2780 54 0.673 
WK2-1 0.99070 23 1.1216 66 1.0112 51 0.861 
WK2-2 0.91910 24 1.1371 65 0.9909 46 0.514 
WK2-3 1.17260 25 1.1452 61 1.3201 41 0.637 
WK3-1 1.06280 22 1.2499 58 1.2044 43 0.662 
WK3-2 1.17010 22 1.2382 54 1.3332 41 0.821 
WK3-3 1.35020 18 1.3565 53 1.6099 40 0.730 
1 M 1.34230 18 1.3452 52 1.4453 38 0.789 
2 M 1.63760 18 1.4836 53 1.8366 38 0.501 
3 M 1.69990 18 1.6444 53 2.8227 38 0.363 
6 M 2.20520 16 1.8600 52 1.6915 36 0.423 


























Mean Dose (mg) n Mean Dose (mg) n p 
WK1-1 6.4600 141 7.3500 10 0.403 
WK1-2 7.2639 144 7.5909 11 0.536 
WK1-3 7.9757 144 7.0455 12 0.534 
WK2-1 8.7500 130 8.3500 10 0.894 
WK2-2 9.5000 124 8.8182 11 0.498 
WK2-3 9.2949 117 8.5455 11 0.401 
WK3-1 9.6404 114 8.2222 9 0.437 
WK3-2 9.5509 108 8.2222 9 0.494 
WK3-3 9.6716 102 7.8333 9 0.333 
1M 9.5850 100 7.5000 9 0.187 
2M 8.5650 100 5.7500 10 0.077 
3 M 7.7374 99 4.9500 10 0.044 
6 M 6.5105 95 4.5500 10 0.127 
12 M 5.5824 91 4.1500 10 0.190 
 
 










Tac Level (µg/L) n Tac Level (µg/L) n p 
WK1-1 7.5023 171 10.8462 13 0.058 
WK1-2 7.6418 170 9.18460 13 0.314 
WK1-3 7.6248 165 7.69230 13 0.798 
WK2-1 7.3329 149 9.31670 12 0.101 
WK2-2 8.0255 137 9.08330 12 0.621 
WK2-3 8.8423 123 9.5250 12 0.589 
WK3-1 8.8542 118 10.4100 10 0.433 
WK3-2 8.9375 112 10.8100 10 0.169 
WK3-3 10.188 104 11.3600 10 0.711 
1M 9.8456 103 9.2600 10 0.621 
2M 9.6725 102 9.9500 10 0.818 
3 M 9.1168 101 9.4000 10 0.765 
6 M 8.6844 96 7.3500 10 0.195 














Dose Corrected Tac 
Level (µg/L/mg) 




WK1-1 1.2207 141 1.5191 10 0.471 
WK1-2 1.1985 144 1.2962 11 0.906 
WK1-3 1.1430 141 1.3183 11 0.785 
WK2-1 1.0449 130 1.2846 10 0.568 
WK2-2 1.0258 124 1.3015 11 0.423 
WK2-3 1.1709 116 1.5369 11 0.451 
WK3-1 1.1566 114 1.6989 9 0.249 
WK3-2 1.2137 108 1.8046 9 0.176 
WK3-3 1.4063 102 1.9386 9 0.361 
1M 1.3439 100 1.6836 9 0.315 
2M 1.5674 100 2.1705 10 0.157 
3 M 1.9767 99 2.9320 10 0.480 
6 M 1.8133 94 2.2444 10 0.320 

















9.3.2 Simultaneous kidney/pancreas patients 










Mean Dose (mg) n Mean Dose (mg) n p 
WK1-1 6.1600 16 5.0000 1 0.573 
WK1-2 6.4375 16 5.0000 1 0.487 
WK1-3 5.9688 16 3.2500 2 0.801 
WK2-1 6.3389 18 7.0000 2 0.760 
WK2-2 6.1605 19 9.0000 2 0.369 
WK2-3 7.3000 17 10.3000 2 0.318 
WK3-1 8.4211 19 13.3333 3 0.055 
WK3-2 9.7500 16 15.0000 3 0.074 
WK3-3 9.0941 17 18.1667 6 <0.0001 
1M 10.2222 18 18.6667 6 <0.0001 
2M 9.8750 20 15.6000 5 0.013 
3 M 10.1389 18 13.6000 5 0.161 
6 M 7.7381 21 11.5000 4 0.080 
12 M 5.7778 18 10.2500 4 0.025 
 
 
Table 9.35 SPK CYP3A5 trough levels 
 
CYP3A5 GG 
(*3/*3) –  
 





Tac Level (µg/L) n Tac Level (µg/L) n p 
WK1-1 11.0808 26 6.4000 6 0.033 
WK1-2 14.2615 26 12.5333 6 0.594 
WK1-3 13.3692 26 9.8000 6 0.135 
WK2-1 10.4269 26 6.4167 6 0.064 
WK2-2 9.4500 26 5.6333 6 0.009 
WK2-3 8.2417 24 6.2833 6 0.192 
WK3-1 8.5652 23 7.0500 6 0.348 
WK3-2 8.0667 21 7.5000 6 0.666 
WK3-3 8.4400 20 6.6833 6 0.119 
1M 9.6750 20 13.7167 6 0.072 
2M 10.2048 21 8.8000 5 0.433 
3 M 10.4833 18 9.7600 5 0.743 
6 M 9.0864 22 4.9250 4 0.005 
12 M 8.5053 19 6.2000 4 0.245 
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Table 9.36 SPK CYP3A5 dose corrected levels 
 
CYP3A5 GG (*3/*3)  
 





Dose Corrected Tac 
Level  
(µg/L per mg) 
n Dose Corrected Tac 
Level  
(µg/L per mg) 
n p 
WK1-1 1.7844 16 0.7400 1 0.224 
WK1-2 2.3849 16 6.0000 1 0.041 
WK1-3 2.5768 16 1.4770 1 0.371 
WK2-1 2.2676 18 1.6258 2 0.754 
WK2-2 1.6361 18 0.7518 2 0.351 
WK2-3 1.7045 17 0.7303 2 0.475 
WK3-1 1.4348 19 0.5503 3 0.382 
WK3-2 1.6051 16 0.4946 3 0.488 
WK3-3 0.9920 16 0.4134 6 0.051 
1M 1.0576 18 0.7813 6 0.288 
2M 1.1478 20 0.6767 5 0.050 
3 M 1.1927 18 0.9042 5 0.390 
6 M 1.3949 21 0.5663 4 0.030 































n p value 
WK1-1 6.170 3 6.1100 9 6.000 5 0.993 
WK1-2 6.5000 3 6.0000 9 6.900 5 0.724 
WK1-3 5.1667 3 6.1000 10 5.100 5 0.275 
WK2-1 7.2500 4 6.9091 11 4.620 5 0.262 
WK2-2 7.5000 5 7.1455 11 5.500 5 0.629 
WK2-3 8.9200 5 7.4636 11 6.000 3 0.601 
WK3-1 10.2000 5 9.4167 12 7.200 5 0.504 
WK3-2 12.5000 5 10.5000 10 8.375 4 0.448 
WK3-3 12.4617 6 10.6667 12 12.220 5 0.815 
1 M 13.3333 6 10.9231 13 14.800 5 0.350 
2 M 9.8333 6 11.7500 12 10.786 7 0.735 
3 M 12.3333 6 10.9091 11 9.417 6 0.601 
6 M 7.8000 5 8.5417 12 8.375 8 0.994 
12 M 6.2500 4 7.0000 12 6.000 6 0.859 
 
 











n Tac Level 
(µg/L) 
n Tac Level 
(µg/L) 
n p value 
WK1-1 8.9714 7 9.4250 16 12.5444 9 0.244 
WK1-2 14.7571 7 12.2563 16 16.2889 9 0.374 
WK1-3 11.2286 7 13.9500 16 11.6222 9 0.411 
WK2-1 8.5143 7 11.2875 16 7.7111 9 0.156 
WK2-2 9.4143 7 8.8375 16 8.0222 9 0.711 
WK2-3 6.7714 7 7.3875 16 9.9857 7 0.127 
WK3-1 7.3286 7 7.9267 15 9.8714 7 0.351 
WK3-2 7.4714 7 8.1286 14 8.0500 6 0.879 
WK3-3 8.3000 6 7.8857 14 8.1167 6 0.940 
1 M 13.8667 6 9.2214 14 10.5833 6 0.144 
2 M 10.3500 6 10.0000 13 9.4571 7 0.904 
3 M 10.1833 6 10.2636 11 10.5833 6 0.986 
6 M 8.7000 5 8.0000 13 9.0125 8 0.731 

























n p value 
WK1-1 1.3433 3 1.6303 9 2.1175 5 0.404 
WK1-2 3.1181 3 2.2259 9 2.9542 5 0.676 
WK1-3 1.4950 2 2.5074 10 2.9282 5 0.353 
WK2-1 1.4454 4 1.9140 11 3.4465 5 0.480 
WK2-2 1.2586 5 1.4000 10 2.1321 5 0.489 
WK2-3 0.8081 5 1.7913 11 2.2305 3 0.493 
WK3-1 0.7345 5 1.0110 12 2.6214 5 0.100 
WK3-2 0.7242 5 1.0366 10 3.2946 4 0.235 
WK3-3 0.7431 6 0.9549 12 0.6088 4 0.602 
1 M 1.0263 6 1.0207 13 0.8597 5 0.848 
2 M 1.1400 6 0.9854 12 1.0963 7 0.801 
3 M 0.9684 6 1.1432 11 1.2675 6 0.740 
6 M 1.2792 5 1.2978 12 1.1986 8 0.957 



























Mean Dose (mg) n Mean Dose (mg) n p 
WK1-1 5.9700 15 7.00 2 0.489 
WK1-2 6.2667 15 7.00 2 0.629 
WK1-3 5.9333 15 6.50 2 0.713 
WK2-1 6.5278 18 5.75 2 0.698 
WK2-2 7.0842 19 4.50 2 0.331 
WK2-3 8.0941 17 4.00 2 0.159 
WK3-1 9.5000 20 5.00 2 0.149 
WK3-2 11.1765 17 5.50 2 0.107 
WK3-3 11.1800 20 6.00 2 0.004 
1M 12.1667 21 6.25 2 0.001 
2M 10.5870 23 6.00 1 0.001 
3 M 10.9762 21 8.00 1 0.826 
6 M 8.4318 22 5.50 2 0.401 
12 M 6.5250 20 2.50 1 0.191 
 
 










Tac Level (µg/L) n Tac Level (µg/L) n p 
WK1-1 9.6029 28 15.2000 3 0.184 
WK1-2 13.4536 28 21.4667 3 0.067 
WK1-3 12.5536 28 16.4333 3 0.187 
WK2-1 9.0500 28 16.5000 3 0.025 
WK2-2 8.4679 28 11.9667 3 0.179 
WK2-3 7.6385 26 10.0000 3 0.487 
WK3-1 8.2200 25 9.5333 3 0.568 
WK3-2 7.9957 23 8.1667 3 0.783 
WK3-3 7.8182 22 10.5000 3 0.101 
1M 10.8545 22 9.8333 3 0.776 
2M 10.3478 23 5.2500 2 0.144 
3 M 10.2905 21 7.1000 1 0.501 
6 M 8.5609 23 7.6500 2 0.860 





















WK1-1 1.7079 15 1.8357 2 0.842 
WK1-2 2.6030 15 2.5571 2 0.974 
WK1-3 2.5089 15 2.5355 2 0.977 
WK2-1 2.0701 18 3.4032 2 0.513 
WK2-2 1.4202 18 2.6950 2 0.172 
WK2-3 1.5051 17 2.4250 2 0.501 
WK3-1 1.2418 20 2.0375 2 0.512 
WK3-2 1.4015 17 1.6700 2 0.899 
WK3-3 0.7415 19 2.0357 2 0.006 
1M 0.9421 21 1.8361 2 0.025 
2M 1.0882 23 0.9333 1 0.362 
3 M 1.1386 21 0.8875 1 0.932 
6 M 1.2324 22 1.9146 2 0.293 
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